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Chapter 1 
General introduction
and aims of this thesis
Parts of the introduction are published as:
Epidemiology of hidradenitis suppurativa:
 prevalence, pathogenesis, and factors associated 
with the development of HS.
Inge E. Deckers, Hessel H. van der Zee, Errol P. Prens
Curr Derm Rep 2014;3:54-60
The handicap of hidradenitis suppurativa.
Inge E. Deckers, Alexa B. Kimball
Dermatol Clin 2016;34:17-22
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1
Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease. Patients 
present with painful deep-seated inflammatory nodules or abscesses, mainly located 
in the inverse body areas such as the axillae and groin.1,2 The name hidradenitis sup-
purativa is derived from the Greek words hidros (sweat), aden (glands) and itis (inflam-
mation) and the Latin word suppurativa (pus-forming). The disease was first described 
by the French surgeon Velpeau in the ‘Dictionnaire de médicine ou repertoire general 
des sciences médicales’.3 In 1864 Verneuil, also a French surgeon, introduced the name 
‘hidrosadénite phlegmoneuse’, because he thought that the abscesses originated from 
the sweat glands, due to their location in the axillae.4 Hereafter, the disease was also 
referred to as Verneuil’s disease. However, already in 1902 it was suggested that the 
sweat glands were not primarily involved in HS.5 In 1989 HS got his third name; acne 
inversa, because it was suggested that HS shared similarities with pathogenesis of acne 
vulgaris.6,7 However, the sebaceous glands are not primarily involved in HS and common 
treatments for acne vulgaris showed limited effects in HS.8–10 Sporadically, the names 
fox den disease or pyoderma fistulans significa are used to describe a severe subtype 
of HS.11,12 In Dutch literature the name acne ectopica is also commonly used, which was 
introduced in a Dutch text book on Dermatology in 1983.13 The net effect is that this 
painful debilitating disease has multiple names, none of which is appropriate. However, 
for this thesis we chose to remain with hidradenitis suppurativa, because it is still most 
commonly used in current literature.
1. ClInICAl PrESEntAtIon
HS is a characterized by painful, inflammatory nodules, sterile abscesses and sinus tract 
formation, followed by scarring and tissue fibrosis (Figure 1).1,14 These lesions are located 
at specific body areas such as the axillary, inguinal, pubic and gluteal area. Less fre-
quently affected body areas are the abdominal, facial, retroauriculair, and the sub- and 
inframammary areas. The presence of double comedones or pseudo-comedones is typi-
cal for HS.14 Canoui-Poitrine et al. suggested that three clinical phenotypes exist.15 The 
most common phenotype is the ‘axillary-mammary’ type, in which mostly the armpits 
and breasts are involved with hypertrophic scars. The ‘follicular’ type is characterized by 
the presence of comedones, papules and folliculitis, located at the armpits and/or breast, 
but also the ears, chest, back and legs are frequently affected. Patients with the ‘gluteal’ 
type show similar lesions as the ‘follicular’ type; however, in these patients most lesions 
are located at the gluteal area. Van der Zee and Jemec recently suggested that there are 
six different types;16 the regular type, the frictional furuncle type (overweight patients 
with lesions at friction sites), the scarring folliculitis type (pustules, cysts, cribiform 
scarring and comedones at the buttocks, inguinal and pubic region), the conglobate 
12
type (mostly in overweight men with cyst formation and acne conglobate on the back 
and face), the syndromic type (patients with concomitant diseases such as pyoderma 
gangrenosum and arthritis) and the ectopic type (involvement of the face).16
2. EPIDEmIology
Several studies have attempted to determine the prevalence of HS. In 1996, Jemec et al. 
reported a prevalence of 4% in young adults and 1% in general population.17 Revuz et 
al. confirmed the prevalence of 1% in 2008, with a questionnaire-based survey among 
6,887 subjects.18 However, recent studies from American populations reported lower 
prevalences of 0.05% to 0.13%.19,20 However, these studies might underestimate the 
prevalence, because patients were only included if they had sought medical care for 
their disease. Unfortunately, because of embarrassment, patients often postpone seek-
ing medical help.21
HS usually develops after puberty with a peak age of onset in the early twenties,2,22,23 
and women are generally more frequently affected than men, with a female-to-male 
ratio of 3:1.17,18 Prepubertal onset is thought to be rare, although multiple case reports of 
children with HS exist.24,25 HS is a chronic disease; von der Werth and Williams showed 
that 90% of their studied patients still had an active disease after a disease duration 
of nearly 19 years.22 Conversely, it has been said that the prevalence diminishes over 
time.14,18,26 Especially the menopause is mentioned as a point in life whereafter women 
would become free of symptoms.2 However, the actual percentage of postmenopausal 
women with active disease is unknown.
Hurley stadium I Hurley stadium II Hurley stadium III
Figure 1. The clinical presentation of hidradenitis suppurativa.
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3. EtIology
3.1	 Pathogenesis
The pathogenesis of HS is still largely unknown, and is probably multifactorial.27 Since 
the last two decades, the primary event is thought to be occlusion of the terminal hair 
follicle,28 caused by infundibular hyperkeratosis and hyperplasia of the follicular epithe-
lium.29,30 This occlusion results in the accumulation of cellular debris, cyst formation, 
and rupture of the hair follicle, followed by abscess formation, and in later stages, the 
development of sinus tracts and scarring.31,32 In unaffected skin of HS patients, a sig-
nificant reduction of sebaceous glands has been observed in comparison with healthy 
subjects.8 The authors hypothesized that the absence of sebum results in higher friction 
in the infundibulum of the hair follicles, resulting in hyperkeratosis and rupture of the 
hair follicles. In addition, it was found that all skin samples from HS patients showed 
perivascular inflammation, perifollicular inflammation, or both.8 This is remarkable, 
since the samples were perilesional, from clinically unaffected skin that showed no signs 
of inflammation or scarring. This would support the hypothesis that an immunological 
dysregulation is also involved in the development of HS.
Many factors, endogenous as well as exogenous, are associated with the development 
and maintenance of the disease. Exogenous factors important in the pathogenesis of HS 
are: smoking, obesity, bacterial superinfections and friction. Endogenous factors include 
genetic predisposition, aberrant immunity, and hormonal influences.
3.1.1 Smoking
Smoking is a factor that is strongly associated with HS. In multiple studies, high percent-
ages of active smokers (60-90%) or ex-smokers (5-15%) have been reported, and smokers 
tend to have a more severe disease than nonsmokers.33–35 Nicotine can be detected in 
axillary sweat for up to eight days after smoking cigarettes, and the levels of nicotine are 
significantly higher in apocrine sweat than in eccrine sweat.36 Since more apocrine sweat 
glands are located in the intertriginous areas, the concentration of nicotine is higher in 
the skin of these areas.36,37 Nicotine promotes inflammatory reactions, like provoking 
mast cell degranulation, and enhancing the survival and chemotaxis of neutrophils.38–40 
Furthermore, an in vitro model has shown that nicotine can induce epidermal hyperpla-
sia and follicular plugging, which is also found in the skin of HS patients.37,41
3.1.2 Obesity
Most HS patients (45-80%) are overweight with a body mass index (BMI) above 25 
kg/m2,23,33 also obesity (BMI > 30 kg/m2) is associated with a more severe disease.34 There 
are multiple explanations why obesity can contribute to the development of HS. First, 
it is hypothesized that in obese patients, the increased skin-to-skin contact enhances 
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mechanical friction, which can cause micro-tears of the hair follicles in predisposed 
individuals.37 These micro-tears can eventually lead to rupture of the hair follicle and 
spilling of the follicular content, resulting in inflammation and abscess formation.8 
Second, the overlapping skin folds may cause sweat retention, which can cause irrita-
tion and maceration when combined with friction, leading to skin inflammation. Third, 
bacterial growth is favored by the often humid and warm microclimate present in the 
skinfolds, causing secondary infections of the inflamed skin.27,42 Fourth, obese patients 
have increased levels of circulation pro-inflammatory cytokines, such as tumor necrosis 
factor alpha (TNF-α), interleukin (IL)-1β and IL-6.43 These cytokines, especially TNF-α 
and IL-1β, are also elevated in the skin of HS patients.44 Therefore, it is conceivable that 
the enhanced levels of pro-inflammatory cytokines, partly produced by adipocytes,43 
contribute to the development of HS.
3.1.3 Genetic factors
In approximately 40% of the patients, HS occurs in one or more family members.23,26 
In 1985 Fitzsimmons et al. suggested that HS follows an autosomal dominant pattern, 
even though only 34% of the patients had a first degree family member with HS.45,46 
They blamed this low percentage on the high number of family members that were still 
under the age of 20. In 2000 von der Werth et al. re-examined the same families, but still 
a 50% frequency for an autosomal dominant transmission was not reached.26 Hereafter, 
multiple studies were conducted to determine the genetic basis in patients with HS. 
Even though several genetic loci have been identified that are associated with HS, no 
causative genes have been found. Mutations in the γ-secretase genes PSENEN, PSEN1 
and NCSTN were identified in families with multiple family members suffering from a 
specific form of HS, in whom not only the normal locations, but also atypical sites were 
affected.47–50 However, these mutations could not be confirmed in a larger HS cohort.47,48 
When the function of γ-secretase is disrupted in mice, it results in follicular keratinization, 
follicular atrophy, the formation of epidermal cysts, absence of sebaceous glands, and 
epidermal hyperplasia, characteristics that also can be found in HS.48 But more research 
is necessary to determine the influence of genetic factors in the pathogenesis of HS.
3.1.4 Aberrant immune response
The chronic inflammatory nature combined with the frequent absence of pathogenic 
bacteria suggests a role of an aberrant immunity in HS. This suspicion is further sup-
ported by the reported co-occurrence with sterile arthritis and Crohn´s disease (CD).51 
Multiple studies have shown that the levels of several inflammatory and anti-inflam-
matory cytokines are elevated in HS lesions.44,52–54 Upregulated cytokines in HS lesions 
include IL-1β, TNF-α, IL-10, IL-11, IL-17A, CXCL9, monokine induced by interferon-γ, and 
B-lymphocyte chemoattractant. On the other hand, IL-2, IL-4, IL-5 and interferon-γ were 
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hardly detectable in HS lesions.44,54,55 The enhanced expression of IL-17A could reflect 
activation of the IL-23/Th17 pathway in lesional HS skin. It was indeed demonstrated 
that IL-12 and IL-23 were both abundantly expressed in macrophages in the dermis of HS 
lesions together with IL-17 producing T cells.53
3.1.5 Bacterial infection
For a long time, it was thought that bacterial infection played an imported role in the 
development of HS. However, bacterial cultures from HS lesions are often sterile or only 
grow commensal skin flora, such as coagulase-negative staphylococci, Staphylococcus 
aureus, and strains of the intestinal flora e.g. Escherichia coli.56–61 Staphylococcus species 
were mostly found in Hurley stage I lesions, whereas in Hurley stage II or III more often 
coagulase-negative staphylococci and a mix group of anaerobic flora were found.62 This 
suggests that bacterial colonization is a secondary event and that superinfections may 
worsen flare ups.14,37
3.1.6 Hormonal influences
A relation between HS and hormones seems conceivable since the onset of the disease 
is mostly after puberty and the prevalence seems to gradually decrease after meno-
pause.63 In addition, women reported premenstrual flare-ups,22 and improvement of 
the disease during pregnancy.63,64 However, no differences have been found in plasma 
androgen levels in women with HS and BMI-matched healthy controls.65,66 Therefore, the 
role of hormones in the development of HS remains questionable.
3.1.7 External factors
HS patients report a wide range of external factors that may induce lesions.22 Morgan 
et al. investigated the role of shaving, the use of chemical depilatories, deodorants, and 
talcum powder as causative factors for HS, and concluded that these factors do not play 
a role in the initiation of HS.67 Probably the only external factor that is associated with HS 
is mechanical friction. Patients report that wearing tight clothes enhanced the number 
of inflammatory lesions and that wearing loose clothes decreased the symptoms of their 
HS.22 In obese patients the abdomen and waist can be more affected due to friction of 
the waist belt, which can also resolve after weight loss.68 The role of mechanical friction 
is further supported by two case reports: a child developed HS-like lesions in a nevus 
comedonicus after she started moving around,69 and a man developed HS-like lesions 
on his leg stump after he started to wear a leg prosthesis.70
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3.2	 Diseases	associated	with	hidradenitis	suppurativa
Multiple diseases have been reported to co-occur with HS. Many of these diseases are 
caused by immunological dysregulation or by a genetic disorder related to the function 
of the hair follicles.
Since infundibular occlusion has been established as a key pathogenic event, HS has 
been grouped with three other diseases that result from follicular occlusion, called the 
follicular occlusion tetrad: acne conglobata, pilonidal cysts and dissecting cellulitis of 
the scalp.71–73 It has been recorded that up to 26% of HS patients have a history of severe 
acne, and up to 30% have a history of pilonidal cysts.15 However, it can be difficult to 
differentiate between HS and a pilonidal cyst on a clinical basis.
HS is frequently associated with inflammatory bowel disease (IBD), mostly with 
CD.51,74–77 In one study, up to 38% of 61 HS patients were diagnosed with CD,74 whereas 
in studies performed in IBD patients the prevalence of HS ranges between 1.2% and 
23%.75,77,78 The clinical presentations of HS and CD can be similar, because both can 
show perianal abscesses and fistulas, have a clinical course with periods of exacerbation 
and remission, and show a good response to biologics such as TNF-α inhibitors.51,79,80 
However, it is difficult to differentiate histologically between HS and CD, because in both 
diseases diffuse tissue inflammation with epithelioid granulomas can be present.81,82 
Also, for HS as well as for CD, smoking is a triggering factor, and is associated with a 
more severe disease.79,80 
Recently, HS has been associated with metabolic syndrome. The cluster of cardiovas-
cular risk factors, including diabetes mellitus, hypertension, dyslipidemia and obesity, 
showed to be more frequently present in patients with HS than in controls.83–85 A recent 
systematic review confirmed the association, showing an increased odds ratio of 2.2 for 
metabolic syndrome in HS.86 Patients with HS that were referred to a dermatologist, 
even had an odds ratio of 3.9 for metabolic syndrome.83 However, it is still under debate 
if the proinflammatory state of metabolic syndrome is causative to HS, or a secondary 
effect of HS.83–85
More rarely, HS has been associated with pyoderma gangrenosum (PG).73,87 PG is a 
rare, chronic, inflammatory skin disease, characterized by progressive ulcers, typically 
affecting the lower extremities or the trunk, but all body areas can be affected.88 One 
study has described eleven HS patients having PG-like ulcers; most of the patients had 
these ulcers at locations where they also suffered from HS.87 Therefore, it is possible that 
these ulcerations were counted as PG, while chronic ulcerations from HS could not be 
excluded.
Spondyloarthropathy has also been associated with HS, mostly in African-American 
or Afro-Caribbean men.73 The peripheral joints were mostly affected, generally in an 
asymmetric pattern, whereby flare-ups of HS triggered the joint symptoms. Laboratory 
testing showed that in most patients the rheumatoid factor was negative, and there 
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was no association with HLA-B27.89–91 In a recent French study, 24 of the 640 HS patients 
(3.7%) had spondyloarthritis according to the European Spondylarthropathy Study 
Group (ESSG) criteria. In total, 43 patients fulfilled the criteria for arthritis, enthesitis and/
or inflammatory back pain. In 16 of these patients HLA-B27 was tested, and was positive 
in seven patients.92
4. DIAgnoSIS
The diagnosis of HS is based on the clinical presentation and no diagnostic tests are 
available to set the diagnosis. The diagnosis has to be established based on the history 
of the patient and the physical examination. During the international symposium of the 
Hidradenitis Suppurativa Foundation in March 2009, three criteria have been adopted 
on which the diagnosis of HS should be made.93,94 First, typical lesions should be pres-
ent i.e. deep-seated nodules, abscesses, draining sinuses, fibrosis and/or bridged scars. 
Second, these lesions should be located at typical localizations such as the axillae, groin, 
perianal and gluteal area. Finally, the disease course has to be characterized by chronic-
ity and relapses.2,93,95
Validated questions have been developed to make the diagnosis through question-
naires.96 The following three questions showed to have high sensitivity (SE) and specific-
ity (SP):
• Do you repeatedly have outbreaks of big sore or painful nodules or boils that heal 
with scars in any of these location: Groins, armpits, sexual organs, anal region and 
under the breasts. (SE: 0.97, SP: 0.82)
• During the last 12 months did you repeatedly have big painful nodules or boils lo-
cated in the armpits or the groin, a disease called hidradenitis suppurativa? (SE: 0.92, 
SP: 0.86)
• Have you had at least two outbreaks of boils during the last 6 months? (SE: 0.95, 
SP: 0.85)
4.1	 Severity	scores
To date, multiple severity scores have been used to assess disease severity. The Hurley 
score is the oldest and still most commonly used (Table I and Figure 1).2,97 Even though 
it is easy in use; it is very static and therefore less suitable for monitoring treatment ef-
ficacy. In 2003 the Sartorius score was introduced which was modified in 2009. It is based 
on the number of areas involved and the number of nodules, fistulas and hypertrophic 
scars.23,98 However, because of its comprehensiveness, it is time consuming, making it 
less suitable for daily practice. One of the latest severity scores is the ’Hidradenitis Sup-
purativa Physician Global Assessment’ (HS-PGA) score. This five scale score ranges from 
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clear to very severe, and is based on the number of noninflammatory nodules, inflam-
matory nodules, abscesses and draining fistulas (Table II). This validated score is easy to 
use and suitable for observing change during treatment, and therefore frequently used 
nowadays.93,99
However, for all these severity scores it remains questionable to determine when a 
treatment has a meaningful effect. Therefore the ‘Hidradenitis Suppurativa Clinical 
Response’ (HiSCR) has been developed as a clinical endpoint in HS treatments.100 For this 
scoring system the number of abscesses, inflammatory nodules and draining fistulas 
have to be counted. Patients who respond to treatment (achieving HiSCR) should have 
at least 50% reduction in the total number of abscesses and inflammatory nodules, 
whereas there should be no increase in the number abscesses or draining fistulas.100
5. tHE ImPACt oF HIDrADEnItIS SuPPurAtIVA
5.1	 Quality	of	life
HS can have a profound influence on quality of life (QoL). Owing to pain, patients are 
unable to perform their everyday tasks, go to work or enjoy sports. In addition, patients 
often feel embarrassed because of the malodorous suppurative discharge and often 
hide the disease even from close relatives.101 Mostly the Dermatology Life Quality Index 
(DLQI) and the Skindex-29 are used to assess QoL in dermatological patients. For both, a 
higher score implies a greater impact on QoL. All studies performed on QoL in patients 
table I. Hurley classification
I Abscess formation, single or multiple, without sinus tracts and cicatrization
II Recurrent abscesses with sinus tract formation and cicatrization. Single or multiple, 
separated lesions
III Multiple interconnected tracts and abscesses throughout an entire area
Hurley classification for clinical staging of disease severity.2,97
table II. Physician’s global assessment scale of hidradenitis suppurativaa
Clear No noninflammatory nodules, inflammatory nodules, draining fistulas or abscesses
Minimal Only noninflammatory nodules, but no inflammatory nodules, draining fistulas or abscesses.
Mild Less than five inflammatory nodules, but no abscesses or draining fistulas;
or one abscess or draining fistula, but no inflammatory nodules
Moderate Five or more inflammatory nodules, but no abscesses or draining fistulas;
or one abscess or draining fistula and at least one inflammatory nodule;
or two to five abscesses or draining fistulas and less than ten inflammatory nodules
Severe Two to five abscesses or draining fistulas and more than ten inflammatory nodules
Very severe More than five abscesses or draining fistulas
a Adjusted physician’s global assessment scale for hidradenitis suppurativa.93,99
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with HS report a diminished QoL (Figure 2).34,101–106 When comparing DLQI scores of pa-
tients with HS with other dermatological patients or controls, patients with HS tend to 
have the highest scores.103,105,107 Onderdijk et al. compared the DLQI scores of HS patients 
with patients with acne, eczema, psoriasis, skin tumors and other skin disease, and found 
that patients with HS had a signifi cant higher scores than these other dermatological 
patients.103 Basra et al. compared the DLQI scores of 45,710 patients with diff erent skin 
diseases from 220 diff erent studies (Figure 3).108 HS had a mean score of 13.3, which was 
one of the highest scores; only burns (scars), erythropoietic protoporphyria, and hirsut-
ism scored higher, suggesting that HS belongs in the top 5 skin diseases with the most 
negatively impacted QoL scores.108
To compare the eff ect of HS on QoL with other non-dermatological patients, the short 
form (SF)-36 can be used.104,105 The SF-36 is a short survey to assess health-related QoL, 
in which a lower score indicates a greater impairment of QoL. When compared with 
diabetes mellitus with or without foot problems, breast cancer, IBD or stroke, HS patients 
still have the worst QoL scores (Table III).104,105,109–112
5.1.1 Causes of low quality of life in hidradenitis suppurativa
When examining predictors of low QoL, young age of onset of HS, a higher number of 
lesions per month, and a more severe disease are associated with a lower QoL.101,105,106 
On the DLQI, patients with Hurley stage III scored signifi cantly higher than patients with 
Hurley stage I.102,104 In addition, the Sartorius score also showed to have a signifi cant 
correlation with the DLQI scores.34 Questions on pain, discomfort and embarrassment 
scored the highest, indicating that these are important factors diminishing QoL.34,101,103 
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Figure 2. Overview of the Dermatological Life Quality Index (DLQI) scores in patients with hidradeni-
tis suppurativa.34,101–104,107
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Fatigue also scores high,106 which is consistent with the work by Matusiak et al;102 they 
found that almost 40% of the HS patients had clinically signifi cant fatigue, with a strong 
correlation between the Hurley stage and the level of fatigue.
5.2	 Depression
HS is often associated with depression but the reported prevalence varies substantially 
across published studies. Shavit et al. investigated the prevalence of depression in a large 
database including 3,207 patients with HS, and found that almost 6% of the patients with 
HS suff ered from depression.113 Three studies using depression questionnaires found a 
prevalence of depression between 9% and 39%.102,103,114 Unfortunately, all three used dif-
ferent depression questionnaires, making direct comparison impossible.102,103,114 In two 
studies, disease severity correlated with the depression scores.102,114 Onderdijk et al. could 
not confi rm the association between depression and Hurley score, but they did fi nd a 
correlation between depression and the number of lesions and fl ares in the last month.103
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Figure 3. An overview of the Dermatological Life Quality Index (DLQI) scores in patients with multiple 
diff erent dermatological diseases. In parentheses the number of studies is indicate on which the 
DLQI score is based.108
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5.3	 Sexual	distress
Patients often report that HS has a great influence on their sexual life. They feel em-
barrassed because of the inflammation and disfiguring scars, often located in intimate 
regions. They also suffer from pain that restrains them from having sexual intercourse. 
Patients report that their partners lose interest in sexual activity when they have ac-
tive lesions.115 To date, one study has investigated the influence of HS on sexual health. 
The investigators found a significant impairment of sexual health in patients with HS 
compared with age-, sex-, and BMI-matched controls.116 Women with the same level of 
disease reported higher sexual distress than men, but surprisingly, there was no correla-
tion between sexual functioning and disease severity. However, two patients without 
genital lesions had similar levels of sexual function as the healthy controls, suggesting 
that the location of inflammation was important in causing sexual distress.116
5.4	 Work
Patients often report that because of the painful lesions they are unable to go to work 
and sometimes even lose their jobs because of the numerous sick days. Matusiak et al. 
found that patients were on average 33.6 days per year absent from work because of 
their HS.117 Out of 30 patients, three reported losing their jobs in the two-year follow-
up period because of frequent absences or inability to perform their work properly. 
Another seven patients reported they were not promoted because of their HS or had 
table III. SF-36 scores of patients with hidradenitis suppurativa, diabetes mellitus, breast cancer, in-
flammatory bowel disease, stroke, and normative sample
SF-36 
domaina
HS105
n=60
HS104
n=55
Dm109
n=49
Without 
foot 
problems
Dm109
n=47
with foot 
problems
Breast 
cancer110
n=50
IBD111
n=793
Stroke112
n=111
normative 
sample105
n=3656
Physical 
functioning
71.3 47.0 79.0 42.0 85.3 78.4 67.5 84.5
Role physical 43.6 45.0 73.0 28.0 72.5 65.1 46.2 81.3
Bodily pain 44.5 440 78.0 59.0 72.1 64.7 64.2 73.5
General health 43.3 45.0 60.0 46.0 55.3 47.2 54.0 69.2
Vitality 40.4 47.0 66.0 54.0 73.6 54.5 51.4 60.1
Social 
functioning
52.5 43.0 83.0 66.0 67.2 75.0 64.5 81.6
Role emotional 42.9 46.0 82.0 71.0 71.3 72.4 50.7 82.2
Mental health 43.0 48.0 79.0 74.0 67.2 65.9 61.0 68.5
mean 47.7 45.6 75.0 55.0 70.6 65.4 57.4 75.1
DM - diabetes mellitus; IBD - inflammatory bowel disease; HS - hidradenitis suppurativa
a Mean score per domain in which a lower score indicates a greater impairment of health related quality of life
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disease-related obstacles regarding promotion or advancement;117 however, other stud-
ies have found fewer missed work days.103,118 Onderdijk et al. even found that patients 
with HS missed fewer work days than controls (3.1 days vs 7.1), although this difference 
was not significant.103
6. trEAtmEntS
To date, there is no cure for HS; treatment generally consists of a combination of medica-
tion and surgery.93 Unfortunately, large randomized controlled trials in HS are scarce and 
most studies are small and retrospective.93 The medical treatment options of HS with 
their mode of action are extensively reviewed in chapter 9. In mild cases, topical applica-
tion of clindamycin lotion or resorcinol can be sufficient,119,120 whereas in more extensive 
cases systemic drug treatments are often needed.93 When extensive sinus formation is 
present, surgical excision is necessary to achieve remission.93 For every patient the most 
suitable treatment should be chosen based on the extensiveness of the disease and the 
preferences of the patient.
6.1	 Antibiotics
The first step in the treatment of mild HS is often topical clindamycin 1% lotion. It is a 
simple, safe and effective treatment for patients with mild HS.119 In more widespread 
disease, antibiotics from the tetracycline group (e.g. doxycycline or minocycline) can be 
effective when given for a longer period.121 These antibiotics are mostly effective because 
of their anti-inflammatory properties. They are less effective in treating or preventing 
exacerbations of HS, since most bacteria cultured in HS are resistant for tetracyclines.58 
The next step in antibiotics is the combined therapy of clindamycin and rifampicin.122–124 
This combination has shown high remission rates, with up to 84% of the patients show-
ing partial to complete response. However, patients mostly need this combination for 
a minimum of ten weeks to achieve remission.122–124 In severe or therapy-resistant HS, 
the combination of rifampicin, moxifloxacin and metronidazole has shown good results, 
with 57% of the patients achieving complete remission.125 However, most patients 
complain of side effects, mostly gastrointestinal problems, leading to early termina-
tion of the treatment. Unfortunately for all antibiotics, recurrence rates are high after 
discontinuation.123,125
6.2	 Biologics
In moderate to severe HS that does not respond to antibiotic treatments, biologics 
are the next option. Especially TNF-α inhibitors (e.g. infliximab and adalimumab) have 
shown to be effective. However, even though biologics are often well tolerated and can 
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suppress the disease for a long period, they are seldom curative.99,126,127 Adalimumab 
is the best documented biologic for the treatment of HS, and it is the only treatment 
proven effective in a large multicenter randomized placebo-controlled trial.99 Every 
week 40 mg of adalimumab showed to be more effective than placebo; however, still 
only 18% of the patients reached the clinical endpoint (clear, moderate to mild response 
with a decrease of at least two grades) after sixteen weeks of treatment.99 Long-term 
treatment is necessary to maintain disease suppression, because after discontinuation 
high recurrence rates have been reported.128 Infliximab in a dosage of 5 mg/kg body 
weight, administered in week 0, 2, 6 and then every 8 weeks showed to be effective in 
patients with HS and is safe for long-term treatment of HS.127,129 In a placebo-controlled 
trial, patients receiving infliximab showed a significant decrease in severity, with 47% 
having an excellent response. However, only 7% of the patients showed total clearance 
of the lesions.127 In addition, relapse rates during treatment are high, half the patients 
showed relapse after a median treatment time of 37 weeks.129 It has been suggested that 
a shorter treatment interval might be more effective in HS.130 However, trials comparing 
different intervals regimes for HS are lacking.
6.3	 Surgical	treatment
Most patients with HS need at least one surgical procedure during their lifetime. This 
can be incision and drainage, excision of a single lesion, or wide surgical excisions.93 Inci-
sion and drainage is performed to relief pain in patients with an acute inflammation;131 
mostly this is done at the emergency room. However, recurrence rates up to 100% have 
been reported, therefore incision and drainage is not an effective treatment in HS.131 
In mild cases, Hurley stage I or II, the lesions can also be excised and closed primar-
ily using stiches. Recurrence rates of 34% have been reported after a follow-up of 27 
months.132 Therefore, for mild cases deroofing is more effective, with a recurrence rate 
of 17%.133 During a deroofing the sinuses are explored using a blunt probe, whereafter 
the sinus roof is excised using electrosurgery. It is important that the wound edges are 
carefully examined for remaining sinus tracts. The wounds are mostly left open for heal-
ing by secondary intention.133,134 In severe HS, when large areas are affected, extensive 
surgery is often needed.135–137 During surgery, all affected tissue should be excised up 
to the healthy fat, and again all wound edges should be checked for remaining sinus 
tracks.135,136 This can be done using electrosurgical wide or staged excision, for which the 
recurrence rates vary between 3% and 34%.131,135–139 Different closure techniques have 
been described to close the large wounds. Rompel and Peters found no difference in 
recurrence rate between the different reconstruction techniques (primary closure, local 
flaps, multiple forms of skin plasty, free skin grafts and healing via secondary inten-
tion),135 whereas Watson et al. showed that primary closure had a higher recurrence rate 
than closure via split-skin graft or local flap cover.140 However, all studies use different 
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closure techniques and different definitions of recurrence, therefore direct comparison 
of these studies is impossible.
6.4	 Lifestyle	changes
Besides medical or surgical treatment, all patients with HS should be given lifestyle 
advice. As discussed in the above section, smoking and obesity are highly associated 
with HS. However, even though smoking is associated with the onset of HS and disease 
severity, it is not clear whether cessation of smoking can improve the disease course 
of HS. In a case report, two patients became disease-free after they stopped smok-
ing.141 However, the clinical impression is that cessation does not improve symptoms 
on short notice.34,142 The long-term impact of smoking cessation is unknown. There is 
strong evidence that weight reductions aids towards disease remission. Kromann et al. 
investigated the impact of weight loss after bariatric surgery on HS symptoms. Half the 
patients who had symptoms before the surgery and who had lost more than 15% of 
their BMI, reported to be free of inflammations. Whereas another 20% of the patients 
reported fewer symptoms after the weight loss.143 These results are supported by case 
reports of patients achieving disease remission after extensive weight loss.68,144
Patients often feel trapped in a negative cycle of lifestyle changes. When addressing 
these risk factors patients often respond that HS causes significant stress because of the 
painful inflammation, making it difficult to quit smoking. When they manage to quit 
smoking they frequently start eating more, resulting in weight gain, which results in 
more stress and feeling the need to restart smoking. Active involvement in sports to 
lose weight is often difficult because of the painful lesions. The net effect of these trade-
offs can unfortunately substantially limit the ability to impact useful lifestyle changes. 
Nonetheless, patients should be encouraged to change their lifestyle, if possible with 
the help of “stop smoking” or “weight loss” programs.
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7. AImS oF tHIS tHESIS
HS is a chronic debilitating disease, and the diagnosis of HS comes with many uncer-
tainties; the course of the disease is unknown, as is whether the disease will flare or if 
patients ever will be free of inflammation. In addition, there remains a great unmet need 
for better therapies and as of today, a cure is distant. Therefore, in this thesis we focused 
on the clinical aspects of HS. 
The aim of the first part was to investigate factors associated with early onset, disease 
severity and remission. First, we wanted to determine the prevalence of early-onset HS, 
because our clinical impression contradicted with the literature that prepubertal onset 
of HS is rare. To do so, in Chapter 2 we determined the prevalence of onset before the 
thirteenth birthday, and in addition determined risk factors for early-onset HS. Follow-
ing in Chapter 3, we determined factors associated with disease severity, sex and family 
history. Last for Chapter 4 we investigated the clinical course of HS, and determined the 
percentage of patients who became disease-free, 22 years after the diagnosis was set by 
a dermatologist. We also sought for factors that were associated with remission.
In the second part of this thesis we looked at two specific comorbidities of HS, namely 
anemia and inflammatory bowel disease (IBD). In Chapter 5, we reported on two pa-
tients with severe HS and concomitant anemia causing severe fatigue, and we reviewed 
the literature. While in Chapter 6 the association between IBD and HS was further in-
vestigated. We determined the prevalence of IBD in patients with HS, and  investigated 
whether patients with IBD and HS had a different HS phenotype.
The third part of this thesis is about the impact of HS on the lives of the patients. In 
small studies HS has shown to have great impact on sexual health. However, since large 
studies are lacking, we wanted to investigate the influence of HS on sexual health and 
quality of life in a large group of patients. The results of this questionnaire-based study 
are presented in Chapter 7. Besides a lower quality of life it is our clinical impression 
that patients with HS also have a lower social economic status (SES) than other dermato-
logical patients. Therefore we compared the SES of HS patients with patients with other 
dermatological diseases in Chapter 8.
In the fourth part of this thesis we looked at the treatment options for HS. We start in 
Chapter 9 with a comprehensive review of most medical treatments of HS with their 
mode of action. In Chapter 10 we show the results of fumaric acids as a new treatment 
option for HS. Fumarates have proven to be very effective in patients with psoriasis due 
to their immunomodulating properties; therefore we hypothesized that they might 
also be effective in patients with HS. Finally, in Chapter 11 we wanted to determine the 
outcome of wide surgical excision in patients with severe HS. To do so we retrospectively 
reviewed the recurrence rate and patients satisfaction of 260 surgical procedures per-
formed in 86 patients with HS
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ABStrACt
Background: The reported mean age of onset of hidradenitis suppurativa (HS) is be-
tween 20 and 24 years. Prepubertal onset is thought to be rare.
objective: We sought to determine the prevalence of early-onset HS and to compare 
clinical characteristics between early-onset and normal-onset HS in a retrospective 
study.
methods: Data were collected from 855 HS patients. Early-onset HS was defined as onset 
before the thirteenth birthday. Clinical characteristics were analyzed in relation to the 
age of onset.
results: In all, 66 patients (7.7%) reported early-onset HS. A family history of HS was sig-
nificantly more prevalent in early-onset patients (55.6% vs 34.2%; OR 2.1, 95% CI 1.2-3.6; 
P = 0.006). They developed inflammatory lesions at more body sites than patients with 
normal-onset HS (OR 3.0, 95% CI 1.8-4.9; P < 0.001). Distribution of the Hurley stages of 
severity showed no differences between the two groups (OR 1.1, 95% CI 0.7-1.8; P = 0.72).
limitations: Some data were based on patient-reported information.
Conclusion: Early-onset HS occurs more frequently than previously believed. Patients 
with early-onset HS often report a family history of HS and develop lesions at more body 
sites.
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IntroDuCtIon
Hidradenitis suppurativa (HS), is characterized by recurrent inflammatory nodules at 
intertriginous body sites.1,2 Onset of HS is generally after puberty, typically between the 
age of 20 and 24 years.3–5 Prepubertal onset is estimated to occur in 2% of patients with 
HS.6,7 When several of our patients reported onset of HS in their early teens, we sought 
to determine the prevalence of early-onset HS and to analyze the clinical characteristics 
of patients with HS in relation to the age of onset.
mEtHoDS
Patients
We collected data from 855 patients given the diagnosis of HS between 2007 and 2014 
in The Netherlands at the Department of Dermatology at the Erasmus University Medi-
cal Center, Rotterdam; the Deventer Hospital, Deventer; and the Department of Plastic 
Surgery at the Diaconessenhuis, Leiden. Data extraction took place partly from our HS 
database, also used by Schrader et al.5 For this type of retrospective analysis, no medical 
ethical committee approval is required under Dutch law.
Data	collection
Patient characteristics were collected from the medical files. A family history was con-
sidered positive when a first- or second-degree relative had HS. The Hurley classification 
was used to assess disease severity.2 Body sites counted were: axillary, inguinal/genital, 
perianal, gluteal, abdominal and (infra) mammary. Normal weight was defined as a body 
mass index (BMI) below 25 kg/m2, overweight as a BMI between 25 and 30 kg/m2, and 
patients with a BMI above 30 kg/m2 were categorized as obese.
Early-	and	normal-onset	HS
Early-onset HS was defined as reported onset of disease before the thirteenth birthday. 
This cutoff point was chosen based on the mean age at menarche of 13.5 years in The 
Netherlands.8 In general, puberty occurs later in boys. Therefore, it is conceivable that 
most patients with onset before their thirteenth birthday were prepubertal or in early 
puberty.
Data	analysis
Statistical analysis was performed using SPSS 21 (IBM Corp, Armonk, NY). Independent 
t-tests were performed for nominal data, presented as mean ± standard deviation 
(SD). Pearson chi-square test was used for categorical data, and presented as number 
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(%). Binary logistic regression was used to investigate the effect of family history on 
early-onset HS, corrected for age and gender. As a second step we took early-onset as 
a predictor for disease severity, i.e. Hurley stage and number of locations affected. Here 
the response variables were ordinal and we used ordinal logistic regression, correcting 
for age and gender, presented as odds ratio (OR) with the 95% confidence interval (CI). 
P-values less than 0.05 were considered significantly different.
rESultS
A total of 620 females and 235 males, mean age 37.9 ± 12.8 years, were included (Table I). 
Body sites most frequently affected were the inguinal/genital (89.7%), axillary (64.3%) 
and gluteal (41.2%) areas. The (infra) mammary (20.7%), perianal (19.5%) and abdominal 
(16.7%) regions were least affected. Most patients were current smokers (70.5%) or ex-
smokers (14.2%), who started smoking at a mean age of 16.1 ± 3.9 years.
Early-onset	HS	associated	with	a	positive	family	history	of	HS	and	more	
widespread	disease
Early onset was reported by 66 patients (7.7%) and was related to a significantly higher 
percentage reporting a family history of HS (55.6% vs 34.2%; P = 0.001); this remained sig-
nificant after correcting for age and gender (OR 2.1, 95% CI 1.2-3.6; P = 0.006). Early onset 
was associated with significantly more affected body sites (Table I). This association re-
mained significant after correcting for age and gender (OR 3.0, 95% CI 1.8-4.9; P < 0.001). 
No difference was found in the distribution of Hurley stages, even after correcting for 
age and gender (OR 1.1, 95% CI 0.7-1.8; P = 0.72).
Fewer	early-onset	patients	were	smokers	whereas	there	was	no	difference	in	the	
BMI
Of the 696 current smokers and ex-smokers, only a few of the early-onset group reported 
smoking before the onset of HS, whereas most of the normal-onset group had smoked 
before they developed symptoms (3/46, 6.5% vs 568/650, 87.4%; P < 0.001). There was no 
difference in weight in the BMI sub-groups (Table I), nor in mean BMI (28.6 ± 7.0 vs 28.0 
± 6.0; P = 0.48) between early-onset and normal-onset HS.
No	differences	in	comorbidities	between	early-onset	and	normal-onset	HS
No difference was found among the percentage of patients reporting acne during pu-
berty (15/56, 26.8% vs 146/580, 25.6%; P = 0.12), concomitant arthritis (3/61, 4.9% vs 38/645, 
5.9%; P = 0.09) or inflammatory bowel disease (1/66, 1.5% vs 24/784, 3.1%; P = 0.63).
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DISCuSSIon
In this retrospective study of 855 patients, 66 (7.7%) reported early-onset HS. This is 
higher than previously reported (2%),7 indicating that early-onset HS is not so rare. Our 
results suggest that for HS, as with psoriasis and atopic dermatitis,9,10 clinically different 
disease subsets can be distinguished based on age of onset.
table I. General characteristics and comparison of patients with early-onset versus normal-onset 
hidradenitis suppurativa
All patients
(n=855)
Early-onset HSa
(n=66)
normal-onset HSb
(n=789)
P-valuec
gender, n (%)
- Male 235 (27.5) 8 (12.1) 227 (28.8) 0.004
- Female 620 (72.5) 58 (87.9) 562 (71.2)
Age years, mean ± SD 37.9 ± 12.8 31.5 ± 13.2 38.5 ± 12.6 <0.001
Disease duration years, 
mean ± SD
13.8 ± 11.1 20.7 ± 13.4 13.3 ± 10.6 <0.001
Family history, n (%)
- Positive 290 (35.8) 35 (55.6) 255 (34.2) 0.001
- Negative 519 (64.2) 28 (44.4) 491 (65.8)
- Unknown 46 3 43
Hurley stage, n (%)
- Stage I 392 (45.8) 33 (50.0) 359 (45.5) 0.37
- Stage II 351 (41.1) 28 (42.4) 323 (40.9)
- Stage III 112 (13.1) 5 (7.6) 107 (13.6)
no. of body sites affected, n (%)
- 1-2 sites 470 (55.2) 23 (34.9) 447 (56.9) <0.001
- 3-4 sites 312 (36.6) 29 (43.9) 283 (36.0)
- 5-6 sites 70 (8.2) 14 (21.2) 56 (7.1)
- Unknown 3 - 3
Smoking status, n (%)
- Current smoker 600 (70.5) 37 (56.1) 563 (71.7) 0.01
- Ex-smoker 121 (14.2) 11 (16.7) 110 (14.0)
- Nonsmoker 130 (15.3) 18 (27.3) 112 (14.3)
- Unknown 4 - 4
BmI kg/m2, n (%)d
- Normal weight 296 (36.0) 23 (37.1) 273 (35.9) 0.97
- Overweight 264 (32.1) 19 (30.6) 245 (32.2)
- Obese 263 (31.9) 20 (32.3) 243 (31.9)
- Unknown 32 4 28
BMI - body mass index; HS - hidradenitis suppurativa
a Age of onset before 13th birthday
b Age of onset after 13th birthday
c Independent t-test for continuous data and two-sided chi-square test for categorical data
d Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
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In the early-onset group 56% reported a family history of HS, a higher proportion 
than the generally reported 35%.3,11 This supports the findings of previous studies that 
patients with a family history of HS develop HS at an earlier age.5,11 It is conceivable 
that a genetic predisposition influences the age of onset. Von der Werth and Williams 
suggested that age of onset also influences the prognosis of HS.12 Our data confirm that 
early onset is associated with the development of a more widespread disease. Although 
a greater number of affected body sites would suggest more severe disease, this was 
not reflected in Hurley staging. A major shortcoming of the Hurley score is that it does 
not take the number of affected body areas into account. In the modified Sartorius score 
the number of affected body sites contributes significantly to the final severity score.11 
However, a previous study did not demonstrate a difference in Sartorius score between 
patients with onset before the age of 16 (n=80), onset between 17-27 years (n=149) and 
onset after 28 years (n=67).11
We found that early-onset patients were more often nonsmokers or began smoking 
after the onset of HS, whereas most normal-onset patients had smoked before they 
developed symptoms. Possibly, early-onset patients were discouraged from starting to 
smoke because it could worsen HS.4
A limitation of our study is that the age of onset was based on patient-reported infor-
mation. Further, the cutoff point for early-onset disease was based on general pubertal 
age in the Netherlands.8 Establishing the pubertal status objectively for every individual 
patient would be preferable, but is not feasible in practice, because the “time to diag-
nosis” is notoriously long in HS.1,13 A third limitation is that the Hurley score was used to 
assess disease severity.
In conclusion, early-onset HS occurred in almost 8% of our HS patients, and was as-
sociated with a family history of HS in 56% and a more widespread disease. Patients 
with early-onset HS should be closely monitored and receive appropriate treatments. 
However, it remains to be determined whether early treatments prevent progression of 
HS.
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ABStrACt
Background: Few comprehensive studies exist on the epidemiology of hidradenitis 
suppurativa (HS), a very distressing skin disease.
objective: We sought to identify disease-related factors associated with severity, sex, 
and family history.
methods: Ordinal logistic regression was used in 846 consecutive Dutch patients with 
HS to calculate odds ratios (ORs) for severity according to Hurley. Sex and family history 
were compared using Student’s t-test and chi-square test.
results: In total, 45.5% of the patients had Hurley I, 41.5% had Hurley II, and 13.0% had 
Hurley III. Severity was associated with male sex (OR 2.11; P < 0.001), disease duration 
(OR 1.03; P < 0.001), body mass index (OR 1.03; P = 0.01), smoking pack-years (OR 1.02; 
P = 0.001), and axillary (OR 2.24; P < 0.001), perianal (OR 1.92; P < 0.001) and mammary le-
sions (OR 1.48; P = 0.03). Women had earlier onset, more inguinal and mammary lesions, 
and more frequent family history of HS. Men more commonly had gluteal, perianal and 
atypical lesions, and a history of severe acne. Patients with a family history had earlier 
onset, longer disease duration, a history of severe acne, more extensive disease, and 
were more often smokers.
limitations: Some parameters were patient-reported.
Conclusion: The severity risk factors identified in this study could help physicians to 
select patients who need close monitoring and who would benefit from early, aggres-
sive therapy.
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IntroDuCtIon
Hidradenitis suppurativa (HS) (or acne inversa) is a chronic inflammatory skin disease 
that presents with recurrent, painful deep-seated nodules or abscesses in the inverse 
areas of the body, usually the axillary, inguinal and anogenital regions.1 It is highly 
distressing and has a large impact on quality of life.2–4 Estimated prevalence rates in 
the Western world range between 1% and 4%.5 The disease generally develops in the 
early twenties.6,7 Disease-associated factors are female sex, a family history, cigarette 
smoking, and obesity.5,8,9
Because to its chronic and recurrent nature, HS is notoriously difficult to treat. Treat-
ment options include topical and systemic antibiotics as well as immunomodulating 
drugs such as anti-tumor necrosis factor alpha biologics. In addition, surgical excision 
with secondary healing is often necessary. Although wide surgical excision is considered 
to be the only curative option,10–13 it can have a major negative impact on patients with 
severe and extensive disease.
Because few comprehensive epidemiological studies have been conducted, it cannot 
be currently predicted which patients will progress to severe HS. We therefore used 
the disease characteristics of 846 patients with HS in The Netherlands to determine 
risk factors for HS severity. These factors might serve as a tool for identifying patients 
at risk for developing severe disease. In these patients, rapid and adequate treatment 
might prevent disease aggravation and reduce the future burden of this devastating 
disease. We also determined the differences in disease characteristics between males 
and females, and between positive and negative family histories. Greater knowledge of 
disease-specific characteristics would help physicians to better understand HS and to 
better inform their patients.
mEtHoDS
Between 2007 and 2013, we collected data from all consecutive patients with HS referred 
to three Dutch clinics with a special interest in HS: the Department of Dermatology 
at Erasmus Medical Center, Rotterdam; the Department of Dermatology at Deventer 
Hospital, Deventer; and the Department of Plastic Surgery at Diaconessenhuis, Leiden. 
The respective diagnoses of HS in these hospitals were made by one of the authors or 
Duco G. van den Broecke, MD, (Department of Plastic Surgery, Diaconessenhuis, Leiden, 
The Netherlands) on the basis of a patient’s history of HS symptoms, and of physical 
examination, as described by Revuz.1
Disease severity was staged according to Hurley.14 Hurley stage I is limited to single or 
multiple abscesses without sinus tracts or scarring. Stage II consists of widely separated 
Part I | Onset and clinical course of HS
48
single or multiple recurrent abscesses with sinus-tract formation and scarring. Hurley III 
is present when an entire area is diffusely involved with multiple interconnected tracts.
Patient characteristics were collected from medical files. A positive family history was 
assumed if patients reported first- or second-degree relatives with HS symptoms. Typical 
lesions in regions other than the predisposed HS regions were classified as atypical. The 
axillary, inguinal, femoral, perianal, genital, gluteal, abdominal, and mammary (i.e. mam-
mary and inframammary) regions were considered as predisposed HS regions. For this 
type of retrospective investigation, no medical ethical committee approval is required 
under Dutch law.
Statistical	analyses
First, we described the patient characteristics for the overall study population and for 
the individual Hurley stages. Second, to identify severity risk factors, we tested the 
patient characteristics for significant odds ratios (ORs) across the Hurley stages. Third, 
we compared the patients’ characteristics based on sex and family history. Patient char-
acteristics were presented using descriptive statistics with continuous data as mean ± 
standard deviation (SD) and categorical data as number (%). Severity risk factors were 
determined using univariable and multivariable ordinal logistic regression models.
These statistics were the most suitable, since the Hurley classification -the dependent 
variable- has more than two response categories that represent a rank order. The models 
also assume that predictors -the patient characteristics- are linearly related to the log 
odds of the Hurley stages. This was tested with a nonsignificant test of parallel lines, 
indicating that the odds are proportional.
Proportional ORs were obtained on the three levels of the Hurley stages, which should 
be interpreted as follows: a significant OR of 2 indicates that the odds of Hurley II and III 
combined versus Hurley I are twice as high for that factor. Likewise, the odds of Hurley 
III versus Hurley I and II combined are also twice as high. Patient characteristics for sex 
and a family history were compared using Student’s t-test for continuous data and chi-
square test for categorical data. For statistical analyses, we used SPSS Statistics 20 (IBM 
Corp, Armonk, NY). A two-sided P-value of less than 0.05 was considered statistically 
significant. For the categorical data, an OR of less than 5% (0.95-1.05) was interpreted as 
not clinically relevant.
rESultS
A total of 846 HS patients were seen, 410 at Erasmus Medical Center, 404 at Deventer 
Hospital, and 32 at Diaconessenhuis, and were included and analyzed (Table  I). The 
mean age was 38.0 ± 12.7 years, with a mean disease duration of 13.8 ± 11.0 years. The 
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table I. Patient characteristics
Hurley I
n=385 
(45.5%)
Hurley II
n=351 
(41.5%)
Hurley III
n=110 
(13.0%)
total
n=846
Sex, n (%)
- Female 310 (80.5) 245 (69.8) 59 (53.6) 614 (72.6)
- Male 75 (19.5) 106 (30.2) 51 (46.4) 232 (27.4)
Age of disease onset years, mean ± SD; n=839 24.2 ± 11.6 24.1 ± 11.0 24.5 ± 10.5 24.2 ± 11.2
Disease duration years, mean ± SD; n=839 11.2 ± 10.2 15.3 ± 10.9 18.1 ± 11.7 13.8 ± 11.0
BmI kg/m2, mean ± SD; n=813 27.6 ± 6.1 28.5 ± 5.9 28.9 ± 7.0 28.1 ± 6.1
BmI subgroups, n (%)a
- Normal weight 156 (41.4) 104 (31.1) 34 (33.7) 294 (36.2)
- Overweight 104 (27.6) 119 (35.5) 33 (32.6) 256 (31.5)
- Obese 117 (31.0) 112 (33.4) 34 (33.7) 263 (32.3)
- Unknown 8 16 9 33
Smoking status, n (%)
- Nonsmoker 72 (18.8) 42 (12.1) 13 (11.8) 127 (15.1)
- Current smoker 260 (67.9) 260 (74.7) 75 (68.2) 595 (70.7)
- Ex-smoker 51 (13.3) 46 (13.2) 22 (20.0) 119 (14.2)
- Unknown 2 3 - 5
Pack years (ex-)smokers, mean ± SD; n=665 15.5 ± 12.7 19.3 ± 13.2 27.9 ± 24.5 18.8 ± 15.6
Family history of HS, n (%)
- Yes 139 (37.3) 109 (33.1) 35 (36.5) 283 (35.5)
- Unknown 12 22 14 48
History of severe acne vulgaris, n (%)
- Yes 68 (23.1) 64 (26.3) 21 (24.4) 153 (24.6)
- Unknown 91 108 24 233
Co-occurrence of Dm, n (%)
- Yes 17 (5.2) 16 (5.8) 14 (16.1) 47 (6.8)
- Unknown 55 75 23 153
Affected regions, n (%)
- Axillary 201 (54.8) 241 (69.3) 90 (81.8) 541 (64.3)
- Inguinal 320 (83.6) 287 (82.5) 95 (86.4) 702 (83.5)
- Femoral 86 (22.5) 79 (23.0) 20 (18.5) 185 (22.2)
- Perianal 51 (13.3) 69 (19.8) 38 (34.5) 158 (18.8)
- Genital 97 (25.3) 99 (28.8) 31 (28.4) 227 (27.2)
- Gluteal 142 (37.1) 148 (42.5) 60 (54.5) 350 (41.6)
- Abdomen 52 (13.6) 65 (18.7) 25 (22.7) 142 (16.9)
- Mammary 61 (15.9) 90 (25.9) 24 (22.0) 175 (20.8)
- Atypical 48 (12.5) 54 (15.4) 23 (20.9) 125 (14.8)
- Unknown 2 7 2 11
BMI - body mass index; DM - diabetes mellitus; HS - hidradenitis suppurativa
a Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
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majority of patients were female (72.6%). Approximately one-third had a normal weight 
(36.2%), one third were overweight (31.5%) and another third were obese (32.3%). The 
overall body mass index (BMI) was 28.1 ± 6.1. A majority was current cigarette smokers 
(70.7%) or ex-cigarette smokers (14.2%); only 15.1% were nonsmokers. About one third 
(35.5%) reported a family history. The body regions most commonly affected were the 
inguinal (83.5%), axillary (64.3%) and gluteal (41.6%) regions. In a quarter of the patients, 
the genital, and femoral areas were involved, followed by the mammary, perianal and 
abdominal region. The least affected body regions were the atypical regions (14.8%). 
A history of severe acne was reported by 24.6% of the patients, and co-occurrence of 
diabetes mellitus (DM) by 6.8%.
The	strongest	severity	risk	factors	are	male	sex,	and	axillary	and	perianal	
involvement
Whereas 13.0% of the patients had Hurley III, the percentages with Hurley I (45.5%) and 
Hurley II (41.5%) were similar (Table  I). Table  II presents the outcomes of the ordinal 
logistic regression models. The majority of the study population was female, with a 
female:male ratio of 2.6:1. This ratio decreased from 4.1:1 in Hurley I, to 2.3:1 in Hurley 
II, and to 1.2:1 in Hurley III, indicating that males are more at risk for developing severe 
disease. This was confirmed by a significant proportional OR of 2.11 (P < 0.001).
Disease duration was longer in severe disease, increasing from 11.2 years in Hurley I, to 
15.3 years in Hurley II, and to 18.1 years in Hurley III, with a significant OR of 1.03 for each 
additional disease year (P < 0.001). BMI (Hurley I 27.6, Hurley II 28.5, and Hurley III 28.9) 
was identified as a severity risk factor, with an OR of 1.03 per BMI unit increase (P = 0.01).
As the calculated pack-years were higher in patients with more severe disease (15.5 
in Hurley I, 19.3 in Hurley II, and 27.9 in Hurley III), they were identified as a severity risk 
factor, with a significant OR of 1.02 per added pack year (P = 0.001). Fewer patients with 
Hurley I were current or ex-smokers (81.2%) than Hurley II (87.9%) and Hurley III (88.2%). 
In the univariable analysis, but not in the multivariable analysis, smoking status had 
significant ORs across the Hurley stages.
In severe disease, more body regions were affected. The percentage of patients with 
affected axillae increased the most, from 54.8% in Hurley I, to 69.3% in Hurley II, and to 
81.8% Hurley III, with a significant OR of 2.24 (P < 0.001). Two more body regions were 
associated with HS severity: the perianal region, with an OR of 1.92 (P < 0.001), and the 
mammary region, with an OR of 1.48 (P = 0.03). In the univariable analysis, but not in 
the multivariable analysis, the gluteal, abdominal and atypical areas had significant ORs 
across the Hurley stages.
Because there was no difference in mean age of disease onset (24.2 years in Hurley 
I, 24.1 years in Hurley II, and 24.5 years in Hurley III) and in having a family history of HS 
(37.3% Hurley I, 33.1% Hurley II, and 36.5% Hurley III), there was no significant difference 
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in the OR. Neither did a history of severe acne influence disease severity. A history of 
severe acne was reported by 26.3% of the patients with Hurley II, against 23.1% of Hurley 
I and 24.4% in Hurley III. At 16.1%, co-occurrence of DM was highest in Hurley III, decreas-
ing to 5.8% in Hurley II and 5.2% in Hurley I. The OR was significant in the univariable 
analysis (OR 2.25, P = 0.004) but not in the multivariable analysis.
table II. Risk factors for disease severity
model 1a univariable (n=846) multivariable (n=846)
or (95%CI) P-valuec or (95%CI) P-valuec
Sex, ref. female
- Male 2.28 (1.71-3.05) <0.001 2.11 (1.54-2.89) <0.001
Age of disease onset years 1.00 (0.99-1.01) 0.92 1.00 (0.98-1.01) 0.73
Disease duration years 1.04 (1.03-1.06) <0.001 1.03 (1.02-1.05) <0.001
BmI 1.03 (1.01-1.05) 0.01 1.03 (1.01-1.05) 0.01
Smoking status, ref. nonsmoker
- Current smoker 1.60 (1.10-2.33) 0.01 0.94 (0.60-1.47) 0.78
- Ex-smoker 1.86 (1.15-3.01) 0.01 1.14 (0.64-2.02) 0.66
Pack years 1.03 (1.02-1.04) <0.001 1.02 (1.01-1.03) 0.001
Family history of HS, ref. no 0.90 (0.68-1.18) 0.45 0.80 (0.58-1.09) 0.15
model 2b univariable (n=846) multivariable (n=846)
or (95%CI) P-valuec or (95%CI) P-valuec
History of severe acne vulgaris, ref. no 1.12 (0.80-1.58) 0.52 1.09 (0.74-1.59) 0.67
Co-occurrence of Dm, ref. no 2.25 (1.29-3.93) 0.004 1.43 (0.77-2.68) 0 .26
Body region affected, ref. region not affected
- Axillary 2.24 (1.70-2.96) <0.001 2.24 (1.63-3.08) <0.001
- Inguinal 1.05 (0.74-1.48) 0.80 1.05 (0.70-1.57) 0.81
- Femoral 0.92 (0.68-1.26) 0.62 0.90 (0.64-1.27) 0.56
- Perianal 2.21 (1.59-3.08) <0.001 1.92 (1.34-2.76) <0.001
- Genital 1.16 (0.87-1.55) 0.31 0.99 (0.72-1.36) 0.93
- Gluteal 1.50 (1.16-1.95) 0.002 1.19 (0.88-1.60) 0.26
- Abdominal 1.55 (1.11-2.19) 0.01 1.28 (0.86-1.89) 0.22
- Mammary 1.54 (1.12-2.10) 0.01 1.48 (1.03-2.11) 0.03
- Atypical 1.47 (1.03-2.10) 0.04 1.25 (0.85-1.84) 0.25
BMI - body mass index; CI - confidence interval; DM - diabetes mellitus; HS - hidradenitis suppurativa; OR - odds ratio;
 ref. - reference category
a Ordinal logistic regression analyses with the Hurley stages as dependent variable: univariable model, unadjusted; and 
multivariable model, adjusted for factors and covariates in model.
b Ordinal logistic regression analyses with the Hurley stages as dependent variable: univariable model, unadjusted; and 
multivariable model, adjusted for statistically significant factors and covariates of the multivariable model 1.
c P-value of ordinal logistic regression analyses.
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table III. Patient characteristics by sex
Female
614 (72.6%)
male
232 (27.4%)
P-valuea
Age of disease onset years, mean ± SD; n=839 23.5 ± 10.8 26.2 ± 12.1 0.003
Disease duration years, mean ± SD; n=839 13.9 ± 10.5 13.4 ± 12.2 0.61
BmI kg/m2, mean ± SD; n=813 28.1 ± 6.3 28.0 ± 5.8 0.79
BmI subgroups, n (%)b 0.24
- Normal weight 217 (36.8) 77 (34.5)
- Overweight 174 (29.5) 82 (36.8)
- Obese 199 (33.7) 64 (28.7)
- Unknown 24 9
Smoking status, n (%) 0.08
- Nonsmoker 103 (16.9) 24 (10.4)
- Current smoker 427 (70.0) 168 (72.7)
- Ex-smoker 80 (13.1) 39 (16.9)
- Unknown 4 1
Pack years (ex-)smokers, mean ± SD; n=665 17.9 ± 13.8 21.1 ± 19.1 0.03
Family history of HS, n (%)
- Yes 223 (38.4) 60 (27.6) 0.02
- Unknown 33 15
History of severe acne vulgaris, n (%)
- Yes 77 (17.6) 76 (40.9) <0.001
- Unknown 177 46
Co-occurrence of Dm, n (%)
- Yes 33 (6.7) 14 (7.1) 0.37
- Unknown 118 35
Affected regions, n (%)
- Axillary 385 (63.2) 156 (67.2) 0.21
- Inguinal 536 (88.0) 166 (71.6) <0.001
- Femoral 125 (20.7) 60 (26.1) 0.19
- Perianal 91 (14.9) 67 (28.9) <0.001
- Genital 173 (28.6) 54 (23.4) 0.15
- Gluteal 234 (38.4) 116 (50.0) 0.004
- Abdomen 101 (16.6) 41 (17.7) 0.36
- Mammary 148 (24.3) 27 (11.7) <0.001
- Atypical 71 (11.6) 54 (23.3) <0.001
- Unknown 9 2
BMI - body mass index; DM - diabetes mellitus; HS - hidradenitis suppurativa
a P-value of Student’s t-test for continuous and chi-square test for categorical data
b Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
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Females	develop	HS	at	an	earlier	age	and	inguinal	and	mammary	regions	are	
more	frequently	involved
The patient characteristics by sex are presented in Table III. In general, HS is more com-
mon in females than in males (72.6% vs 27.4%). Mean age of disease onset was lower in 
women than in men (23.5 vs 26.2 years; P = 0.003). More females reported a family history 
of HS (38.4% vs 27.6%; P = 0.02) and a lower percentage reported a history of severe acne 
(17.6% vs 40.9%; P < 0.001). Although a higher percentage of women were nonsmokers 
(16.9% vs 10.4%; P = 0.08), this was not significant. Females, however, did have fewer 
pack-years than male patients (17.9 vs 21.1 pack-years; P = 0.03). BMI and co-occurrence 
of DM did not differ significantly. The predisposed areas for females were the inguinal 
region (88.0% vs 71.6%; P < 0.001), and mammary region (24.3% vs 11.7%; P < 0.001). Men 
more commonly had lesions in the gluteal (50.0% vs 38.4%; P = 0.004), perianal (28.9% 
vs 14.9%; P < 0.001) and atypical (23.3% vs 11.6%; P < 0.001) regions.
A	positive	family	history	leads	to	an	earlier	disease	onset	and	more	extensive	
disease,	but	not	to	more	severe	disease
Patients with a family history of HS (Table IV) were more often females (78.8% vs 69.5%; 
P = 0.02), had a lower mean age of disease onset (20.2 vs 26.2 years; P < 0.001), and had 
a longer disease duration (16.3 vs 12.4 years; P < 0.001). Fewer of them were nonsmokers 
(12.7% vs 17.0%; P = 0.01). Although a significantly higher percentage of patients with a 
family history reported a history of severe acne (28.6% vs 21.5%; P < 0.001), co-occurrence 
of DM was less common (5.4% vs 7.5%; P < 0.001). Except for the genital and atypical 
regions, all other areas were affected more frequently in patients with a family history 
(P < 0.001 - P = 0.003).
DISCuSSIon
This analysis of 846 HS patients in The Netherlands determined five severity risk fac-
tors: male sex, obesity, smoking pack-years, disease duration, and lesions in the axillary, 
perianal and mammary regions.
Our finding of a higher risk of severe disease in males was previously suggested by 
Matusiak et al.15 in 54 patients with HS, and more recently by Vazquez et al.16 in 268 
patients with HS. The outcome that obesity (measured as BMI) is a severity risk factor 
was in accordance with the results presented by Sartorius et al.7 in 115 patients with HS, 
and with those presented by Canoui-Poitrine et al.6 in 302 patients with HS. But while 
Vazquez et al.16 and Sartorius et al.7 also found that severe HS is associated with cigarette 
smoking in general, our results suggest that this is not the case. We found that smok-
ing pack-years, in which the number of cigarettes and duration of smoking are taken 
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table IV. Patient characteristics by family history of hidradenitis suppurativa
Family history
of HS
283 (35.5%)
no family history
of HS
515 (64.5%)
P-valuea
Sex, n (%) 0.02
- Female 223 (78.8) 358 (69.5)
- Male 60 (21.2) 157 (30.5)
Age of disease onset years, mean ± SD; n=793 20.2 ± 8.8 26.2 ± 11.9 <0.001
Disease duration years, mean ± SD; n=793 16.3 ± 11.2 12.4 ± 10.6 <0.001
BmI kg/m2, mean ± SD; n=769 28.4 ± 6.6 28.1 ± 5.9 0.51
BmI subgroups, n (%)b 0.06
- Normal weight 103 (37.3) 170 (34.5)
- Overweight 74 (26.8) 168 (34.1)
- Obese 99 (35.9) 155 (31.4)
- Unknown 7 22
Smoking status, n (%) 0.01
- Nonsmoker 36 (12.7) 87 (17.0)
- Current smoker 207 (73.1) 345 (67.5)
- Ex-smoker 40 (14.1) 79 (15.5)
- Unknown - 4
Pack years (ex-)smokers, mean ± SD; n=570 18.0 ± 13.6 19.1 ± 16.7 0.40
History of severe acne vulgaris, n (%)
- Yes 68 (28.6) 81 (21.5) <0.001
- Unknown 45 139
Co-occurrence of Dm, n (%)
- Yes 14 (5.4) 32 (7.5) <0.001
- Unknown 25 91
Affected regions, n (%)
- Axillary 199 (70.3) 323 (63.1) <0.001
- Inguinal 258 (91.2) 408 (79.7) <0.001
- Femoral 73 (25.9) 110 (21.7)  0.003
- Perianal 69 (24.4) 87 (17.0) <0.001
- Genital 77 (27.3) 135 (26.6) 0.18
- Gluteal 151 (53.4) 187 (36.5) <0.001
- Abdomen 62 (21.9) 76 (14.8) <0.001
- Mammary 69 (24.4) 104 (20.3) <0.001
- Atypical 44 (15.5) 77 (15.0) 0.06
- Unknown 1 8
BMI - body mass index; DM - diabetes mellitus; HS - hidradenitis suppurativa.
a P-value of Student t-test for continuous and chi-square test for categorical data.
b Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
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into account, were of influence on disease severity. Although, among other factors, 
smoking pack-years were adjusted for disease duration in the multivariable analysis, a 
higher number of pack-years can only accumulate over time. As a severity risk factor 
that has never been reported, we identified longer disease duration. These two factors, 
smoking pack-years and longer disease duration, both suggest that time is a substantial 
factor in the development of severe HS. The final severity risk factor that we identified 
was disease involvement of the axillary, perianal and mammary regions. Although the 
axillary and inguinal were most commonly affected, involvement of the axillary region 
only increased significantly in more severe disease. This supports axillary involvement 
as a severity risk factor. The only body sites previously reported to be associated with 
disease severity were the atypical locations.6 Furthermore, our study did not confirm the 
previously suggested relation between a history of severe acne and severe HS.7
In general, HS is associated with female sex.5 Our finding that 72.6% of patients with HS 
were female is consistent with previous estimates, which ranged from 70.5% to 86%.6–8,16 
In addition, our results not only suggest that males have more severe disease, but also 
that HS manifests earlier in females, that females more often report a family history, 
that more males have a history of severe acne, and that different body regions were 
involved in males than in females. Men had more lesions in the gluteal, perianal, and 
atypical regions, and women had more lesions in the inguinal, and mammary areas. This 
is in agreement with Canoui-Poitrine et al.6 who stated that “the front part of the body 
was predominantly involved in female patients, whereas involvement of the back of the 
body was a hallmark of male patients. “Although predisposition of females for the mam-
mary region can be expected, involvement of this region was not uncommon in males.
There is currently a lively discussion on whether or not there is a genetic predisposi-
tion to HS. In our study, a family history of HS was reported in more than a third of our 
patients, which is similar to the percentages of 35.5% and 38% described.6,7 Previously, it 
was only reported that earlier disease onset was associated with a family history of HS.6 
Our results add that, in patients with a family history of HS, the disease developed earlier 
and lasted longer, more patients were female, were smokers or ex-smokers, a higher 
percentage had severe acne, and almost all body areas were affected more often.
Our finding that 13.0% of the patients had Hurley III is higher than previously reported 
in a hospital setting (3.9%)6 and population-based (2.2%),16 but lower than in patients 
qualifying for surgical intervention (22.2%).15 The most likely explanation for this is that 
our clinics are mainly tertiary referral centers. The rates we observed of 45.5% Hurley I, 
and 41.5% Hurley II lie in the percentages reported in previous studies, which ranged 
from 24.1% to 68.2% for Hurley I and 27.6% to 53.7% for Hurley II.6,15,16
To our knowledge, this study represents the largest HS population studied to date. 
Only experienced physicians classified disease severity in all patients according to 
Hurley. Because the study population comprised a substantial number of patients with 
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severe disease, it enabled us to use tailored statistics to identify severity risk factors. A 
limitation of the study is that part of the data was self-reported (age of disease onset, 
family history, co-occurrence of DM, history of severe acne, and smoking status).
In conclusion, while we have demonstrated that HS severity is associated with male 
sex, obesity, smoking pack-years, disease duration, and involvement of axillary, perianal 
and mammary regions, it is not associated with age of disease onset, a family history 
of HS, history of severe acne, or co-occurrence of DM. These severity risk factors could 
serve as a tool to identify young patients with HS at risk, and should alert the physician 
to the need to monitor these patients closely and to start earlier with aggressive surgery 
or pharmaceutical therapies.
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ABStrACt
Background: Hidradenitis suppurativa (HS) causes considerable morbidity. The long-
term prognosis is of obvious interest to both patients and physicians. We conducted this 
study to determine the prognosis and risk factors in patients diagnosed with HS.
objective: To describe the long-term prognosis and the clinical course of HS and its 
association to known risk factors.
methods: A postal follow-up survey with uncomplicated factual questions was con-
ducted. As all the patients were well acquainted with their long-standing disease, this 
was thought to be sufficient for meaningful results. All cases were diagnosed by a der-
matologist. Overall, 212 patients diagnosed with HS between 1981 and 2001 were studied 
after a median follow-up period of 22 years (range 12-32).
results: The overall response rate was 71.2%, with 60.8% (129/212) valid (fully completed) 
questionnaires. Remission was reported by 39.4% (50/127) and improvement by 31.5% 
(40/127). Unchanged severity was reported by 20.5% (26/127) and 8.7% (11/127) experi-
enced disease worsening. Tobacco smoking was reported by 92.2% (119/129). Among 
nonsmokers, 48.5% (33/68) reported remission versus 28.8% (17/59) of active smokers. A 
higher proportion of nonobese patients (44.8%, 43/96) reported remission than obese 
patients (22.6%, 7/31).
Conclusions: We found that 39.4% of the sample reported remission of HS. Suspected 
risk factors appeared to influence the prognosis. Smoking and obesity were significantly 
linked to a lower rate of self-reported remission. The notion that lifestyle factors play a 
role in HS appears to be supported by this survey.
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IntroDuCtIon
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurring, debilitating skin 
disease of the hair follicles. It usually presents after puberty with painful, deep-seated, 
inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the 
axillary, inguinal and anogenital regions (Dessau definition, first International Confer-
ence on Hidradenitis Suppurativa/Acne Inversa, 30 March to 1 April 2006, Dessau, 
Germany).1,2 It follows from this definition that HS is likely to have a major impact on the 
lives of patients, a suggestion that is supported by the therapeutic challenges presented 
by HS. Encouragingly, therapy is currently attracting renewed attention owing to new 
treatment opportunities.3 Data on the prognosis or the natural evolution of the disease 
are nevertheless of great interest to all those involved.
Although long-term follow-up is common for malignant skin disease,4 knowledge of 
the natural course of most benign dermatological diseases remains sporadic, and the 
prognosis of only a few diseases has been systematically explored.5–8 Knowledge about 
the natural course of HS is limited to sporadic accounts and a paper from von der Werth 
and Williams.9 Their study was based on patients undergoing treatment at the Depart-
ment of Dermatology in Nottingham, U.K., and revealed interesting data regarding age 
of onset, disease duration, possible remission, family history, aggravating factors and 
the effects of menstrual cycle and menopause on women with HS.9
Subsequently, obesity and tobacco smoking have been identified as additional risk 
factors.10–14 Both factors have been linked to clinical disease severity,15 and it has been 
suggested that weight reduction in the obese may ameliorate HS.16,17 It has furthermore 
been implied that HS symptoms ameliorate spontaneously with age,9 and that some 
patients can become disease-free over time.18 However, data are limited.
We have therefore conducted a long-term follow-up of patients diagnosed with HS, 
but not necessarily subsequently treated at our institutions, in order to describe the 
clinical course of HS in greater detail.
PAtIEntS AnD mEtHoDS
Study	design
A postal questionnaire based long-term follow-up study with simple factual questions 
was conducted, partly of retrospective character and partly of current relevance. All 
patients were initially diagnosed by a dermatologist, and the clear symptomatology 
and long experience of the patients polled was thought to provide data of acceptable 
quality. To increase response rates, nonrespondents were either sent reminders by mail 
of telephoned.
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Participants
Eligible patients (n=212) in two cohorts were identified: one Danish (n=141) and one 
Dutch (n=79). Patients were diagnosed with HS between 1981 and 2001, and identified 
through medical records. Patients were excluded when contact information was not 
available (n=7) or if they had died (n=13). Current contact details were retrieved in the 
host countries’ social security number systems, or the addresses were looked up in medi-
cal records and cross-checked with public telephone books. There were 26 male and 
186 female patients in the combined cohort (12.3% male), and the mean age was 52.1 
years [95% confidence interval (CI) 50.8-53.2] at follow-up. The follow-up period was 12-32 
years, with a median of 22 years.
Eligibility	criteria	and	questionnaire
Patients were eligible if they had been diagnosed with HS by a qualified dermatolo-
gist and had a diagnosis recorded in their medical records. A seven-page, 43-question 
questionnaire was mailed to the 212 eligible participants, with a paid-postage return 
envelope enclosed. Questions regarding primary outcome measures such as develop-
ment of disease, smoking, weight/height and family history were considered central. 
Questionnaires were counted as complete when 80% of central questions and 50% of 
other questions were answered. HS has easily identifiable symptoms, and patients who 
were diagnosed with HS by a dermatologist were considered able to answer simple and 
factual questions regarding the evolution of their disease.19 A medical language expert 
and back translation was used ensuring the best possible conformity in the question-
naire in English, Danish and Dutch. No ethical approval for this study was necessary 
according Danish and Dutch law regarding the questionnaire. All data were anonymized 
before analysis.
Outcome	measures
The outcome measures were basic data regarding remission, factors associated with 
remission and known risk factors. Self-reported remission (i.e. no inflammatory boils 
the last 6 months) was considered the primary endpoint, and used in comparisons 
where possible. Regarding prognostic factors we chose dichotomous categorical mea-
sures: active smoking versus nonsmoking, obesity [body mass index (BMI) > 30] versus 
nonobesity and family history versus no family history. The obesity versus nonobesity 
categorization was based on our recent study of morbidly obese experiencing ameliora-
tion of HS due to weight loss after bariatric surgery.16
Statistics
Unless otherwise noted, all statistic calculations were performed using SPSS Statistics 
version 20 (IBM, Armonk, NY, U.S.A.) for Mac OS X. Results are presented as a percentage, 
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or as a mean with a 95% CI or standard deviation (SD) where relevant. Comparing means 
was done assuming normal distribution where acceptable (n≈50) and using relevant 
parametric tests (t-test or ANOVA). Regarding prognostic factors for remission, multi-
variate analysis was done by logistic regression. With remission as the dependent, we 
controlled for categorical factors (active smoking, obesity, sex and familial disposition 
for HS) and age as a continuous variable. Point prevalence for the samples are reported 
with 95% CIs. Rates were compared using chi-square test using 2 x 2 cross tabulation 
if possible. In all comparisons P < 0.05 was considered significant. Effect size (ES) was 
calculated by hand as bias-corrected (Hedges) Cohen’s d, and was reported as either 
small, medium or large according to Hojat and Xu.20
rESultS
There was a response from 71.4% of the patients, yielding 60.8% (129/212) complete 
questionnaires. Incomplete questionnaires were scrutinized and excluded if found to 
be < 50% complete. The nonrespondents (28.8%) and participants denying ever having 
had a diagnosis of HS (10.4%) amounted to 39.2% (83/212). No differences were found 
between the Danish and Dutch cohorts for basic characteristics such as age or sex.
Among the valid respondents (n=129) there were 13 men and 116 women (10.1% male). 
Respondents were aged 30-86 years (mean 53.7 years, 95% CI 52.3-55.3) (Table  I). Their 
BMI ranged from 18.3 to 48.0 kg/m2 (mean 27.0, 95% CI 26.1-27.9). The year of diagnosis 
was in the range 1981-2001 and median was 1990; hence, the shortest follow-up period 
was 12 years, the longest period was 32 years and the median and average follow-up 
period was 22 years. Generally, nonrespondents were younger than respondents, with a 
mean age of 49.4 years (95% CI 47.6-51.4). In comparison with responders the mean dif-
ference of 4.3 years was significant (P = 0.001); however, the ES was only small to medium 
(ES 0.4). The male-to-female ratio was 13:70 (16% male) (Table I). There was no significant 
difference in this ratio compared with responders.
table I. Respondent versus nonrespondent characteristics
respondents nonrespondents whole cohort
Number of patients (%) 129 (60.8) 83 (39.2) 212 (100)
Age years, mean (95% CI) 53.7 (52.3-55.3) 49.4 (47.6-51.4) 52.1 (50.8-53.2)
male, n (%) 13 (10.1) 13 (15.7) 26 (12.3)
Female, n (%) 116 (89.9) 70 (84.3) 186 (87.7)
CI - confidence interval
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Disease	characteristics	in	respondents
In the cohort, 38.0% of patients (49/129) had a family history of HS defined as an affected 
first- or second-degree relative. Approximately two-fifths of respondents (41.9%, 54/129) 
indicated no familial disposition to HS, and 20.2% (26/129) registered their familial dis-
position as unknown. Symptomatic lesions were most frequently located in the groin 
(47.2%, 60/127) or genital area (29.9%, 38/127). Lesions in axillae were reported by 25.6% 
of patients (32/125) and inframammary lesions by 12.0% (15/125). More than one-third of 
the sample (33.9%, 43/127) had more than one affected region. Scarring was reported by 
77.9% (67/86) of the respondents.
In describing the development of their disease, remission was reported by 39.4% of 
patients (50/127) and improvement by 31.5% (40/127). Only 20.5% (26/127) considered 
their disease severity to be unchanged, and 8.7% (11/127) indicated that their disease 
had worsened over time. Patients reporting remission were generally older; their mean 
age of achieving remission was 55.8 years (95% CI 53.4-58.3). Patients who reported ac-
tive disease had a mean age of 52.4 years (95% CI 50.3-54.5). The mean difference -3.5 
years (P = 0.036, ES 0.4). In general, once a region was affected it remained so. This was 
reported by 64.1% (66/103) of patients, whereas 33.0% (34/103) experienced activity in 
both established and new locations. Only 2.9% (three of 103) experienced total reso-
lution in one location and activity in a new location. Within the group of participants 
reporting cessation of disease activity (39.4%, 50/127), the age of disease resolution was 
23-69 years, with a mean of 41.8 years (95% CI 38.7-45.0). Among patients indicating that 
they still suffered from active HS, 43.8% (32/73) reported symptoms a few times a year; 
31.5% (23/73) monthly symptoms, 4.1% (three of 73) symptoms every week and 20.6% 
(15/73) continuous activity.
The	effect	of	pregnancy	and	menopause
The majority of women (71.8%, 61/85) reported no effect of pregnancy on their HS, while 
20.0% (17/85) indicated amelioration and 8.2% (seven of 85) deterioration. Considering 
the influence of menopause on disease evolution, the majority of women (47.5%, 29/61) 
reported that menopause attenuated their symptoms. Some 37.7% (23/61) felt no dif-
ference after menopause and 14.8% (9/61) indicated worsening of their HS following 
menopause.
Risk	factors	and	comorbidities
The lifelong incidence of tobacco smoking was 92.2% (119/129). In this sample 45.7% 
(59/129) were still active smokers, whereas 46.5% (60/129) reported having stopped 
smoking and 7.8% (10/129) had never smoked. The most prevalent self-reported comor-
bidities were hypertension, acne and diabetes; however, the sample generally had a 
high prevalence of comorbidities, which are listed in Table II.
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Treatment
A majority (61.0%, 64/105) had used systemic antibiotics, and fewer (46.9%, 45/96) had 
been treated with topical antibiotics. A majority (77.2%, 95/123) also indicated that they 
had been treated with incision, whereas treatment with excision or deroofing had been 
used in 55.8% (63/113) or 57.7% (64/111), respectively.
Prognostic	factors
Looking at the association between smoking and development of disease, 48.5% (33/68) 
of former smokers or nonsmokers were disease-free, whereas only 28.8% (17/59) of the 
active smokers achieved remission (Figure 1). Approximately two-thirds (66.0%, 33/50) 
who reported remission of the disease were nonsmokers, whereas 34.0% were active 
smokers (17/50). The odds ratio (OR) for self-reported remission in nonsmoking partici-
pants was 2.8 (95% CI 1.3-6.3; P = 0.012). The association between obesity and evolution 
of disease is illustrated in Figure 2. Nonobese participants had an OR for remission of 
3.9 (95% CI 1.4-11.0). HS remission was reported by 48.1% (26/54) of those not describing 
familial disposition, whereas 32.7% (16/49) of patients with a known first-degree relative 
with HS indicated remission of the disease (Figure 3). For participants with no known fa-
milial disposition, the OR for remission was nonsignificant (OR 0.6, 95% CI 0.3-1.4). When 
controlling for age, smoking and obesity the OR was 0.95 (95% CI 0.91-1.00; P = 0.03). 
However, the OR is only slightly smaller than 1. Sex was not associated with remission 
(OR 3.7, 95% CI 0.9-14.3; P = 0.62).
table II. Self-reported prevalence of comorbidities in sample
total cohort,
x/na (%)
Age,
mean ± SD
male,
x/na (%)
Female,
x/na (%)
BmI,
mean ± SD
Hypertension 35/126 (27.8) 58.7 ± 8.8 3/13 (23) 32/113 (28) 28.5 ± 6.0
Facial acne 30/126 (23.8) 52.2 ± 9.5 6/12 (50) 24/114 (21) 26.6 ± 6.3
Diabetes mellitus 23/124 (18.5) 60.7 ± 8.9 3/11 (27) 20/113 (18) 31.0 ± 6.6
Sinus pilonidalis 21/123 (17.1) 50.4 ± 10.1 2/10 (20) 19/113 (17) 27.8 ± 7.6
Rheumatoid arthritis 16/124 (13.2) 57.4 ± 8.5 1/11 (9) 15/110 (14) 30.1 ± 7.5
Thyroid disease 16/127 (12.6) 52.6 ± 7.9 1/13 (8) 15/114 (13) 27.4 ± 6.1
Asthma/COLD 15/126 (11.9) 57.4 ± 7.2 2/13 (15) 13/113 (12) 26.7 ± 7.1
Acne back scarring 14/123 (11.4) 50.9 ± 10.9 4/12 (33) 10/111 (9) 27.9 ± 7.5
Inflammatory bowel disease 6/121 (5.0) 53.0 ± 9.2 0/9 (0) 6/112 (5) 26.5 ± 6.4
Stroke 3/126 (2.4) 46.7 ± 3.5 1/13(8) 2/113 (2) 23.3 ± 6.6
COLD - chronic obstructive lung disease; n - number; SD - standard deviation; x - patients with the disease
a Some participants left fields blank resulting in the slight variation in n
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Figure 1. Association between active smoking and active hidradenitis suppurativa.
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Figure 2. Association between body mass index (BMI) > 30 and active hidradenitis suppurativa.
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Figure 3. Association between family history of hidradenitis suppurativa and active disease.
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DISCuSSIon
The long-term evolution or prognosis of any disease is of interest not only to patients, 
but also to the treating physicians, yet for most diseases data beyond a 5-year horizon 
are scarce. We have therefore reported results regarding the course of HS after a mean 
follow-up of 22 years. We found that 39.4% of the sample reported remission of HS 
during this period. Previously suspected risk factors appeared to influence the chance 
of remission, as a majority of patients reporting remission also indicated that they had 
stopped smoking or had never smoked. We have previously shown that a 15% weight 
reduction in patients with BMI > 30 ameliorates HS.16 Similarly, nonobesity was signifi-
cantly linked to a higher rate of self-reported remission. Thus, the notion that lifestyle 
factors (i.e. nonsmoking and nonobesity) play a role in the development of many cases 
of HS appears to be supported by this survey. However, heredity may also play a role, 
as a familial disposition appeared to reduce the likelihood of remission, indicating that 
genetics may also be an important etiological factor.
The role of tobacco smoking with regard to HS is subject of much speculations. König 
et al. suggested smoking as the triggering factor, but indicated no specific mechanism.13 
In agreement with previous reports, in this study we found that > 90% of those who 
responded to our survey were active or former smokers. In earlier studies smoking has 
been reported at rates of 70-90% in populations of patients with HS.13,18,21 Yet data on 
the possible beneficial effects of smoking cessation are rare. One study of de novo oc-
currence rates following surgery reported fewer or no new lesions following HS surgery 
when combined with smoking cessation.21
Kurzen et al. presented a host of potential mechanisms of cigarette smoking in the 
pathogenesis of HS.2 These include the selectively inhibitory effect of alkaloids on micro-
organisms, with the exception of Staphylococcus aureus. Alkaloids appear to be able to 
trigger positive feedback promoting growth and proliferation of S. aureus, thus chang-
ing the microbiome. This possible mechanism is contradicted by the low prevalence of 
S. aureus found in HS lesions, although the preclinical evolution before symptoms occur 
may play a role. The prolonged secretion of nicotine in sweat is also mentioned as a 
possible cause. The effects of nicotine include epidermal hyperplasia, release of tumor 
necrosis factor alpha promotion of follicular occlusion and reduced macrophage and 
lymphocyte activity.2 Tobacco smoke also contains polyaromatic carbohydrates, which 
may play a role in the development of HS.22
 Our findings therefore lend support to the importance of tobacco in the etiology of 
HS. Surveys of disease severity have previously indicated a positive correlation between 
disease severity and smoking.10 The present survey indicates that the chance of remis-
sion may be greater in those who stop smoking. This effect was most conspicuous for 
patients of normal weight, but a similar trend was noticed even in overweight patients.
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Obesity is another possible risk factor. The supporting data consists of surveys of 
patients from many populations, as well as a positive correlation between BMI and 
disease severity.10 In contrast to tobacco smoking, some evidence of a more dynamic 
association between BMI and HS has been published.16 Data therefore exist to suggest 
that obesity is linked to the likelihood of developing HS and the severity of HS, and 
that weight reduction may improve HS.16 The proposed underlying mechanisms include 
local factors on the surface of the skin due to the warm and humid milieu in the skin 
folds of obese patients, as well as shear forces from clothes and skin-skin contact.15,16 
More general factors such as the association between obesity and chronic low-grade 
inflammation may also be involved.22
Although statistically not significant, the genetic predisposition of patients may 
influence the prognosis of HS. Familial disposition to HS is commonly accepted, with 
approximately one-third of patients listing a positive family history of HS. Furthermore, 
some researchers have described an autosomal dominant inheritance pattern with a 
variable penetrance.23,24 The molecular genetics of HS have been a topic of interest 
since the seminal identification of candidate genes by Wang et al. in 2010.25 The authors 
reported mutations of genes regulating the transmembrane protein, γ-secretase. In 
some families loss-of-function mutations in γ-secretase seem to predispose for HS-like 
lesions.25 Miskinyte et al. also reported associated mutations in the γ-secretase stabiliz-
ing protein nicastrin.26 In contrast, Pink et al. were only able to find these mutations in a 
minority of the patients studied.27
This survey indicates a trend towards a lower chance of remission in those patients 
who report HS in a first- or second-degree relative compared with patients with no fam-
ily history. This may imply the importance of genetic factors in a subgroup of patients. 
Confounders such as smoking or obesity did not explain the findings, and patients 
indicating no family history of HS appeared to be more overweight and smoke more, 
supporting the suggestion that different subpopulations of HS may exist.28
The validity of these observations obviously requires discussion. A postal question-
naire does not have the same reliability as a physical examination, yet it is suggested 
that the validity of self-reported disease evolution in a long-standing disease with such 
clear symptoms as HS may provide useful results. It is further hypothesized that the 
stringent inclusion criteria may have improved the validity of the observations. The ini-
tial diagnosis of HS was based on a physical examination by a dermatologist, and most 
of the patients had a disease sufficiently severe to warrant not only specialist referral, 
but also outpatient management at a hospital over a period of time, indicating a high 
likelihood that they were well acquainted with their disease.
The validity of results in this study is further supported by good response rates after 
a long follow-up period.29 The fact that the patients in this study were similar, although 
recruited from two different countries, also supports the soundness of the observations, 
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as does the patient characteristics, which appear similar to those previously reported 
by von der Werth and Williams.9 The follow-up period in this study is longer and the 
age span among participants is wider, indicating that the results are more likely to be 
representative with regard to the full course of the disease. The results are also in agree-
ment with some of the proposed associations reported in recent literature indicating a 
possible link to the pathogenesis of the disease.
The response rate in our study is comparable with that in similar studies.18,29,30 Response 
bias must nevertheless be considered, as it is generally accepted that persons with a 
particular symptom or condition are more likely to participate in studies related to that 
symptom or condition because of the relevance of the study to their lives.29 Accordingly, 
the response rate to a HS-oriented questionnaire is likely to be higher in a group that 
feels affected by HS symptoms, thus potentially overestimating the prevalence of active 
disease and underestimating the rate of remission in this sample.
The sample shows large heterogeneity regarding age and follow-up period. It does 
not describe the entire lifespan or even duration of disease for every patient. We there-
fore cannot know whether patients with full remission will experience recurrences in the 
future or whether the patients who had only 12 years follow-up will achieve remission. 
Also, as we rely on self-reported outcomes for follow-up, uncertainties or imprecisions 
are likely. We have therefore interpreted the data conservatively.
Part I | Onset and clinical course of HS
70
rEFErEnCES
1  Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366: 158–164.
2  Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? Exp Dermatol 2008; 
17: 455–456.
3  Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidrad-
enitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846–855.
4  Iorio ML, Ter Louw RP, Kauffman CL, Davison SP. Evidence-based medicine: facial skin malignancy. 
Plast Reconstr Surg 2013; 132: 1631–1643.
5  Dahl M V. Granuloma annulare: long-term follow-up. Arch Dermatol 2007; 143: 945–955.
6  Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am 
Acad Dermatol 2006; 55: 438–441.
7  Gelmetti C, Rigoni C, Alessi E, et al. Pityriasis lichenoides in children: a long-term follow-up of 
eighty-nine cases. J Am Acad Dermatol 1990; 23: 473–478.
8  Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of the nails: Treatment and long‐term 
follow‐up of 46 patients. Br J Dermatol 2001; 144: 1000–1005.
9  Von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol 
Venereol 2000; 14: 389–392.
10  Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of hidradenitis suppurativa reflect-
ing the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831–839.
11  Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome 
in patients with acne inversa. PLoS One 2012; 7: e31810.
12  Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated fac-
tors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133: 97–103.
13  König A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis 
suppurativa. Dermatology 1999; 198: 261–264.
14  Cesko E, Körber A, Dissemond J. Smoking and obesity are associated factors in acne inversa: results 
of a retrospective investigation in 100 patients. Eur J Dermatol 2009; 19: 490–493.
15  Deckers IE, van der Zee HH, Prens EP. Epidemiology of Hidradenitis Suppurativa: Prevalence, Patho-
genesis, and Factors Associated with the Development of HS. Curr Dermatol Rep 2014; 3: 54–60.
16  Kromann C, Ibler KS, Kristiansen V, Jemec GB. The influence of body weight on the prevalence and 
severity of hidradenitis suppurativa. Acta Derm Venereol 2014; 94: 553–557.
17  Thomas CL, Gordon KD, Mortimer PS. Rapid resolution of hidradenitis suppurativa after bariatric 
surgical intervention. Clin Exp Dermatol 2014; 39: 315–318.
18  Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis 
suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596–601.
19  Esmann S, Dufour DN, Jemec GBE. Questionnaire-based diagnosis of hidradenitis suppurativa: 
specificity, sensitivity and positive predictive value of specific diagnostic questions. Br J Dermatol 
2010; 163: 102–106.
Risk factors, clinical course and long-term prognosis | Chapter 4
71
4
20  Hojat M, Xu G. A visitor’s guide to effect sizes–statistical significance versus practical (clinical) 
importance of research findings. Adv Heal Sci Educ Theory Pract 2004; 9: 241–249.
21  Kurzen H, Schönfelder-Funcke S, Hartschuh W. [Surgical treatment of acne inversa at the university 
of Heidelberg]. Coloproctology 2000; 22: 76–80 (in German).
22  van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical pheno-
typing, pathogenesis and novel treatments. Exp Dermatol 2012; 21: 735–739.
23  Von der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revis-
ited. Br J Dermatol 2000; 142: 947–953.
24  Fitzsimmons JS, Guilbert PR. A family study of hidradenitis suppurativa. J Med Genet 1985; 22: 
367–373.
25  Wang B, Yang W, Wen W, et al. γ-secretase gene mutations in familial acne inversa. Science 2010; 330: 
1065.
26  Miskinyte S, Nassif A, Merabtene F, et al. Nicastrin mutations in French families with hidradenitis 
suppurativa. J Invest Dermatol 2012; 132: 1728–1730.
27  Pink AE, Simpson MA, Desai N, et al. Mutations in the γ-secretase genes NCSTN, PSENEN, and 
PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol 2012; 132: 
2459–2461.
28  Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa 
phenotypes: Latent class analysis of a cross-sectional study. J Invest Dermatol 2013; 133: 1506–1511.
29  Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical 
journals. J Clin Epidemiol 1997; 50: 1129–1136.
30  Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. 
JAMA 1999; 282: 1523–1529.

73
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Part II
Comorbidities	of	
Hidradenitis	Suppurativa

75
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Chapter 5 
Severe fatigue based on anemia 
in patients with hidradenitis 
suppurativa: report of two cases and 
a review of the literature
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Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease.1 Patients often 
report fatigue, which is generally attributed to the debilitating psychosocial impact of 
HS.2,3 However, sometimes severe anemia causes the fatigue. The co-occurrence of HS 
and anemia is mentioned in reviews on the disease,1,4 but they refer to a single case 
series from 1968.5 Since, no studies have been published on this subject. Therefore, we 
present two representative cases of severe HS with fatigue, based on chronic marked 
anemia.
The first case is a 46-year-old, otherwise healthy, man with a six-year history of HS, 
Hurley stage III, on his buttocks, groin and peri-genital area. He presented with puru-
lent blood loss from his HS lesions and intense fatigue (Figure 1a). Previous treatments 
with isotretinoin and multiple antibiotics were ineffective. Laboratory tests revealed a 
microcytic anemia (hemoglobin (Hb): 4.5 mmol/L) (Table I), for which he received three 
packed-cells and was referred to internal medicine. Colonoscopy revealed no abnor-
malities, gastroscopy was discontinued because of patient’s anxiety. Helicobacter Pylori-
breathing test was negative. Iron supplementation was started, temporarily improving 
his hemoglobin level. Clindamycin 3dd200 mg yielded minor effect on his HS. Extensive 
wide excision was performed of all HS affected skin with closure by split-skin grafting. 
Six months postoperatively the wounds were healed (Figure 1b), his fatigue resolved and 
his hemoglobin level normalized (Hb: 9.4 mmol/L) (Table I).
The second case is a 61-year-old women, suffering from HS since the age of 14, Hurley 
stage III, located in the axillae, groin, pubic and gluteal area. She had a medical history 
of fatigue, diabetes and hypertension. Previous treatments with antibiotics were inef-
fective. Laboratory testing revealed normocytic anemia (Hb: 5.0 mmol/L) (Table I). She 
was referred to internal medicine who concluded that her anemia was caused by iron 
deficiency and chronic disease, since no other cause was found. She received multiple 
blood transfusions, temporarily increasing her hemoglobin. Adalimumab was started 
for her HS, with modest efficacy. Multiple extensive surgical excisions were performed 
on her axillae, groin and gluteal area, with subsequent blood loss requiring blood trans-
fusions. Hereafter infliximab infusions were started. The remaining HS lesions improved 
and the hemoglobin level normalized (Hb 8.5 mmol/L) (Table I).
HS patients often report fatigue, which is attributed to the debilitating course and 
great psychological impact of HS.2,3 However, a more general underlying cause, chronic 
marked anemia, is sometimes overlooked. In 1968, Tennant et al. reported on anemia 
associated with HS.5 In their population, 10 out of 42 (24%) patients with severe HS had 
marked anemia (Hb < 6.3 mmol/L). They concluded that anemia was probably caused 
by chronic inflammatory processes.5 Anemia as consequence of chronic disease is be-
lieved to be caused by the effects of elevated levels of pro-inflammatory cytokines.6 
Interferon-γ, interleukin (IL)- 1 and tumor necrosis factor alpha (TNF-α) can inhibit renal 
production of erythropoietin and reduce its physiological effect on the bone marrow.6,7 
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Additionally, these cytokines can enhance the uptake of iron by activated macrophages,6 
whereas TNF-α can also decrease the intestinal iron absorption,8,9 both resulting in less 
iron available for erythropoiesis. In HS, elevated levels of IL-1ß, IL-10 and TNF-α have 
been demonstrated.10 We argue that these increased cytokine levels, contribute to the 
development of anemia in patients with severe HS. In addition, HS patients can lose 
significant amounts of blood via sanguineous drainage from their fistulas, also contrib-
uting to the development or preservation of anemia.
In conclusion, fatigue is often mentioned by HS patients and can be caused by severe 
anemia. It is important to check for anemia, especially when considering extensive sur-
gery, and because the fatigue can worsen the already poor quality of life of HS patients.
A
B
Figure 1. Hidradenitis suppurativa in a 46-year-old male. (a) At first presentation, note the sanguine-
ous discharge from the fistulas. (b) Six months after extensive surgery.
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table I. Laboratory values of the first and second case
Case 1: 46-year-old male Case 2: 61-year-old female
First presentation Six months after
extensive surgery
First presentation After six months of
infliximab therapy
Hemoglobin
(n: male: 8.6-10.5 mmol/l,
female: 7.5-8.5 mmol/l)
4.5 mmol/l ↓ 9.4 mmol/l 5.0 mmol/l ↓ 8.5 mmol/l
Hematocrit
(n: 0.40-0.50 l/l)
0.27 l/l ↓ 0.45 l/l 0.27 l/l ↓ 0.41 l/l
Erythrocytes
(n: 4.40-5.60 *1012/l)
3.95*1012/l ↓ 4.98*1012/l 3.17*1012/l ↓ -
mCV
(n: 80-100 fL)
67 fL ↓ 91 fL 84 fL 117 fL ↑
rDw
(n: 12-16%)
19.2% ↑ 16.9% ↑ 18.9% ↑ 14.5%
thrombocytes
(n: 150-370 *109/l)
937*109/l ↑ 395*109/l ↑ 590*109/l ↑ 331*109/l
leukocytes
(n: 3.5-10.0 *109/l)
18.0*109/l ↑ 15.8*109/l ↑ - -
CrP
(n: 0.0-9.0 mg/l)
86 mg/l ↑ - 226 mg/l ↑ 48 mg/l ↑
CRP - C-reactive protein; MCV - mean corpuscular volume; n - normal value; RDW - red blood cell distribution width,
↑= enhanced level, ↓= decreased level
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ABStrACt
Background: Hidradenitis suppurativa (HS) is a well-established comorbidity in inflam-
matory bowel disease (IBD; Crohn’s disease or ulcerative colitis). However, the prevalence 
of IBD in patients with HS is unknown.
objective: To determine the prevalence of IBD in patients with HS, and to determine if 
HS with associated IBD is a distinct HS phenotype.
methods: For this multicenter cross-sectional study HS patients were actively asked if 
they had IBD during consultation, medical files were checked to confirm the diagnosis of 
IBD. In addition, clinical characteristics of all patients with HS were collected.
results: IBD has prevalence of 3.3% (95% CI 2.3-4.4) in 1,076 HS patients. The prevalence 
of Crohn’s disease was 2.5% (95% CI 1.6-3.4) and of ulcerative colitis was 0.8% (95% CI 0.3-
1.4). HS-IBD patients were less frequently obese (13.9% vs 31.2%, P = 0.04) than HS-only 
patients, but there were no differences in gender, family history of HS, disease severity, 
or smoking status.
Conclusion: The prevalence of IBD in patients with HS (3.3%) is four to eight times higher 
than in the general Northern European population. However, patients with HS and IBD 
do not represent a distinct HS phenotype.
Inflammatory bowel disease in HS | Chapter 6
85
6
IntroDuCtIon
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by 
recurrent nodules and abscesses followed by sinus tract formation and scarring. The 
axillary, inguinal and gluteal area are the most frequently involved body areas.1,2 In Eu-
rope the prevalence of HS is approximately 1%, with women being affected three times 
more frequently than men.3 The pathogenesis of HS is still not fully understood; but 
it is thought that genetic predisposition and aberrant immunity play important roles, 
combined with external risk factors such as smoking and obesity.1,3,4 There is no cure 
for HS; treatment often consists of long-term topical or oral antibiotics, and biologics.5 
When extensive sinus tract formation or fibrosis is present, surgery becomes unavoid-
able, whereby all affected tissue should be excised.5
HS has frequently been associated with inflammatory bowel disease (IBD), usually 
with Crohn’s disease (CD) and to a lesser extent with ulcerative colitis (UC).6–9 HS and 
CD share various similarities. They are both chronic inflammatory diseases of which the 
pathogenesis is not fully understood, but in which an aberrant immunity is believed to 
play an important role.4,10,11 Also smoking is a risk factor for both diseases and it can ag-
gravate disease severity.2,3,10 The clinical course of HS as well as of CD is characterized by 
periods of exacerbation and remission, and they respond well to biologics such as tumor 
necrosis factor alpha (TNF-α) inhibitors.8,11,12 Also the clinical presentation of the diseases 
show similarities. Since in both diseases perianal involvement with sterile abscesses and 
sinus tracts can be present, it is almost impossible to differentiate between cutaneous 
CD and concurrent HS.8,9
Previous studies showed an association between HS and IBD. Based on a question-
naire among IBD patients a prevalence of 23% was suggested.13 A more recent study, in 
which the questionnaire based diagnoses were confirmed by telephone, established a 
lower prevalence of 6.8-10.6%.14 Moreover, Yadav et al. found in their population-based 
cohort study that only eight out of 679 IBD patients suffered from HS, resulting in a 
prevalence of 1.2%.7 However, all these studies investigated the prevalence of HS in 
patients with IBD; the reverse association, HS patients who also suffer from IBD, has not 
yet been reported.
The aim of this study was to determine the prevalence of IBD in patients with HS, 
by actively asking 1,076 HS patients if they have IBD during intake, and by reviewing 
the gastroenterological medical files of those who answered affirmative. In addition, we 
assessed clinical features (e.g. disease characteristics, comorbidities and risk factors) in 
patients who had only HS, and those who had both IBD and HS, to determine whether 
these patients represented a distinct HS phenotype.
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PAtIEntS AnD mEtHoDS
For this multicenter cross-sectional study, data were collected between 2007 and 2015 
from HS patients who visited the Departments of Dermatology at Erasmus Medical 
Center Rotterdam, The Netherlands (ID, HZ, EP); Deventer Hospital, The Netherlands (JB); 
University Medical Center Groningen, The Netherlands (MK, BH); and Hôpital Erasme, 
Belgium (FB, VM). The diagnosis HS was made based on the patients history of HS symp-
toms and physical examination.1 For this type of analysis, medical ethical committee 
approval is not required under Dutch law.
Data	collection
During consultations all consecutive HS patients were actively asked if they suffered 
from CD or UC. The affirmative responses were confirmed as IBD if the diagnosis IBD was 
made by a gastroenterologist based on endoscopy, preferably with histopathological 
evidence (further referred to as HS-IBD).
Clinical characteristics were further collected from the medical files, e.g. disease sever-
ity, age of onset of HS, family history of HS, and the body sites affected by HS. The Hurley 
classification was used to assess disease severity.1 The body sites counted were: axillary, 
inguinal/femoral, gluteal, perianal and genital region. Abdomen, (infra)mammary and 
atypical regions were grouped as other. HS was considered familial, when a first- or 
second-degree relative also suffered from HS. Furthermore, patients’ smoking habits 
were assessed, and BMI was calculated based on reported body weight and height.
Statistical	analysis
Statistical analysis was performed using SPSS version 21 (IBM Corp, Armonk, NY). The 
prevalence was calculated as the percentage with the 95% confidence interval (CI). Inde-
pendent t-test was performed for normally distributed nominal data, presented as mean 
± standard deviation (SD). Mann-Whitney U test for non-normally distributed nominal 
data, presented as median with the interquartile range [IQR]. A Pearson chi-square test 
(n≥5) or a Fisher exact test (n<5) was used for categorical data, presented as number 
(n) with the corresponding percentage. Missing data were excluded from analysis. A 
P-value less than 0.05 was considered statistically significant.
rESultS
Data were collected of 1,076 HS patients, 324 males (30.1%) and 752 females (69.9%), 
with a mean age of 38.4 ± 12.7 years. Most patients had Hurley stage I (43.9%) or stage 
II (44.2%) and suffered from HS for a median period of 11.0 years [IQR: 5.0-21.0] (Table I).
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IBD	has	a	prevalence	of	3.3%	in	patients	with	HS
In 36 out of 1,076 HS patients the diagnosis IBD could be confirmed, resulting in a preva-
lence of 3.3% (95% CI 2.3-4.4). Of these 36 HS-IBD patients, 27 suffered from CD (75.0%) 
and nine from UC (25.0%), resulting in a prevalence of 2.5% (95% CI 1.6-3.4) for CD and 
0.8% (95% CI 0.3-1.4) for UC in patients with HS.
table I. General characteristics and comparison of patients with solely hidradenitis suppurativa ver-
sus patients with both hidradenitis suppurativa and inflammatory bowel disease (HS-IBD)
All patients
(n=1076)
HS
(n=1040)
HS-IBD
(n=36)
P-valuea
gender, n (%)
- Female 752 (69.9) 725 (69.7) 27 (75.0) 0.58
- Male 324 (30.1) 315 (30.3) 9 (25.0)
Age years, mean ± SD 38.4 ± 12.7  38.5 ± 12.7 36.5 ± 12.6 0.37
Age of disease onset of HS years, mean ± SD 23.9 ± 10.7  23.9 ± 10.7 23.8 ± 10.0 0.97
Disease duration of HS years, median [IQR] 11.0 [5.0-21.0] 12.0 [5.0-21.0] 9.0 [3.0-16.0] 0.14
Family history of HS, n (%)
- Positive 353 (35.8) 343 (36.0) 10 (30.3) 0.58
Smoking status, n (%)
- Current smoker 700 (65.7) 680 (66.1) 20 (55.5) 0.37
- Ex-smoker 137 (12.9) 132 (12.8) 5 (13.9)
- Nonsmoker 228 (21.4) 217 (21.1) 11 (30.6)
BmI kg/m2, mean ± SD 27.8 ± 6.0  27.9 ± 6.0 25.4 ± 5.1 0.01
BmI subgroups,b n (%)
- Normal weight 389 (37.3) 369 (36.6) 20 (55.6) 0.04
- Overweight 336 (32.2) 325 (32.2) 11 (30.5)
- Obese 319 (30.5) 314 (31.2) 5 (13.9)
Hurley stage, n (%)
- Stage I 472 (43.9) 460 (44.2) 12 (33.3) 0.27
- Stage II 476 (44.2) 455 (43.8) 21 (58.3)
- Stage III 128 (11.9) 125 (12.0) 3 (8.4)
Affected body regions, n (%)
- Axillary 679 (63.3) 658 (63.5) 21 (58.3) 0.60
- Inguinal/femoral 899 (83.8) 871 (84.0) 28 (77.8) 0.36
- Genital 337 (31.4) 321 (31.0) 16 (44.4) 0.10
- Gluteal 460 (42.9) 444 (42.8) 16 (44.4) 0.87
- Perianal 218 (20.3) 208 (20.0) 10 (27.8) 0.29
- Otherc 373 (34.8) 366 (35.3) 7 (19.4) 0.05
BMI - body mass index; HS - hidradenitis suppurativa; HS-IBD - hidradenitis suppurativa patients with inflammatory bowel 
disease
a P-value of independed t-test or Mann Whitney U test for continuous data and two-side chi-square test or Fisher exact test 
for categorical data
b Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
c Other: mammary region, abdominal region or atypical regions affected
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Clinical	characteristics	of	HS-IBD	patients
The clinical characteristics of the 36 HS-IBD patients are shown in Table II and in Supple-
ment Table I. HS-IBD patients developed symptoms of HS at a mean age of 23.8 ± 10.0 
years, whereas their IBD symptoms started at a mean age of 26.9 ± 11.2 years. From 31 
of the 36 HS-IBD patients the age of onset of both diseases was known. Fifteen of these 
patients had HS before developing IBD (48.4%), four developed HS and IBD at the same 
table II. Clinical characteristics of patients with hidradenitis suppurativa and inflammatory bowel 
disease
HS and Crohn’s disease
(n=27)
HS and ulcerative colitis
(n=9)
gender, n (%)
- Female 20 (74.1) 7 (77.8)
- Male 7 (25.9) 2 (22.2)
Age of disease onset of HS years, median [IQR] 23.0 [16.0-28.0]  19.5 [16.0-24.5]
Age of disease onset of IBD years, median [IQR] 23.0 [17.3-35.3] 29.0 [25.0-39.3]
First HS or first IBD, n (%) (n=31)
- First developed HS 10 (41.7) 5 (71.4)
- First developed IBD 10 (41.7) 2 (28.6)
- HS and IBD at same time 4 (16.7) 0
Family history of HS, n (%)
- Positive 7 (28.0) 3 (37.5)
Smoking status, n (%)
- Current smoker 14 (51.9) 6 (66.7)
- Ex-smoker 4 (14.8) 1 (11.1)
- Nonsmoker 9 (33.3) 2 (22.2)
BmI kg/m2, median [IQR] 23.0 [21.2-26.3]  27.1 [21.8-32.8]
BmI subgroups,a n (%)
- Normal weight 16 (59.3) 4 (44.4)
- Overweight 9 (33.3) 2 (22.2)
- Obese 2 (7.4) 3 (33.3)
Hurley stage, n (%)
- Stage I 9 (33.3) 3 (33.3)
- Stage II 15 (55.6) 6 (66.7)
- Stage III 3 (11.1) 0
Affected body regions, n (%)
- Axillary 16 (59.3) 5 (55.6)
- Inguinal/femoral 20 (74.1) 8 (88.9)
- Genital 10 (37.0) 6 (66.6)
- Gluteal/perianal 13 (48.1) 5 (55.6)
- Otherb 3 (11.1) 4 (44.4)
BMI - body mass index; HS - hidradenitis suppurativa; IBD - inflammatory bowel disease
a Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
b Other: mammary region, abdominal region or atypical regions affected
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time (12.9%), and twelve patients had symptoms of IBD before developing HS (38.7%). 
Especially patients with UC had HS before they developed symptoms of UC (Table II).
HS-IBD	is	not	a	distinct	HS	phenotype
When comparing the clinical characteristics of the 36 HS-IBD patients with the 1,040 HS 
patients, we found that obesity was significantly less frequent among HS-IBD patients 
(13.9% vs 31.2%; P = 0.04). In addition, HS-IBD patients were more often affected in the 
genital area (44.4% vs 31.0%), whereas less frequently affected in the atypical body areas 
(19.4% vs 35.3%); however, these differences were not significant. There was no differ-
ence in gender, family history of HS, disease severity, disease duration or smoking status 
(Table I).
DISCuSSIon
This multicenter cross-sectional study shows that 36 out of 1,076 HS patients (3.3%) had 
IBD, resulting in a prevalence of 2.5% for CD and 0.8% for UC in HS patients. In com-
parison, the estimated prevalence of IBD in the general population in Northern Europe 
ranges between 0.41% and 0.74%; with a prevalence of CD between 0.14% and 0.32% 
and of UC between 0.24% to 0.41%.15–18 These data indicate that the prevalence of IBD is 
four to eight times higher in our HS cohort than in the general population. For CD, the 
prevalence is even eight to eighteen times higher. These results confirm the previously 
observed association between HS and IBD, especially between HS and CD.6,8,14,19
When comparing clinical characteristics of HS-IBD patients with HS-only patients, we 
found that only 14% of the HS-IBD patients were obese compared with a third of the HS-
only patients. This might be explained by the finding that IBD patients more often suffer 
from malnutrition and weight loss.20 We anticipated to find more perianal involvement 
of HS and a higher percentage of smokers among HS-IBD patients.12,21 However, this 
could not be confirmed by our data. HS-IBD patients, especially patients with UC, were 
more often affected in the genital area, but this was not significant. Therefore, our data 
indicate that HS-IBD patients do not present a distinct HS phenotype, since there was 
no difference in gender, disease severity, family history of HS or smoking status between 
HS-IBD and HS-only patients.7,13
It has been reported that IBD usually precedes HS;13,19,21 however, in our population 
more patients developed HS before IBD. Because IBD can develop later, dermatologist 
should pay attention to symptoms of IBD. When HS patients present with IBD suspicious 
symptoms, e.g. bloody stool or recurrent abdominal pain, they should be referred to a 
gastroenterologist for further analysis.
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The association of HS and IBD is conceivable as they share multiple similarities. First, 
smoking triggers both HS and CD, and smokers tend to have more severe disease than 
nonsmokers.10,22 However, in UC patients, smoking tends to have protective effect.10 
Since most HS patients were active or former smokers, this might explain the lower prev-
alence of UC in HS patients. Second, HS and cutaneous CD share clinical and histological 
similarities making it difficult to differentiate in certain cases.23,24 Both can present with 
perianal inflammatory lesions, abscesses and sinus tract formation. Histology cannot 
differentiate HS from CD since both diseases are characterized by the presence of dif-
fuse tissue inflammation with epithelioid granulomas.23,24 Cutaneous CD is most likely 
when enterocutaneous fistulas are present and/or no other skin regions are affected by 
typical HS lesions. Concurrent HS is more likely when other body areas are also affected 
by HS.6,9,11 An endoscopy or radiological imaging is advisable when perianal sinuses or 
fistulas are present in patients with HS. Third, the clinical improvement induced by anti-
TNF-α in both diseases also suggests a shared inflammatory pathway.11,12 Interestingly in 
both diseases infliximab is an effective treatment, whereas they both show only minor 
response on etanercept.5,25 Furthermore, involvement of the interleukin (IL)-23/Th-17 
pathway is suggested in both CD and HS.10,26 Finally, HS and IBD both have a genetic 
predisposition. In CD polymorphisms in DNA-regions containing nucleotide oligomer-
ization domain 2 (NOD2) genes are implicated.10,27 However, in two small pilot studies, 
polymorphisms in the CARD15/NOD2 coding sequence were not confirmed in HS.27,28 In 
a larger IBD cohort higher frequencies of the single-nucleotide polymorphisms SULT1B1, 
SULT1E1 and ELOVL7 were found in patients with HS and IBD, which might be potential 
candidate genes for HS.14 However, no causative genes have yet been identified for HS 
and more research is needed to determine which genetic alterations are associated with 
HS.29
Our study is the first to determine the prevalence of IBD in a large cohort of patients 
with HS, whereby each HS patient was seen and diagnosed by a dermatologist. However, 
our study also has limitations; the prevalence of IBD might be underestimated, because 
some HS patients could still develop IBD in the future. A prospective registry in which 
patients are followed for multiple years would provide a better opportunity to deter-
mine the exact prevalence of IBD in HS. However, these registries are still in their infancy, 
therefore it will take years before results of such studies will be available.30,31 Because 
there are no prevalence data available of IBD in the Netherlands and Belgium, we used 
IBD data from Germany, The United Kingdom, Denmark and Sweden to compare our 
prevalence. We are aware that in Europe the incidence of IBD is higher in Northern Euro-
pean countries than in Southern countries;32 therefore we have chosen these countries, 
as they are geographically near to the Netherlands and Belgium.
Concluding, in this study we show a prevalence of 3.3% of IBD in patients with HS, 
which is four to eight times higher than in the general Northern European population. 
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Because it is not possible to identify IBD patients by their HS phenotype, it is advisable to 
ask patients with HS about abdominal complaints, such as recurrent abdominal pain and 
bloody stool. If IBD is suspected or patients have intersphincteric fistulas, an endoscopy 
is advisable to exclude IBD.
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Supplement table I. Clinical characteristics of the 36 patients with hidradenitis suppurativa and in-
flammatory bowel disease
Patient 
ID
Sex; Age 
(years)
Smoking 
status
IBD Age onset HS 
(years)
Age onset IBD 
(years)
Hurley 
stage
Body regions affecteda
1 M; 17 No CD 16 11 I axillary
2 M; 18 Yes CD 16 12 I axillary, inguinal, gluteal
3 F; 20 No CD 11 - II axillary, inguinal, gluteal
4 F; 21 Yes CD 19 17 I inguinal
5 F; 23 No CD 16 16 I axillary
6 M; 25 No CD 22 - II axillary
7 F; 26 No UC 14 - II axillary, inguinal, genital, 
gluteal
8 M; 26 Yes CD 16 - III axillary, inguinal, gluteal, 
perianal, other
9 F; 28 Yes UC 16 10 II axillary, inguinal, other
10 F; 28 Quit CD 23 23 II inguinal, genital
11 F; 28 No CD 20 21 II axillary, other
12 M; 29 Yes UC 26 29 II axillary, inguinal, genital, 
gluteal
13 F; 30 Yes CD 28 11 I inguinal
14 F; 31 No CD 24 30 I inguinal, gluteal
15 F; 32 Quit CD 16 17 II axillary, inguinal, gluteal, 
perianal
16 F; 32 Yes CD 24 19 II axillary, genital, gluteal, 
perianal
17 F; 33 Yes UC 20 29 II inguinal, genital
18 F; 34 Yes UC 19 28 II inguinal, genital, other
19 F; 34 Yes CD 31 18 II inguinal
20 F; 36 Yes CD 20 18 II axillary, inguinal, genital, 
perianal, other
21 F; 37 Yes CD 36 27 II axillary, inguinal, genital
22 F; 37 Quit CD 26 20 I axillary, inguinal
23 F; 38 No CD 23 23 III genital
24 F; 41 Yes CD 23 23 II inguinal
25 F; 41 Yes UC 16 24 I axillary, inguinal, gluteal, 
perianal, other
26 F; 41 No CD 10 30 II inguinal, genital, gluteal, 
perianal
27 F; 45 Yes CD 26 29 II axillary, inguinal, perianal
28 M; 46 Quit CD 40 43 II axillary, inguinal, gluteal, 
perianal
29 F; 48 Quit UC 20 34 I inguinal, genital
30 F; 48 Yes UC 47 41 I axillary, inguinal, genital, 
gluteal, other
31 F; 50 Yes CD 22 47 I inguinal, genital
32 F; 50 No CD 32 42 I axillary, inguinal, genital, 
gluteal
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Supplement table I. Clinical characteristics of the 36 patients with hidradenitis suppurativa and in-
flammatory bowel disease (continued)
Patient 
ID
Sex; Age 
(years)
Smoking 
status
IBD Age onset HS 
(years)
Age onset IBD 
(years)
Hurley 
stage
Body regions affecteda
33 M; 53 Yes CD 42 43 II inguinal, gluteal, perianal
34 F; 56 Yes CD 19 37 II axillary, inguinal, genital
35 M; 63 Yes CD 55 47 III genital, gluteal, perianal
36 M; 70 No UC - 43 II gluteal
IBD - inflammatory bowel disease; HS - hidradenitis suppurativa; M - male; F - female; CD - Crohn’s disease; UC - ulcerative 
colitis. Missing data are marked with -
a Other; mammary region, abdominal region or atypical regions affected

97
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Part III
The	Impact	of	
Hidradenitis	Suppurativa

99
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Chapter 7 
Sexual health and quality of life are 
severely impaired in hidradenitis 
suppurativa: a multicenter 
cross-sectional study
Ineke C. Janse, Inge E. Deckers, Anita D. van der Maten,
 Andrea W.M. Evers, Jurr Boer, Hessel H. van der Zee, 
Errol P. Prens, Barbara Horváth
Submitted for publication
Part III | The impact of HS
100
ABStrACt
Background: Hidradenitis suppurativa (HS) has a major impact on the quality of life 
(QoL). Although it has commonly been assumed that HS impairs sexual health, only a 
single case-control study has been performed on sexual functioning in a small group of 
HS patients.
objectives: The objective of this study was to investigate the QoL with a particular 
focus on sexual health in a substantial population of HS patients.
methods: In total, 916 HS patients received an invitation to participate in this multi-
center cross-sectional survey.
results: 300 patients completed the questionnaires. This study showed a diminished 
QoL and sexual health in HS patients (FSFI score: 21.6 ± 9.6, IIEF score: 49.7 ± 20.7, ASEX 
score: 16.7 ± 5.3 and DLQI score: 12.5 ± 7.5). Sexual health was associated with QoL in 
women but not in men. Female gender and late onset of HS were associated with poor 
sexual function. Impairment of QoL was associated with anogenital involvement, early 
onset of HS, disease severity and disease activity.
limitations: The sexual health questionnaires were not validated for patients with 
chronic skin diseases.
Conclusion: HS is associated with an impaired sexual health and QoL. Physicians should 
not hesitate to ask HS patients about their sexual function and, when needed, offer them 
psychological support.
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IntroDuCtIon
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease of the folliculopilo-
sebaceous unit with a European prevalence of approximately 1% and a female prepon-
derance of 3:1.1 HS is characterized by the presence of painful nodules, draining sinuses 
and bridged scars at inverse body sites.2,3 The incidence is the highest between the 
second and third decade of life.4,5
Previous studies have demonstrated that HS has a great impact on quality of life 
(QoL).6–11 Compared with patients who suffer from other chronic skin diseases like pso-
riasis or neurofibromatosis type 1, HS patients have the lowest QoL.6–11 Impairment in 
QoL in HS seems to be associated with disease severity.6–10
One of the key components of QoL is sexual functioning, which involves physical, psy-
chological and emotional factors.12 Sexual dysfunction refers to a disturbance in one of the 
following phases of the sexual response cycle: sexual desire, sexual arousal, orgasm and reso-
lution.13,14 As HS usually affects intimate body regions and occurs during young adulthood, it 
is plausible that HS influences sexual health. Kurek et al.15 found sexual dysfunctioning in all 
44 HS patients. Sexual function was more impaired in women than in men.15
Although it has been assumed that HS impairs sexuality, the study of Kurek et al.15 
is the only case-control study that has been performed on sexual functioning in HS.15 
Because this study was carried out in a limited number of patients, the impact of HS 
on sexual health and QoL remains unclear. Therefore, the objective of this study was 
to investigate QoL with a particular focus on sexual health in a larger group of patients 
with HS. Additionally, we aimed to identify parameters associated with impaired sexual 
health and QoL in HS.
mAtErIAlS AnD mEtHoDS
Subjects	and	design
This multicenter cross-sectional study was performed in the Dermatology Depart-
ments of the University Medical Center Groningen (UMCG), Erasmus Medical Center 
Rotterdam and Deventer Hospital, The Netherlands. In total, 916 patients diagnosed 
with HS between 2007 and September 2014 received a postal invitation to participate 
in this study. The diagnosis was made by a dermatologist and it was based on patients 
history and on physical examinations.3 Patients with HS that visited the website of the 
hidradenitis patients’ association were also invited.16 An online questionnaire was avail-
able from the fourth of May until the third of August 2015 via a link on the website of the 
hidradenitis patients’ association (Qualtrics 2015, LLC, Provo, Utah). A reminder was sent 
to nonrespondents after five weeks. The UMCG Ethics Committee confirmed that this 
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study, because of its non-interventional character, did not need to undergo full medical 
ethical review.
Questionnaire
To gain valid insight in the impact of the disease, the timespan covered by the question-
naires was set at one year.
Patient characteristics and disease severity
The questionnaire collected information on patient characteristics as shown in Table I. 
Disease severity was determined by using the pain score on the visual analog scale (VAS), 
patient global assessment (PtGA) and Hurley score.17 Our PtGA ranged from ‘complete 
control of disease’ (score of 0) to ‘no control of disease’ (score of 3); a PtGA score ≥ 1 was 
defined as active disease.
Sexual health questionnaires
Three self-administered questionnaires were used for the assessment of sexual health: 
the Female Sexual Function Index (FSFI),18–20 International Index of Erectile Function 
(IIEF)21,22 and Arizona Sexual Experience scale (ASEX).23 Sexual dysfunction is indicated 
in females by a FSFI score ≤ 26.55; in males it is indicated if the erectile function domain 
score of the IIEF is ≤ 25.18,19,22 A total ASEX score of ≥ 19, any one item with a score of ≥ 5 
or any three items with a score of ≥ 4 indicates sexual dysfunction for both genders.23 A 
high score on the FSFI and IIEF indicates a better sexual function whereas a high score 
on the ASEX indicate greater impairment in sexual health. To determine if patients have 
had sexual intercourse in the past year, we used IIEF question 3 and FSFI question 17.
Quality of life questionnaire
The Dermatology Life Quality Index (DLQI) is a commonly used questionnaire for the 
assessment of QoL in skin diseases, in which a higher score indicates greater impairment 
of the QoL.24,25
Statistical	analyses
Statistical analyses were performed using IBM SPSS Statistics version 22.0 for Windows 
(SPSS Inc., Chicago, IL, USA). In case of missing values in the DLQI, the score was calcu-
lated according to the procedure described in the manual. For the FSFI and IIEF, missing 
item-scores were replaced by the mean score of the other items of the same domain. The 
ASEX score was not calculated if scores were missing.
Descriptive statistics were applied to report the questionnaire outcomes. All con-
tinuous outcomes were described as mean ± standard deviation (SD). To calculate 
the differences between mean scores of two groups in normally distributed data, the 
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independent Student’s t-test was used. The Pearson correlation coefficient (r) and the 
Spearman correlation coefficient (rs) were used to determine correlations. A P-value less 
than 0.05 was considered statistically significant.
rESultS
Inclusion	and	exclusion
Of the 916 invited patients, seven patients refused participation, three patients were 
unable to participate because of comorbidity (Down’s syndrome or mental illness) 
and 573 patients did not respond to the invitation. A total of 333 patients filled out the 
questionnaire, which corresponds with a response rate of 36%. Additionally to the 333 
patients, 22 patients were included through application via the Dutch hidradenitis pa-
tients’ association website. The questionnaires of 31 patients were returned incompletely 
table I. Patient characteristics
n=300
gender, n (%)
- Male 66 (22)
- Female 234 (78)
Age years, mean ± SD 44.6 ± 12.3
Anogenital involvement, n (%)
- Yes 117 (39)
- No 183 (61)
relationship status, n (%)
- In a relationship 226 (75)
- Not in a relationship 74 (25)
BmI kg/m2, mean ± SD 28.1 ± 6.2
Current smoking behavior, n (%)
- Smoker 171 (57)
- Nonsmoker 129 (43)
Age of onset years, mean ± SD 24.3 ± 11.6
Duration of disease years, mean ± SD 20.7 ± 11.2
VAS pain score, mean ± SD 4.7 ± 2.8
PtgA, n (%)
- Reasonable control of disease 99 (33)
- Limited control of disease 132 (44)
- No control of disease 69 (23)
Hurley stage, n (%)
- Stage I 96 (32)
- Stage II 123 (41)
- Stage III 81 (27)
BMI - body mass index; PtGA - patient global assessment; VAS - visual analog scale
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and therefore excluded. A PtGA score of 0 was found in 24 patients; these patients were 
only included in the analyses regarding disease activity. The final sample for analysis 
consisted of 300 HS patients.
Subjects
In total 66 men and 234 women responded, resulting in a ratio of 1:3.5. Baseline charac-
teristics are shown in Table I. In addition to the completed questionnaires, we received 
numerous personal reactions from HS patients who made clear that they still struggle 
with recognition and understanding of their disease.
Sexual	Health
Female Sexual Function Index
The mean FSFI score was 21.6 ± 9.6. Sexual dysfunction (FSFI ≤ 26.55) was found in 62% 
of the female patients. The presence of anogenital involvement (AGI) did not influence 
the FSFI score (AGI: 21.7 ± 9.1 vs no AGI: 21.6 ± 9.9; P = 0.95). The FSFI scores of sexually 
active patients in a relationship (SAPIR) (25.6 ± 6.3) were not different from sexually ac-
tive patients not in a relationship (SAPNIR) (24.9 ± 7.9; P = 0.56). The FSFI score and age of 
onset showed a negative correlation (r = -0.252, P < 0.001), indicating that patients with 
a later age of onset of HS had worse sexual function. A negative correlation was also 
present between the FSFI score and DLQI score (without question 9, concerning sexual 
difficulties) (r = -0.194, P = 0.003), indicating that poor sexual health associates with poor 
QoL. No association was found between the FSFI score and duration of disease, VAS pain 
score, PtGA score or Hurley stage.
International Index of Erectile Function
The mean IIEF-total score was 49.7 ± 20.7, and the IIEF erectile function domain score was 
20.6 ± 9.7. The presence of AGI and having a relationship did not significantly influence 
the IIEF-total score (AGI: 54.4 ± 17.6 vs no AGI: 46.6 ± 22.1; P= 0.14) (SAPIR: 57.2 ± 16.5 vs 
SAPNIR: 45.6 ± 25.6; P = 0.09). No association was found between the IIEF-total score and 
age of onset, disease duration, VAS pain score, PtGA score, Hurley stage or DLQI score.
Arizona Sexual Experience scale
The mean ASEX score was 16.7 ± 5.3. The criteria of sexual dysfunction were met by 42% 
of the patients. The ASEX score was significantly higher in women than in men (17.4 ± 
5.2 vs 14.0 ± 4.7; P < 0.001) indicating that women experienced a more impaired sexual 
health. The presence of AGI or having a relationship did not significantly influence the 
ASEX score (AGI: 16.4 ± 5.0 vs no AGI: 16.9 ± 5.4; P = 0.39) (SAPIR: 15.5 ± 4.3 vs SAPNIR: 
15.3 ± 4.8; P = 0.87). In women, there was a positive correlation between the ASEX score 
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and age of onset (r = 0.254, P < 0.001), indicating that females who were older at onset 
of HS had worse sexual function. This correlation was not observed in men (r = 0.025, 
P = 0.85). No association was found between the ASEX score and DLQI (for women and 
men separately), disease duration, VAS pain score, PtGA score or Hurley stage.
Quality	of	life
Dermatology Life Quality Index
The mean DLQI score was 12.5 ± 7.5. There was no significant difference in DLQI score 
between women and men (12.8 ± 7.5 vs 11.7 ± 7.4; P = 0.33). The presence of AGI signifi-
cantly influenced the DLQI score (AGI: 14.1 ± 7.4 vs no AGI: 11.5 ± 7.4; P = 0.003). The DLQI 
score did not differ between patients in a relationship compared with patients not in a 
relationship (12.4 ± 7.4 vs 12.9 ± 7.8; P = 0.60). The DLQI score showed a significant posi-
tive correlation with VAS pain score (r = 0.667, P < 0.001), PtGA score (rs = 0.503, P < 0.001) 
and Hurley stage (rs = 0.502, P < 0.001), indicating that patients with severe disease had 
worse QoL. Also a negative correlation was observed between the DLQI score and age 
of onset (r = -0.147, P = 0.01), indicating that low QoL was associated with young age of 
disease onset. No association was found between the DLQI score and disease duration. 
The outcomes of DLQI item 9 are displayed in Table II.
Disease	activity
Patients with active disease had significantly higher DLQI scores and lower FSFI scores 
than patients without active disease (DLQI: 12.5 ± 7.5 vs 4.8 ± 4.7; P < 0.001) (FSFI: 21.6 ± 
9.6 vs 27.9 ± 8.5; P = 0.01). The IIEF score and ASEX score did not differ between patients 
with or without active disease (IIEF: 49.7 ± 20.7 vs 33.3 ± 25.9; P = 0.06, ASEX: 16.7 ± 5.3 vs 
15.2 ± 5.0; P = 0.17).
table II. DLQI item 9: ‘Over the last week, how much has your skin caused any sexual difficulties?’
Answer options: n %
Not at all 60 20.0
A little 104 34.7
A lot 61 20.3
Very much 44 14.7
Not relevant 31 10.3
DLQI - Dermatology Life Quality Index
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Decline	in	sexual	activity	after	onset	of	hidradenitis	suppurativa
In total, 179 of the 300 patients (59.7%) indicated that their sexual activity had declined 
after disease onset. The factors associated with this decline in sexual activity are dis-
played in Table III.
Attention	given	to	sexual	health
The answers to the questions about attention given to sexual health by doctors are 
displayed in Table IV. Almost half of the patients indicated that the doctor did not give 
enough attention towards sexual problems, and a third of the patients stated that doc-
tors should pay more attention to sexual problems.
table III. Decline of sexual activity after onset of disease
“To what extent do the following items have influence on your sexual health?”
never
n (%)
Sometimes
n (%)
often
n (%)
Always
n (%)
Influence on physical appearance
- Men 8 (21) 18 (47) 6 (16) 6 (16)
- Women 16 (11) 35 (25) 47 (33) 43 (31)
Fear of partner for contagiousness
- Men 25 (66) 8 (21) 3 (8) 2 (5)
- Women 107 (76) 22 (16) 7 (5) 5 (4)
Fear of passing HS on to children
- Men 28 (74) 5 (13) 4 (11) 1 (3)
- Women 69 (49) 21 (15) 27 (19) 24 (17)
Diminished sexual desire of patient
- Men 5 (13) 18 (47) 11 (29) 4 (11)
- Women 13 (9) 43 (31) 64 (45) 21 (15)
Diminished sexual desire of partner
- Men 15 (40) 15 (40) 5 (13) 3 (8)
- Women 72 (51) 45 (32) 15 (11) 9 (6)
Inconvenience caused by inflammation 
of the skin
- Men 4 (11) 12 (32) 15 (40) 7 (18)
- Women 2 (1) 18 (13) 66 (47) 55 (39)
Inconvenience caused by medication
- Men 25 (66) 8 (21) 4 (11) 1 (3)
- Women 52 (37) 44 (31) 26 (18) 19 (14)
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DISCuSSIon
In this multicenter cross-sectional study we investigated sexual health and QoL in a 
substantial group of patients with HS. The group of patients was representative for the 
general HS population in terms of gender and disease characteristics.2
The results show that HS has a major impact on sexual health and QoL. Compared with 
sexual health scores of healthy females as known from the literature (FSFI 31.2 ± 3.9, ASEX 
13.5 ± 3.9), the scores of our HS patients (FSFI 21.6 ± 9.6, ASEX 17.4 ± 5.2) were worse.20,23 
Similarly, the sexual health scores of the male patients (IIEF 49.7 ± 20.7, ASEX 14.0 ± 4.7) 
were worse than scores of healthy males (IIEF 54.5 ± 13.6, ASEX 13.5 ± 3.9), and a high 
number of our patients had erectile dysfunction.23,26 The DLQI score of 12.5 ± 7.5 indicates 
that HS has a very large impact on the patients’ QoL.25 Our data were compatible with 
the findings of Kurek et al.,15 who found a FSFI score of 22.1 ± 10.2 and IIEF score of 42.6 ± 
27.1 in patients with HS.
AGI and disease severity did not influence sexual health in HS. However, the majority 
of the women stated that their sexual health declined because of the influence of HS on 
their physical appearance. As the physical symptoms of HS cannot completely explain 
the impaired sexual health in HS, we presume that psychological factors also play a role. 
The association between QoL and sexual health in women supports this hypothesis. 
Unlike sexual health, the QoL was negatively influenced by AGI, disease severity and 
disease activity. These findings are in line with those of previous studies.6,7,9,10
We found that age of onset influenced sexual health and QoL. Interestingly, female 
patients with an older age of onset had poorer sexual functioning than females with 
a young age of onset. This might be because HS patients have to make adjustments to 
their sexual life when HS starts after they became sexually active.13 Our observation that 
patients with younger age of onset had a poorer QoL is in line with earlier findings, and 
probably results from a negative correlation between age at disease onset and disease 
severity.8,9
table IV. Attention given to sexual problems
n %
‘Doctors give enough attention to sexual problems’
- Yes 18 6
- No 132 44
- Unknown 150 50
‘Doctors should give more attention to sexual problems’
- Yes 101 34
- No 88 29
- Unknown 111 37
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Sexual health was associated with QoL in women but not in men. This gender differ-
ence may result from the fact that intimate body regions are more frequently affected 
in women than in men.15 Moreover, we found a higher impairment of sexual health in 
women, probably because they have a higher emotional and neuroendocrine respon-
siveness.15
In order to give a wider context to the results, a comparison between HS and psoriasis 
is made. It is known that the impact of psoriasis on the QoL is as large as the impact of 
diabetes, cancer and heart disease;27 also, psoriasis has a considerable effect on sexual 
health.28 HS and psoriasis have similar effects on sexual health,28,29 although DLQI scores 
from patients with psoriasis (6.3-7.5) indicate the QoL is lower in HS than in psoriasis.28,30–32 
Finally, similar to HS, it seems that there is no relation between disease severity or AGI 
and sexual health in psoriasis.28
Only a small number of patients experienced sufficient attention from clinicians for 
their sexual problems. The fact that clinicians remain reluctant to address sexual prob-
lems could be explained by unawareness, shame, the complexity of sexual problems, 
difficulty in treatment and limited time.33
Our study has some limitations. First, the sexual health questionnaires are not vali-
dated for patients with chronic skin diseases. Second, with a response rate of 36%, there 
is a chance for selection bias. The low response rate is probably caused by the intimate 
nature of the questions.28 However, since our patients characteristic were comparable 
to previous HS populations, it is possible to extrapolate our findings to the general HS 
population.2
In summary, this study demonstrates that HS has a major impact on sexual health 
and QoL. Sexual health is associated with QoL in women but not in men. Impairment 
in sexual health is associated with female gender and late onset of the disease. Early 
disease onset, disease activity and disease severity were important risk factors for im-
pairment of QoL. The clinician should treat HS early and aggressively in an attempt to 
prevent permanent physical impairment. Furthermore, clinicians should discuss sexual 
function with HS patients, and offer them psychological intervention.
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ABStrACt
Background: Hidradenitis suppurativa (HS) is a chronic debilitating disease, whereby 
school attendance and employment can be disturbed.
objective: To determine the socioeconomic status (SES) in patients with HS relative to 
dermatological patients, and whether specific clinical HS characteristics correlate with 
SES.
methods: For this multicenter cross-sectional study, data were collected of patients with 
HS and sex and age matched dermatological patients in a 1:2 ratio. SES was derived from 
the mean household income and real estate value on a neighborhood level. Univariable 
and multivariable ordinal logistic regression were used to determine if clinical character-
istics were associated with SES in patients with HS.
results: The SES distribution among 1,018 HS patients was significantly lower (low SES: 
46.4%, medium SES: 39.0%, high SES: 14.6%), than among 2,039 age and sex matched 
dermatological control patients (low SES: 34.3%, medium SES: 40.1%, high SES: 25.6%; 
P < 0.001). In HS patients a low SES was associated with axillary involvement (OR 1.42, 
95% CI 1.02-1.99), high body mass index (OR 1.03, 95% CI 1.01-1.06) and lower current 
age (OR 0.98, 95% CI 0.97-0.99), but not with diseases severity or age of onset, in the 
multivariable logistic regression.
limitations: SES was based on postal code level and causality cannot be determined.
Conclusion: Patients with HS have a significant lower SES than other dermatological 
patients. Low SES was associated with obesity, but not with disease severity. Since low 
SES is associated with an unhealthy lifestyle such as smoking and obesity, low SES might 
be a risk factor for developing HS.
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IntroDuCtIon
Hidradenitis suppurativa (HS), is a chronic skin disease, characterized by painful deep-
seated nodules or abscesses mainly located at the axillary, inguinal and anogenital 
area.1,2 The prevalence of HS ranges between 0.05% and 4%, and women are more 
frequently affected than men.1,3,4 Smoking and obesity are not only suggested as risk 
factors for the development of HS, but are also associated with disease severity.5,6 To 
date there is no cure for HS, and patients are often treated with long-term antibiotics or 
in more severe cases with biologics; generally, surgery is needed to induce remmision.3
It is not surprising that the combination of chronic painful lesions and a lack of a defi-
nite cure, leads to a diminished quality of life (QoL). Compared with patients with other 
dermatological diseases, patients with HS have the lowest QoL.7,8 There are conflicting 
results on the impact of HS on work ability. Matusiak et al.9 showed that HS patients miss 
on average 33.6 workdays per year because of their HS. They even suggested that of their 
cohort of 30 patients, seven did not get a promotion and three lost their jobs because 
of HS.9 However, two other studies showed that HS patients missed only 2 to 3 workdays 
per year.7,10
The clinical impression is that patients with HS have a lower socioeconomic status 
(SES) than other dermatological patients. It has been suggested that HS disrupts school 
attendance and employment.11 However, previous studies showed that 60-80% of HS 
patients had secondary or tertiary education level,4,10,12 but in only one study a control 
group was available. To the best of our knowledge, no studies have been performed in 
which the income or real estate value were used to determine the SES in HS.
The primary aim of this study was to determine the SES of patients with HS and a 
control group of patients with common skin diseases. SES was based on the mean 
household income and the mean real estate value per postal code area. The secondary 
aim was to determine if specific clinical HS characteristics were associated with a lower 
SES; this in order to get an impression whether HS is a risk factor for lower SES.
mEtHoDS
The Departments of Dermatology at Erasmus University Medical Center Rotterdam, 
Deventer Hospital, and University Medical Center Groningen, The Netherlands have a 
special interest in HS. Between 2007 and 2015 data were collected of 1,059 HS patients. All 
patients were diagnosed by a dermatologist; the diagnosis was based on patients’ his-
tory of HS symptoms and on physical examination.1,2 Of these HS patients, the six digit 
postal codes were collected. In addition, postal codes were collected of a sex and age 
distribution matched dermatological control group in a 1:2 ratio (Supplement Table  I). 
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The medical ethical review board of the Erasmus University Medical Center Rotterdam 
has reviewed and approved the protocol under number MEC-2014-230.
Socioeconomic	status
The SES was based on an indicator developed by Statistics Netherlands (Centraal Bureau 
van de Statistiek).13 Statistics Netherlands is an autonomous agency, and has the task to 
carry out statistical research for the Dutch government for practice, policy and research 
purposes.14 On a neighborhood level, based on the six-digit postal code, the most recent 
mean household income after tax and mean real estate value were determined (both 
from 2013). These data were available at Statistics Netherlands and were collected by the 
Dutch tax authorities. On average a six-digit postal code comprises data from 17 house-
holds, providing a small enough sample to obtain an accurate impression of the SES in 
that neighborhood.13 The household income and real estate value had to be combined 
into one variable that could be used as a representative of SES. This was done using 
principal component analysis, in which the mean household income and the mean real 
estate value per postal code area were equally included.13 Hereafter this combined vari-
able was categorized in three groups, namely 1st to 3rd deciles for low SES, 4th to 7th deciles 
for medium SES and 8th to 10th deciles for high SES.15 This method has been shown to be 
a valid predictor of SES, and to be valid for ten years before and after the reference year 
(2013).15,16
Data	collection	of	patients	with	hidradenitis	suppurativa
Additional data were collected from the medical files of the patients with HS, e.g. age 
of onset of HS, family history of HS (first- or second-degree family member affected), 
the body regions affected by HS and smoking status. The body mass index (BMI) was 
calculated based on reported body weight and height. Disease severity was assessed 
using the Hurley classification of the worst location affected.2
Dermatological	control	patients
This SES indicator was known to be only reliable when compared with an age comparable 
group.13 Therefore we have chosen sex and age matched controls to make comparisons 
of the SES. For every center, control patients were frequency matched on a 1:2 ratio 
(Supplement Table  I). Because of the chronic nature of HS, we chose mostly patients 
with chronic skin diseases, such as eczema and psoriasis, but also data of patients with 
other dermatological diseases were collected (Supplement Table II).
Statistical	analysis
Statistical analysis was performed using SPSS version 21 (IBM Corp, Armonk, NY). A chi-
square test was used to answer the primary research question, presented as number (n) 
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with their corresponding percentage. Independent t-tests were performed for nominal 
data, presented as mean ± standard deviation (SD). As a subgroup analysis the specific 
dermatological control diseases were compared with the HS group. A P-value less than 
0.05 was considered statistically significant. As a secondary step we determined whether 
patients- or disease characteristics were risk factors for a lower SES among patients with 
HS. Twelve out of the 13 tests of parallel lines were nonsignificant and therefore an ordi-
nal logistic regression model was applied. Based on clinical expertise and the literature, 
candidate predictors were included (Table III). First univariable ordinal logistic regression 
was performed, with SES as the dependent variable, in which a significant odds ratio 
(OR) > 1 is a predictor for low SES. Hereafter in the multivariable model, all variables were 
included to observe if patient- and disease characteristics were independent predictors 
of SES. In order to prevent overfitting, a maximum of 49 degrees of freedom could be 
spent based on the sample sizes of the SES distribution among HS patients (Table I).17 
Data are presented as OR with the 95% confidence interval (CI). Proportional ORs were 
obtained on the three levels of SES, and should be interpreted as follows: a significant 
OR of 2 indicates that the odds of low SES are twice as high as medium and high SES 
combined. Missing values of the patients’ and disease characteristics were included in 
the univariable and multivariable model.
rESultS
Data were collected from 1,059 HS patients and 2,088 age and sex matched dermatologi-
cal control patients. Because of invalid or irretrievable addresses, 28 HS patients were 
excluded. In addition, 13 HS patients and 49 control patients were excluded because 
of missing data on SES (mean income or real estate value missing for the correspond-
ing postal code). In total 1018 HS patients (mean age 38.7 ± 12.7 and 71.7% female) and 
2039 dermatological control patients were analyzed (Table  I and Supplement Table  I). 
The control group consisted mostly of eczema patients (n=708), psoriasis (n=549), naevi 
(n=327), skin cancer (n=141) and a rest group (n=314) of combined diseases (Supplement 
Table II).
Patients	with	hidradenitis	suppurativa	have	a	significant	lower	socioeconomic	
status
Of the patients with HS 46.4% had a low SES, 39.0% a medium SES and 14.6% a high SES; 
this is lower than the SES of the general Dutch population (30% low SES, 40% medium 
SES and 30% high SES by definition). The SES of HS patients was significantly lower than 
that of the age and sex matched dermatological control group (34.3% low SES, 40.1% 
medium SES, and 25.6% high SES, P < 0.001) (Table I). In addition, in a subgroup analysis 
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for the specifi c dermatological control diseases, HS had the lowest SES, followed by 
psoriasis and eczema, whereas patients with skin cancer had the highest SES (Figure 1).
table I. Socioeconomic status and general characteristics of patients with hidradenitis suppurativa 
and other dermatological control patients
Hidradenitis 
suppurativa
(n=1018)
Control dermatological 
diseasesa
(n=2039)
P-valueb
gender, n (%)
- Female 730 (71.7) 1464 (71.8) 0.96
- Male 288 (28.3) 575 (28.2)
Age years, mean ± SD 38.7 ± 12.7 38.9 ± 13.3 0.64
Socioeconomic status,c n (%)
- Low SES 472 (46.4) 699 (34.3) < 0.001
- Medium SES 397 (39.0) 817 (40.1)
- High SES 149 (14.6) 523 (25.6)
a Control dermatological diseases: e.g. eczema, psoriasis, naevi and skin cancer (Supplement Table II)
b t-test for nominal data and chi-square test for categorical data
c Socioeconomic status (SES) was based on mean household income and real estate value per postal code area, which 
were on national level divided in low SES (1st to 3rd deciles), medium SES (4th to 7th deciles) and high SES (8th to 10th deciles)13
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Figure 1. Socioeconomic status (SES) of hidradenitis suppurativa and control dermatologic diseases. 
Hidradenitis suppurativa showed to have the lowest SES of every skin disease when compared using 
chi-square test. The asterix shows the P-value of the comparison of hidradenitis suppurativa with the 
corresponding skin disease; * P = 0.005 and ** P < 0.001.
Socioeconomic status in HS | Chapter 8
119
8
Axillary	involvement,	age	and	BMI	are	indicators	for	lower	socioeconomic	status	
in	patients	with	hidradenitis	suppurativa
Affection of the axillary region was the only disease characteristic associated with a 
lower SES, with 69.5% of the low SES patients having axillary involvement versus 51.0% 
of the high SES patients (OR 1.42, 95% CI 1.03-1.99; P = 0.04) (Table  II and III). None of 
the other body regions showed a relation with SES. Patients with low SES were more 
table II. Patient and disease characteristics of hidradenitis suppurativa for every socioeconomic sta-
tusa
low SES 
(n=472)
medium SES
(n=397)
High SES
(n=149)
gender, n (%)
- Female 332 (70.3) 297 (74.8) 101 (67.8)
- Male 140 (29.7) 100 (25.2) 48 (32.2)
Age years, mean ± SD 37.4 ± 12.5 39.4 ± 12.7 40.9 ± 13.1
Age of disease onset years, mean ± SD 23.4 ± 10.5 23.8 ± 10.8 25.7 ± 12.8
Family history, n (%)
- Positive 173 (41.2) 125 (34.8) 49 (35.5)
Hurley stage, n (%)
- Hurley I 212 (44.9) 166 (41.8) 64 (43.0)
- Hurley II 208 (44.1) 190 (47.9) 64 (43.0)
- Hurley III 52 (11.0) 41 (10.3) 21 (14.0)
Body region affected, n (%)
- Axillary 326 (69.5) 251 (63.4) 76 (51.0)
- Inguinal/femoral 404 (86.1) 345 (87.1) 122 (81.9)
- Genital 146 (31.1) 125 (31.6) 40 (26.8)
- Gluteal/perianal 223 (47.5) 186 (47.0) 77 (51.7)
- Otherb 178 (38.0) 142 (35.9) 49 (32.9)
no. of body sites affected, n (%)
- 1-2 sites 206 (44.0) 188 (47.5) 81 (54.4)
- 3-5 sites 262 (56.0) 208 (52.5) 68 (45.6)
BmI kg/m2, mean ± SD 28.4 ± 6.4 27.9 ± 5.7 26.3 ± 4.6
BmI subgroups,c n (%)
- Normal 161 (35.2) 134 (34.7) 62 (44.3)
- Overweight 128 (28.0) 134 (34.7) 56 (40.0)
- Obese 168 (36.8) 118 (30.6) 22 (15.7)
Smoking status, n (%)
- Active smoker 341 (73.3) 280 (71.4) 94 (64.0)
- Ex-smoker 47 (10.1) 63 (16.1) 24 (16.3)
- Nonsmoker 77 (16.6) 49 (12.5) 29 (19.7)
BMI - body mass index; SES - socioeconomic status
a SES was based on mean household income and real estate value per postal code area, which were on national level di-
vided in low SES (1st to 3rd deciles), medium SES (4th to 7th deciles) and high SES (8th to 10th deciles)13
b Other: mammary region, abdominal region or atypical regions affected
c Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
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often affected at more body regions in the univariable analysis, but this did not remain 
significant in the multivariable analysis. In the uni- and multivariable analysis, there was 
no difference in distribution of SES across different categories of disease severity accord-
ing to Hurley, family history of HS or age of disease onset.
BMI and age also showed to be associated with SES (Table II and III). The mean BMI was 
higher in the low SES group than in the high SES group (mean BMI 28.4 ± 6.4 vs 26.3 ± 
4.6; OR 1.03, 95% CI 1.01-1.06; P = 0.003). Also in the low SES group 36.8% of the patients 
with HS were obese versus 15.7% of the high SES patients. Patients were older in the high 
SES group (40.9 ± 13.1 years) than in the low SES group (37.4 ± 12.5 years; OR 0.98, 95% CI 
0.97-0.99; P = 0.001). Among HS patients, smoking status showed no relation with SES.
table III. Univariable and multivariable analysis of factors associated with socioeconomic status in 
hidradenitis suppurativa
univariablea (n=1018) multivariablea (n=1018)
or (95% CI) P-value or (95% CI) P-value
gender, ref. male
- Female 0.96 (0.74-1.24) 0.75 0.90 (0.67-1.20) 0.47
Age years 0.98 (0.98-0.99) 0.001 0.98 (0.97-0.99) 0.001
Age of disease onset years 0.99 (0.98-1.00) 0.06 1.01 (0.99-1.02) 0.24
Family history, ref. no
- Positive 1.26 (0.98-1.62) 0.08 1.27 (0.96-1.67) 0.09
Hurley stage, ref. Hurley I
- Hurley II 0.93 (0.72-1.18) 0.54 0.86 (0.66-1.12) 0.25
- Hurley III 0.86 (0.58-1.28) 0.45 0.91 (0.59-1.41) 0.68
Body region affected, ref. not affected
- Axillary 1.62 (1.27-2.07) <0.001 1.42 (1.02-1.99) 0.04
- Inguinal/femoral 1.13 (0.81-1.59) 0.47 1.17 (0.78-1.77) 0.44
- Genital 1.08 (0.84-1.40) 0.53 1.17 (0.86-1.59) 0.33
- Gluteal/perianal 0.94 (0.74-1.18) 0.59 0.86 (0.62-1.20) 0.38
- Other 1.15 (0.90-1.47) 0.25 0.87 (0.63-1.20) 0.40
no. of body sites affected, ref. 1-2
- 3-5 sites 1.28 (1.01-1.62) 0.04 1.19 (0.73-1.93) 0.49
BmI kg/m2 1.03 (1.01-1.05) 0.002 1.03 (1.01-1.06) 0.003
Smoking status, ref. nonsmoker
- Active smoker 1.05 (0.75-1.46) 0.79 1.22 (0.84-1.76) 0.29
- Ex-smoker 0.66 (0.43-1.02) 0.06 0.78 (0.49-1.25) 0.31
BMI - body mass index; OR - odds ratio; CI - confidence interval
a Ordinal logistic regression analysis with socioeconomic status as dependent variable: univariable model, unadjusted; and 
multivariable model, adjusted for factors and covariates in the model (OR>1 is a predictor for low socioeconomic status)
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DISCuSSIon
This multicenter cross-sectional study shows that patients with HS have a lower SES than 
the general Dutch population, and age and sex matched dermatological patients. In a 
representative sample of the population 30% would have a low SES, 40% a medium 
SES and 30% a high SES;15 however, in our HS population 46% had a low SES and only 
15% a high SES. For our control group we chose mostly patients with psoriasis and ec-
zema, because these are also chronic skin diseases that affect young people and have 
a high disease burden.18–20 Although 45% of the patients with psoriasis and 32% of the 
patients with eczema had a low SES; in the direct comparison, the SES of patients with 
HS remained significantly lower (Figure  1). Patients with naevi had a SES comparable 
with the general population, whereas our results confirm that patients with skin cancer 
have a higher SES.15,21 As expected, older patients with HS had a higher SES. In general, 
with increasing age people have a higher income and are able to afford more expensive 
real estates.13 Therefore an age and sex matched control group was used to make SES 
comparisons.
The secondary aim of this study was to investigate if specific patient or disease char-
acteristics were associated with the SES. We anticipated that if HS would lead to a lower 
SES, patients with a more severe disease would have a lower SES because of the inability 
to perform their jobs or frequent sick leave.9 However, we did not find a difference in 
Hurley stage distribution among the SES groups. Low SES was associated with more 
affected body regions in the univariable analysis but not in the multivariable model. 
Only axillary involvement showed a relation with low SES, but this relationship could not 
be observed for any other body region affected by HS. 
We hypothesized that if a lower SES is a consequence of HS, patients with a young 
age of onset might have a lower SES, because of missed education or job opportunities. 
However, there was no difference in age of onset between the different SES groups. Also 
previous studies reported that 60-80% of the patients had secondary or tertiary educa-
tion (high school, college or university).4,10,12 However, education level alone is not reli-
able for determining SES, because there is only a modest correlation between education 
level and income.22 In addition, the number of workdays missed by HS patients seems 
limited.7,10 Therefore it could be possible that the lower SES was pre-existent to HS. 
We observed that HS patients with a low SES were more often obese than HS pa-
tients with a high SES. In a European study, people from low SES neighborhoods were 
shown to have a higher BMI.23 Inhabitants from these neighborhoods also showed more 
obesity-related behavior, such as eating less fruit and vegetables, whereas they drank 
more beverages with a high sugar content.23 In the general population smoking is also 
associated low SES.23–26 Since both smoking and obesity are risk factors for HS, it could 
be that people with a low SES have a higher risk of developing HS;5,6 but because of 
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the cross-sectional study design we were unable to confirm causality. The only way to 
properly investigate causality is to set up a large prospective population-based study to 
determine which risk factors are causative for HS.
Another limitation of our study is the definition of SES. Ideally SES consists of personal 
income, education level and occupation.22 For this study we used aggregated data on 
postal code level. Even though this postal code data showed to be a good predictor of 
individual SES,13,15,16 it is possible that someone with a higher income lived in a low SES 
neighborhood or vice versa. Also SES differs across the Netherlands,27 therefore we col-
lected data from three hospitals that are located in different geographical areas. Since 
all three centers have special interest in HS, patients are referred from wide surrounding 
areas; therefore they cover a wide area of The Netherlands. However, two hospitals were 
tertiary referral centers, which might result in an overrepresentation of HS patients with 
severe disease.6
Concluding, this study shows that patients with HS have a significantly lower SES the 
general Dutch population and than other dermatological patients. We did not observe 
an association between SES and disease severity or age of onset. Therefore low SES may 
be an independent risk factor for HS, since unhealthy behavior such as smoking and 
obesity is more prevalent in people with low SES. A prospective cohort study is needed 
to determine causality.
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Supplement table I. General characteristics of patients with hidradenitis suppurativa and dermato-
logical control patients per hospital
Hidradenitis 
suppurativa
Control dermatological 
diseasesa
P-valueb
Erasmus medical Center rotterdam (n=474) (n=961)
gender, n (%)
- Female 320 (67.5) 648 (67.4) 0.98
- Male 154 (32.5) 313 (32.6)
Age years, mean ± SD 37.7 ± 13.1 37.4 ± 13.3 0.75
Deventer Hospital (n=395) (n=784)
gender, n (%)
- Female 306 (77.5) 611 (77.9) 0.86
- Male 89 (22.5) 173 (22.1)
Age years, mean ± SD 38.2 ± 12.1 39.1 ± 13.6 0.23
university medical Center groningen (n=149) (n=294)
gender, n (%)
- Female 104 (69.8) 205 (69.7) 0.99
- Male 45 (30.2) 89 (30.3)
Age years, mean ± SD 43.4 ± 11.9 43.3 ± 11.7 0.99
a Control dermatological diseases: e.g. eczema, psoriasis, naevi and skin cancer (Supplement Table II)
b t-test for nominal data and chi-square test for categorical data
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Supplement table II. Diagnoses of dermatological control patients
n=2039
Eczema 708
Psoriasis 549
naevi 327
Skin cancer 141
other
- Verruca 89
- Urticaria 46
- Varices 58
- Alopecia 31
- Rosacea 31
- Vitiligo 11
- Actinic keratosis 7
- Dermatomycosis 7
- Prurigo/pruritus 4
- Chronic discoid lupus erythematosus 3
- Condylomata 3
- Pityriasis versicolor 3
- Lichen planus/sclerosus 3
- Hyperhidrosis 3
- Dermatofibroma 3
- Bullous pemphigoid 2
- Ulcers 2
- Erythema migrans 1
- Purpura 1
- Deep venous thrombosis 1
- Lentigo solaris 1
- Hemangioma 1
- Sarcoidosis 1
- Perniones 1
- Xanthelasmata 1
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ABStrACt
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by 
recurrent inflammatory nodules mostly located in the armpits and groin. Over the years 
multiple treatment options for HS have been proposed; however, to date a cure is still 
lacking. In this update we provide an overview of most drug treatments reported on for 
HS, where possible with their mode of action and side effects.
In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracy-
clines are a first-line systemic option in more widespread or severe cases, followed by 
the combination of clindamycin with rifampicin. However, the recurrence rate is high 
after discontinuation of clindamycin plus rifampicin combination therapy. Long-term 
treatment with retinoids, especially acitretin is feasible, although teratogenicity has to 
be taken into account in females of reproductive age. Multiple anti-inflammatory drugs 
have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their 
effectiveness in HS is based on small case series with varying results. If most common 
treatments have failed, biologics (e.g. infliximab or adalimumab) are the next step. Al-
though not addressed in this review, surgical interventions are often needed to achieve 
remission.
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1. IntroDuCtIon
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent inflam-
matory skin disease.1,2 The diagnosis is based on the clinical presentation. Patients pres-
ent with comedones, inflamed or non-inflamed nodules and abscesses, often followed 
by sinus tract formation and scarring. These lesions are generally present in the axillary, 
inguinal, pubic and gluteal area, and the infra-mammary area in female patients. To 
make the diagnosis, these painful or purulent nodules have to occur at least twice per 
six months.3 The disease usually develops after puberty, when patients are in their early 
twenties. However, although rare, HS can also develop in children.4,5 The disease has a 
prevalence ranging from 0.05% to 4%, and females are more often affected than males, 
with a female to male ratio of 3:1.6–8 Disease severity can be assessed using different se-
verity scores. The oldest and still most commonly used severity assessment is the Hurley 
score (Table I and Figure 1).2,9 It is easy to use, but static and therefore less suitable for 
monitoring treatment efficacy. The Modified Sartorius Score is more dynamic. It is based 
on the number of areas involved and the number of nodules, fistulas and hypertrophic 
scars.10,11 However, because of its comprehensiveness, it is time consuming, making it 
less suitable for daily practice. The Hidradenitis Suppurativa Physician Global Assess-
table I. Hurley’s classification for clinical staging of disease severity in hidradenitis suppurativa2,9
Stage Description
I Abscess formation, single or multiple, without sinus tracts and cicatrization
II Recurrent abscesses with tract formation and cicatrization. Single or multiple separated lesions
III Multiple interconnected tracts and abscesses throughout an entire anatomical area
Hurley stage I Hurley stage II Hurley stage III
Figure 1. Clinical presentation of the three stages of disease severity of hidradenitis suppurativa ac-
cording to Hurley.2,9
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ment (HS-PGA) score is suitable for observing change during treatment and is easy to 
use and validated,3,12 therefore it is frequently used at present (Table II).
The pathogenesis of HS is still not fully understood. The primary event is thought to be 
infundibular hyperkeratosis and hyperplasia of the follicular epithelium causing occlu-
sion of hair follicles.13,14 This leads to accumulation of cellular debris and cyst formation, 
and eventually rupture of the hair follicle causing abscess formation and the develop-
ment of sinus tracts and scarring.15,16 The role of an aberrant immune response gets more 
attention in the pathogenesis of HS. Elevated levels of interleukin (IL)-1β, IL-10 and tumor 
necrosis factor alpha (TNF-α) have been found in lesional and perilesional skin.17 Also 
overexpression of macrophages producing IL-12 and IL-23, and IL-17 producing cells were 
found in lesional HS skin.18 These results were recently confirmed by Kelly at al.19 They 
also demonstrated activated caspase-1 in HS skin, which is associated with IL-1β and 
IL-18 production. These results suggest that the IL-23/Th17 and the caspase-1 pathways 
play an important role in the pathogenesis of HS.17–19
To date, there is no medical cure for HS, and multiple treatments have been suggested 
for HS. Often a combination of drug treatment and surgical intervention is needed to 
achieve remission. Recently the European Guidelines for the treatment of HS have been 
published,3 giving advice on the therapeutic steps to be taken in the treatment of HS. 
In this comprehensive review we will give an overview of most HS drug treatments with 
their mode of action. The commonly used antibiotics and biologics will be discussed, as 
will a few more experimental and future therapeutic options.
2. toPICAl trEAtmEntS
For mild HS, where only comedones, papules, pustules or inflammatory nodules are 
present, topical treatment, together with lifestyle advices, are often sufficient. The best 
results are achieved when a combination of a peeling cream, to resolve and prevent 
table II. Physician’s global assessment scale of hidradenitis suppurativaa
Clear No inflammatory or noninflammatory nodules
Minimal Only noninflammatory nodules
Mild Less than five inflammatory nodules;
or only one abscess or draining fistula present
Moderate Five or more inflammatory nodules;
or one abscess or draining fistula and at least one inflammatory nodule;
or two to five abscesses or draining fistulas and less than ten inflammatory nodules
Severe Two to five abscesses or draining fistulas and ten or more inflammatory nodules
Very severe More than five abscesses or draining fistulas
a Adjusted physician’s global assessment scale for hidradenitis suppurativa.3,12
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follicular blockage, is given with a local antibiotic, as a topical anti-inflammatory agent 
and to prevent secondary infection.
2.1	 Topical	clindamycin
Topical clindamycin is a simple and widely used treatment for HS.20 Daily topical applica-
tion of clindamycin 1% proved more effective than placebo in a small double-blind study 
of patients with Hurley stage I and mild stage II HS. After three months of clindamycin 
application a significant reduction in pustules, inflammatory nodules and abscesses 
was observed. The only side effect was a slight burning sensation after application.21 For 
solitary nodules, clindamycin lotion is an effective, safe and low-cost option.
2.2	 Resorcinol	cream
In our center resorcinol cream is commonly used. It has a peeling effect on the skin, due 
to its keratolytic properties at higher concentrations. It is hypothesized that it targets 
the follicular keratin plug, which is considered be a primary event in the pathogenesis 
of HS.13,14,22 In addition, it also has an antiseptic effect. The effectiveness of resorcinol 
10-15% has been described in a small study of twelve patients. After daily application, 
patients reported a decrease in pain and a reduction of the number of days the nodules 
and abscesses persisted.23 In our clinical experience, resorcinol effectively prevents new 
inflammatory lesions by reducing follicular occlusion and it also helps to resolve active 
nodules faster. However, patients should be warned that resorcinol should be applied to 
limited skin areas to prevent systemic exposure due to absorption, and that it can have 
a discoloring effect on their skin and cloths. In addition, due to insufficient data, the use 
of resorcinol should be avoided during pregnancy.22,23
2.3	 Other	topical	agents
Topical antiseptics, such as iodine scrubs or chlorhexidine, are widely used for HS.20 They 
can be effective by preventing secondary bacterial infection of lesions. However, their 
efficacy in HS has never properly been investigated.
Azelaic acid is registered for mild acne. In vitro it has been shown to have antifungal 
and bacteriostatic properties, and to inhibit keratinocyte proliferation.22,24 It is suggested 
that azelaic acid can have preventive properties in HS; however, this is based on clinical 
experience and no studies are available on its use in HS.22 Nothing is known about the 
efficacy or usefulness in HS of topical agents such as salicylic acid, tretinoin, adapalene 
and benzoyl peroxide, which form the basis of treatment for acne vulgaris.
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3. SyStEmIC AntIBIotICS
Even though bacterial infections are not primarily involved in the early phase of the 
pathogenesis of HS, antibiotics are the treatment of first choice.3 Cultures of HS lesions 
are often sterile or show common skin flora.3,25,26 Most commonly found bacteria are 
coagulase-negative staphylococci (CoNS), Staphylococcus aureus, and strains of the 
intestinal flora such as Proteus mirabilis, Enterococcus faecalis, or Escherichia coli.26–31 
S. aureus is mostly cultured from chronic suppurative lesions, suggesting that it is not 
pathogenic in HS, but mostly a superinfection of already existing lesions.27,30 CoNS are 
more often found in deep lesions. In addition, it has recently been shown that Staphylo-
coccus lugdunesis was often found in Hurley stage I lesions, whereas in Hurley stage II or 
III more often a mixed group of anaerobic flora can be found, including strict anaerobes, 
anaerobic actinomycetes, and streptococci of the milleri group.32 However, antibiotics 
are also thought to be effective because of their anti-inflammatory properties, and in 
addition by treating or preventing superinfections. In mild cases long-term antibiotics 
can lead to total remission (Table III). However, when fistulas, scars or fibrosis are pres-
table III. An overview of articles published on systemic antibiotic for hidradenitis suppurativa
na Dose and duration outcome
tetracyclines
Jemec and 
Wendelboe37
24 Tetracycline 500 mg bd,
3 months
Reduction in physicians’ and patients’ overall 
evaluation, soreness, and abscesses. No data on 
number of responders. No difference in results 
compared with clindamycin 1% lotion
Clindamycin and rifampicin
Mendonça and 
Griffiths46
14 Clindamycin 300 mg bd,
rifampicin 300 mg bd,
10 weeks
Eight showed complete remission, two switched 
from clindamycin to minocycline and four stopped 
because of side effects
Gener et al.47 70b Clindamycin 300 mg bd,
rifampicin 600 mg qd,
10 weeks
Eight showed complete response, 51 partial 
response and, three no response or worsening. 
Eight stopped because of side effects
Van der Zee et al.48 34 Different dose schemes and 
treatment durations
Sixteen showed complete remission, twelve partial 
remission, and no response in six patients
Bettoli et al.49 23 Clindamycin 600 mg qd,
rifampicin 600 mg qd,
10 weeks
Seventeen showed response (reduction of 25% 
in Sartorius score). No response in three patients. 
Three stopped because of side effects or personal 
reasons
rifampicin, moxifloxacin and metronidazole
Join-Lambert et al.54 28 Rifampicin 10 mg/kg qd,
moxifloxacin 400 mg qd,
metronidazole 500 mg tid, 
minimum 6 weeks
Sixteen showed complete remission, and twelve 
partial remission
n - number of patients treated; qd - once daily; bd - twice per day; tid - three times per day
a Number of patients treated with systemic antibiotics with their treatment outcome
b 116 patients were treated, but no data available on the effectiveness of 46 patients.
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ent, antibiotics are rarely curative, but they can reduce the amount of inflammation and 
improve conditions for surgery.
3.1	 Tetracyclines
Antibiotics from the tetracycline group are the first-line systemic treatment for HS.20,29,33 
Tetracyclines are broad-spectrum antibiotics and act by inhibition of bacterial protein 
synthesis through reversible binding to the 30S ribosomal subunit.34 In addition, 
tetracyclines have multiple nonantibiotic properties. They act in an anti-inflammatory 
fashion by suppressing chemotaxis and neutrophil migration, inhibiting the expression 
of nitric oxide synthase, downregulating pro-inflammatory cytokines such as TNF-α and 
IL-1β, and upregulating the anti-inflammatory cytokine IL-10.34–36 Furthermore, they can 
inhibit angiogenesis,35 which is a common process in HS inflammation.
Because of these anti-inflammatory properties and a mild side effect profile, tetra-
cyclines are useful for long-term treatment and stabilization of HS.29,33 However, they 
are less effective in treating or preventing exacerbations of HS. Matusiak et al. cultured 
the bacteria isolated from HS patients and found that 64% of the isolated strains were 
resistant for tetracyclines.29 In addition, in a randomized double blind controlled trial, 
topical clindamycin 1% lotion was shown to be as effective as systemic tetracycline 
500 mg twice daily in terms of number of nodules, abscesses and patients pain score.37 
Although no studies are available on the effectiveness of doxycycline or minocycline in 
HS, we believe that they can be very effective in mild HS when given for several months.
Common side effects of tetracyclines are photosensitivity, gastrointestinal com-
plaints, and irreversible dental staining in children.36,38 Tetracyclines should not be 
taken together with iron supplements, antacids or milk, because together they can form 
insoluble complexes in the intestine, and reduce their absorption. In addition, the use 
of tetracyclines during pregnancy is contraindicated because of the risk of intrauterine 
dental staining and hepatic necrosis in pregnant women.39
3.2	 Clindamycin	and	rifampicin	combination	therapy
Most studies on antibiotics in HS have been published on the combination therapy 
of clindamycin and rifampicin. Clindamycin is produced by substituting chlorine to 
the hydroxyl group of lincomycin, an antibiotic isolated from a strain of Streptomyces 
lincolnesis in the early 1960s.40 Clindamycin is a broad-spectrum antibiotic, and is ef-
fective against Gram-positive bacteria and strains of S. aureus, with the exception of 
Streptococcus faecalis. However, most aerobic Gram-negative bacteria are resistant to 
clindamycin.40 Clindamycin binds to the 50S ribosomal subunit leading to inhibition 
of the bacterial protein synthesis. Besides its bacteriostatic effects, clindamycin has 
marked immune-enhancing properties. It enhances chemotaxis and phagocytosis, and 
increases TNF and IL-6 release.41,42
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Rifampicin is a chemically modified version of rifamycin, a natural metabolite of 
Nocardia mediterranei, and is active against Gram-positive cocci (including S. aureus), 
Gram-negative cocci and bacilli, and most anaerobes. Its bactericidal action is by inhi-
bition of bacterial DNA-dependent RNA polymerase, and is effective at extremely low 
concentrations and penetrates well into many body tissues.43 Rifampicin also has mild 
immunosuppressive properties, which is not unexpected since it is structurally related 
to the clear immunosuppressive macrolides such as tacrolimus and rapamycin. It sup-
presses T cell function and in vitro it was shown to reduce lymphocyte transformation.44 
In vitro, rifampicin has also been shown to inhibit IL-1β and TNF-α secretion, whereas IL-6 
and IL-10 secretion was significantly increased in rifampicin-treated mononuclear cells.45
For HS the most common regimen is clindamycin 300 mg twice daily, and rifampicin 
600 mg once daily or 300 mg twice daily, for a period of ten weeks. To date, four studies 
have been published in which a total 187 patients were treated.46–49 However, since in 
these studies different doses and different outcome variables were used to assess ef-
ficacy (Table III), it is difficult to compare or group these studies. In three retrospective 
studies, 164 patients were treated, of whom 88 patients completed a ten-week course 
of clindamycin 300 mg twice daily, and rifampicin 600 mg once daily or 300 mg twice 
daily.46–48 Twenty-one patients could not complete the treatment period because of side 
effects, mostly diarrhea and nausea. No data were available for 55 patients regarding the 
efficacy after ten-weeks, or different dosage regimens were used. Of the 88 patients, 25 
had a complete remission (28.4%) and another 57 showed a partial response (64.8%). 
In only six patients was the treatment either not effective or worsening was observed 
(6.8%). However, relapse rates of up to 61.5% have been reported after discontinuation 
of the therapy.46–48 In the only prospective study available to date, 20 of 23 patients 
completed the ten-week treatment course, and of these 17 had a reduction of 25% in 
the Sartorius score. One patient stopped prematurely because of gastrointestinal side 
effects.49
It has been suggested that clindamycin and rifampicin have a synergistic bactericidal 
effect on S. aureus in vivo.50 However, some studies have shown that the serum concen-
tration of clindamycin is dramatically reduced, even up to 82% of the peak concentration, 
when given together with rifampicin.51–53 Rifampicin is a potent inducer of cytochrome 
P450, whereas clindamycin is metabolized through a member of the cytochrome P450 
system, namely CYP3A4. This might explain the low serum levels of clindamycin. In ad-
dition, when both are taken orally, rifampicin may reduce the hepatic first-pass effect of 
clindamycin, further reducing the bioavailability of clindamycin.51
Most common side effects of clindamycin as well as of rifampicin are gastrointestinal 
complaints, such as nausea, vomiting, and diarrhea.40,44 In addition rifampicin can cause 
a red/orange discoloration to urine, sputum and tears, and can permanently discolor soft 
contact lenses.44 Clindamycin is considered relatively safe for use during pregnancies, 
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since it is unlikely that children of women treated with clindamycin during pregnancy 
have a high risk of congenital anomalies.39 However, for rifampicin insufficient data 
are available on use during pregnancy and therefore its use should be avoided during 
pregnancy.39 Because rifampicin interferes with the metabolism of oral contraceptives, 
female patients should use extra birth control measures.44
3.3	 Rifampicin,	moxifloxacin	and	metronidazole	triple	therapy
For severe or therapy-resistant patients, the combination of rifampicin, moxifloxacin 
and metronidazole is an alternative therapeutic option.54 Metronidazole was originally 
intended as an antiprotozoal agent that later proved very effective for Gram-negative 
anaerobic bacteria. In bacteria, it forms a redox intermediate metabolite causing DNA 
strand breakage, repair inhibition and ultimately disrupted transcription and cell death.55 
In addition, it has immunosuppressive properties. Metronidazole can decrease the level 
of IL-1β, IL-6, IL-8, IL-12, interferon (INF)-γ and TNF-α. It also has anti-inflammatory effects 
by blocking the migration of leukocytes from blood into the tissues.56 Moxifloxacin is an 
extended-spectrum fluoroquinolone that inhibits bacterial DNA topoisomerases, influ-
encing the replication, transcription, repair, and recombination of the bacterial DNA.57 
Moxifloxacin is a broad-spectrum antibiotic, and is effective against Gram-positive, 
Gram-negative and atypical respiratory pathogens. It also has shown to be effective 
against S. aureus and S. pyogenes. Furthermore, moxifloxacin has immunomodulatory 
properties; it inhibits the secretion of IL-1α and TNF-α by monocytes.58 Moxifloxacin is 
not metabolized through the cytochrome P450, therefore its availability is not affected 
when taken together with rifampicin.
In a retrospective study by Lamber et al., 28 HS patients were treated with the combi-
nation of rifampicin (10 mg/kg once daily), moxifloxacin (400 mg once daily) and met-
ronidazole (500 mg three times daily). Sixteen patients in this study showed complete 
remission and another twelve patients showed a partial response.54 To avoid neurologi-
cal complaints, the metronidazole was stopped after six weeks, but reintroduced in four 
patients because of recurrence.54 Over the past few years we have treated multiple HS 
patients with the above “triple therapy” with good results as long as the patients are 
taking the drugs.
The most common side effects of metronidazole are nausea, headache, and metallic 
taste. A serious but rare adverse effect of metronidazole is central or peripheral nervous 
system toxicity. In a recent review, Cação et al. reported on 84 cases of metronidazole-
induced neurotoxicity.59 In most cases (90.5%) the central nervous system (CNS) was 
involved, mostly causing cerebellar ataxia, encephalopathy, or seizures. In addition, 
polyneuropathy was reported in 26 cases. After discontinuation of the metronidazole, 
the CNS toxicity resolved in 92%, whereas 37% of the patients with polyneuropathy 
had complete resolution.59 Patients with longer treatment duration or higher doses did 
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not seem to be at a higher risk of developing CNS toxicity.60 It is important to inform 
patients to stop or minimize alcohol intake during treatment with metronidazole since 
this can lead to disulfiram-like reactions.55 Most frequent side effects of moxifloxacin 
are nausea, diarrhea, and dizziness. In addition, it can cause QTc-interval prolongation, 
therefore combination with class IA or class III antiarrhythmic drugs should be avoided.57 
The bioavailability of moxifloxacin is substantially reduced when taken together with 
antacids, sucralfate, or iron preparations.
All three antibiotics are contraindicated during pregnancy or breast-feeding. Female 
patients should use extra contraceptive measures because of the interaction of rifampi-
cin with oral contraceptives.
4. BIologICS
Since the early 2000s biologics are an upcoming treatment for HS. The efficacy of inf-
liximab, a TNF-α inhibitor, was first described in HS patients with concomitant Crohn’s 
disease (CD).61,62 The first case was a 30-year-old female CD patient who developed 
perianal abscesses, later followed by inflammatory nodules in both axillae. Antibiotic 
therapies had only temporary effect. After one dose of infliximab all here lesions signifi-
cantly improved, and after the second dose the patient stayed in remission for up to six 
months.61 Shortly after, Katsanos et al. reported on a 39-year-old male CD patient who 
presented with bilateral fistulizing axillary HS. He was started on infliximab and after 
one year all of his fistulas dried up and closed.62 In the following years, multiple case 
studies followed on the use of TNF-α inhibitors in HS. Other biologics were also given, 
such as adalimumab, etanercept, and anakinra. Recently the results of the first large 
randomized controlled multicenter trial on the use of adalimumab in HS patients has 
been published.12 Even though biologics are seldom curative in HS, they can suppress 
the symptoms and can often be given for a prolonged period, making them a good 
treatment option for chronic HS. The negative aspects of biologics are the costs and that 
reimbursement is not covered by all insurance companies.63
Overall, anti-TNF-α biologics are well tolerated, and patients can be treated for pro-
longed periods.12,64,65 The most common side effects are injection-site skin reactions or 
infusion reactions. Mostly they are a mild and transient local erythema, nodules, urticarial 
plaque, or pruritus. Patients on infliximab may develop hypersensitivity reactions such 
as generalized urticaria up to anaphylactic shock. Patients treated with adalimumab 
and infliximab, have a higher frequency of upper respiratory tract infections, rhinitis, 
bronchitis, and urinary tract infections.12,66,67 Since TNF-α plays an essential role in the 
host immune response against tuberculosis (TB), it is known that TNF-α inhibitors can 
increase the risk of TB. Therefore, screening of all patients for latent TB before therapy is 
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mandatory. In addition, the presence of heart failure, hepatitis B infection and malignan-
cies should be ruled out before therapy is started.65,66 Since biologics might have an 
effect on the immune response in neonates, it is contraindicated during pregnancy and 
women should use adequate contraceptives for up to at least five half-lives after the 
last dose. They are also contraindicated during lactation, since biologics are secreted in 
breast milk.3,65,66
4.1	 Infliximab
Infliximab is a chimeric monoclonal antibody consisting of the human IgG1 still contain-
ing a murine fragment of the antigen-biding (Fab) portion specific for TNF-α. It binds 
to the soluble and transmembrane forms of TNF-α, inhibiting TNF-α from binding to its 
receptors.68 Multiple studies have reported on the efficacy of infliximab in patients with 
HS.69–71 Mostly the same dose is given as in psoriasis, with 5 mg/kg infliximab at week 
0, 2 and 6, and continued every 8 weeks thereafter.3,72 Even though an improvement 
is often reported in the inflammatory lesions during infliximab therapy, recurrence is 
high also during therapy. Up to 50% develops new lesions after a treatment period of 
37 weeks.69–71 Moriatry et al. suggested that an eight-week interval is too long for HS 
patients and that a four-week interval is more effective,71 because most patients report a 
gradual increase in inflammatory lesions around six weeks after infusion. In our experi-
ence, a six-week interval maintenance scheme works well in most HS patients. Shorter 
intervals for infliximab infusions are not recommended because they generally lead to 
more side effects and because of the cost aspects. Unfortunately, no trials have been 
done comparing different interval schemes of infliximab in patients with HS.
4.2	 Adalimumab
Adalimumab is a fully human recombinant IgG1 monoclonal antibody against TNF-α. It 
binds soluble TNF-α and thereby prevents its interaction with TNFR1- and TNFR2-type 
cell receptors.66 In addition, it changes levels of adhesion molecules responsible for leu-
cocyte migration, and reduces serum concentrations of C-reactive protein, erythrocyte 
sedimentation rate, and IL-6.66
The first reports of the use of adalimumab in HS patients dates from 2006.73,74 Initially it 
showed efficacy in an African American male with concomitant seronegative arthritis,73 
and later in a Caucasian male with concomitant inflammatory bowel disease.74 Over the 
years multiple studies followed, reporting different clinical outcomes. Two prospective 
studies using a dose of 40 mg every other week showed initial improvement.75,76 How-
ever, after twelve weeks of treatment no difference could be observed compared with 
baseline or with placebo. Nonetheless, these studies report on high recurrence rates 
after discontinuation.75,76 It has been suggested that a weekly dose is more effective.3 In 
a retrospective study Blanco et al. initially started with 40 mg every other week, but in 
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five of the six patients the dose had to be increased to 40 mg every week to prevent re-
lapse.64 In a large prospective randomized placebo-controlled trial, 40 mg adalimumab 
weekly was more effective than 40 mg every other week or placebo after 16 weeks of 
treatment.12 However, of the weekly patients, only 18% achieved the clinical end-point 
(clear, moderate to mild response with a decrease of at least two grades). This response 
rate dropped further when at 16 weeks the dose was decreased to 40 mg every other 
week. Therefore, a high-dose regimen seems to be needed to suppress HS.12
4.2.1. Infliximab versus adalimumab
Only one retrospective study compared the effectiveness of infliximab with adalim-
umab.77 Ten patients were treated for eight weeks with three courses of infliximab 5 mg/
kg, whereas in the other group, ten patients were treated for a year with adalimumab 40 
mg every other week. After one year the three courses of infliximab seemed more effec-
tive than continuous adalimumab.77 However, it was not mentioned whether infliximab 
patients received other treatments during the follow-up period. In addition, as set out 
above, an every-other-week dosing regimen seems to be insufficient for HS.
4.3	 Etanercept
Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding por-
tion of the human p75 TNF receptor, and the constant portion of IgG1. Etanercept binds 
and neutralizes the soluble TNF, transmembrane TNF, and lymphotoxin. In addition, it 
can alter dendritic-cell, T cell and neutrophil emigration.65
The first prospective open-label study of etanercept in HS showed promising results. 
Patients were treated with 50 mg etanercept subcutaneous every week. After twelve 
weeks six out of ten patients showed a decrease of more than 50% in disease activity. 
This effect remained in the twelve-week follow-up period.78 However, in a later open-
label and in a placebo-controlled studies, these results could not be reproduced.79,80 In 
the open-label study 15 patients were treated with 50 mg weekly. Only ten completed 
the twelve-week treatment period, of whom three reached the primary end-point, a 50% 
reduction in the Physicians Global Assessment (PGA) score.79 In the placebo-controlled 
trial, ten patients were treated with etanercept 50 mg twice weekly and ten received pla-
cebo. After twelve weeks of treatment, there was no difference in PGA, patients’ global 
assessment, or DLQI between etanercept and placebo. In addition, in the following 
twelve-weeks open-label phase, no improvement was observed.80 Therefore, etanercept 
is not a first choice biologic in HS.
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4.4	 Other	biological	treatments
4.4.1. Ustekinumab
Ustekinumab is a human monoclonal antibody that binds to the p40 subunit of IL-12 
and IL-23, preventing them from binding to their receptor.81 To date, eight HS patients 
have been treated with 45 mg ustekinumab subcutaneously, mostly at week 0, 4 and 
12, followed by every three months. Four patients showed a complete remission of 
their HS, three patients had a partial response, and one patient did not respond to 
ustekinumab treatment.82–85 During the 23rd European Academy of Dermatology and 
Venereology (EADV) congress in 2014 in Amsterdam, Blok et al. presented the results 
of the first prospective open-label study of ustekinumab in HS patients.86 Seventeen 
patients were treated with 45-90 mg, administered at weeks 0, 4, 16 and 28. Twelve pa-
tients completed the treatment protocol. A reduction of ≥50% in the modified Sartorius 
score was achieved by six patients (35%) at week 40, and another eight (47%) showed a 
moderate response (reduction of 25-50% in the modified Sartorius score). Five patients 
dropped out because of lack of efficacy, side effects, or psychological problems.86,87
4.4.2. Anakinra
Anakinra is a recombinant human IL-1 receptor antagonist that blocks the inflammatory 
effects of IL-1.88 In HS elevated levels of IL-1 have been demonstrated in lesional and 
perilesional skin.17 To date, ten patients have been treated with anakinra with mixed re-
sults.89–93 In seven patients anakinra showed clear improvement of the HS lesions,89,90,93 
whereas in the other three patients with severe HS, anakinra was ineffective.91,92 We 
await the results of a prospective, placebo-controlled trial with great interest to see the 
position of anakinra as a treatment option for HS.
5. otHEr AntI-InFlAmmAtory DrugS
5.1	 Dapsone
Dapsone is an aniline derivate from the sulfone group.94 It has not only antimicrobial 
and antiprotozoal properties, but it also has anti-inflammatory properties similar to 
those of nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, it can suppress the 
levels of IL-8 and TNF-α.94 To date, two retrospective studies have been published on the 
use of dapsone for HS. Kaur and Lewis reviewed five cases of refractory HS treated with 
50-150 mg of dapsone per day. All five patients showed improvement after four to twelve 
weeks of treatment.95 In a later series of 24 patients treated with 50-200 mg per day, nine 
patients showed slight to clinically significant improvement, whereas the other 15 did 
not respond to dapsone therapy.96
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5.2	 Fumaric	acid	ester	derivatives	(fumarates)
In Europe, fumarates are a common treatment for psoriasis because of their immuno-
modulatory and anti-inflammatory effects.72 Among other multiple effects, they impair 
IL-12 and IL-23 production by dendritic cells and macrophages.97 Our department has 
recently reported on the use of fumarates in HS.98 Seven patients with moderate to se-
vere HS were treated with fumarates in a progressive dosage scheme up to 720 mg a day. 
After 20 weeks of treatment only one patient showed clear improvement, but two others 
reported reduced inflammation with lesions that resolved faster. Therefore, treatment 
was continued and after 28 weeks all three showed slight to clear improvement. Two 
patients continued up to one year with clear improvement of their HS. However, four 
patients stopped after 20 weeks due to lack of efficacy and one patient stopped after 28 
weeks because of persistent diarrhea.98
5.3	 Cyclosporine
Cyclosporine is a calcineurin inhibitor and a potent immunosuppressive drug.99 It sup-
presses IL-2 production, and in the epidermis and dermis cyclosporine causes a depletion 
of lymphocytes and macrophages. It also inhibits the activation of T cells, natural killer 
cells and antigen-presenting cells. In addition, cyclosporine can inhibit keratinocyte 
hyperproliferation.99 To date, only a few cases have been reported on the use of cyclo-
sporine in HS. Four patients with recalcitrant HS showed significant improvement after 
treatment with 3-5 mg/kg cyclosporine per day.100–102 However, randomized controlled 
trials and larger case series are lacking on the effectiveness of cyclosporine in HS.
5.4	 Systemic	and	intralesional	steroids
Because of their anti-inflammatory and immunosuppressive properties, systemic 
steroids have always been widely used in dermatology. They are often mentioned as 
a treatment option for HS,3,103,104 and in a survey among physicians interested in HS 
from the UK, a quarter responded that prednisolone was one of their top ten treatment 
choices for HS.20 A short-term treatment of 0.5-0.7 mg/kg can be used to control acute 
flares.3,103 However, reports on the use of oral steroids in HS date from more than 25 years 
ago, and no recent studies are available.
The use of intralesional corticosteroids is mostly based on clinical experience, but they 
are often used for solitary inflammatory nodules.3,20 Intralesional injection of 5-10 mg/
ml, can cause a rapid reduction of the nodules and is in our opinion a good option for 
single recalcitrant inflammatory nodules.3,22
5.5	 Azathioprine
Azathioprine is a purine antagonist with immunosuppressive, immunomodulating and 
anti-inflammatory properties. In a small retrospective study of nine HS patients, azathio-
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prine was ineffective in five patients, and the other three showed only slight improve-
ment.105 However, the therapeutic effects of azathioprine are normally reached after two 
to three months, and six patients were treated for six weeks or fewer due to side effects. 
In addition, the therapeutic range of azathioprine is 1-3 mg/kg, but in five patients the 
dose remained below 1 mg/kg. Therefore, it is possible that azathioprine was ineffective 
due to a too short treatment duration and too low dosing.105
5.6	 Colchicine
The anti-inflammatory drug colchicine accumulates in neutrophils, inhibits neutrophil 
expression of cell adhesion molecules, and decreases neutrophil degranulation, chemo-
taxis and phagocytosis.106,107 In a small case series of eight HS patients, colchicine did not 
show any clinical improvement. Six patients dropped out before the end of the study 
because of lack of efficacy. Of the two patients who completed the four month period, 
only one showed slight improvement.107
5.7	 Methotrexate
Methotrexate is an anti-inflammatory and immunosuppressive drug that is often used 
for treating psoriasis, psoriatic arthritis, or rheumatoid arthritis.108 In a report on three HS 
patients, a dose of 12.5-15 mg per week did not have any effect on the existing lesions nor 
did it reduce the number of flare-ups.109
6. rEtIonoIDS
6.1	 Isotretinoin
The vitamin A derivate, isotretinoin is naturally present in small amounts in the blood 
and tissue. It has an antiproliferative effect on sebocytes, it inhibits cell differentiation 
and sebum secretion, and reduces the size of the sebaceous glands. In addition, it has 
anti-inflammatory, immunomodulatory, and antineoplastic properties.110 The use of 
isotretinoin for HS comes from the former belief that HS is associated with acne vulgaris. 
However, in HS the sebaceous glands are not primarily affected and there is no evident 
seborrhea.111 Even though multiple studies reported the lack of efficacy of isotretinoin in 
HS,112–114 it is still often prescribed for this condition.20 Blok et al. reviewed seven papers 
in which isotretinoin were used for HS. In total, 174 patients were treated, of whom only 
32 reported significant improvement (18%), 30 moderate improvement (17%), and in 
112 patients no response was observed (64%).115 Therefore, isotretinoin should not be 
prescribed for standard HS, and should only be considered if patients have concomitant 
acne vulgaris. Isotretinoin is highly teratogenic, therefore female patients should use 
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adequate contraceptives, up to six months after therapy, and pregnancy test should 
routinely be performed.
6.2	 Acitretin
Originally etretinate was the first retinoid registered for psoriasis, but its use was limited 
because of its unfavorable pharmacokinetic profile with a very long elimination time and 
teratogenic effects. It was later replaced by acitretin, which was derived from etretinate, 
but had a shorter half-life.116 Acitretin has anti-inflammatory properties and modulates 
the cellular differentiation, proliferation, and cornification of the epidermis.116,117 Most 
importantly it influences the process of hyperkeratosis of the infundibular follicular 
epithelium, which is primary involved in the pathogenesis of HS.13,14,117 In a retrospective 
study of Boer and Nazary, all twelve treated patients showed a positive response to 0.25-
0.88 mg/kg acitretin for a period of nine to twelve months. Nine out of twelve patients 
achieved a marked or complete remission, whereas the other three had a mild to moder-
ate response. All patients reported cheilitis as a side effect.117 In a recent prospective 
study, 17 patients were treated with 0.5-0.6 mg/kg.118 Nine patients completed the nine-
month treatment period, of whom eight achieved the clinical endpoint, a reduction of 
50% in the HS Severity Index (HSSI). Drop-out was mostly because of ineffectiveness 
or side effects.118 Like isotretinoin, acitretin is teratogenic, and major human fetal ab-
normalities are associated with retinoid use during pregnancy. Female patients should 
use adequate contraceptives up to two years after discontinuation, since, especially in 
the presence of ethanol, acitretin converts to etretinate, which takes two years to be 
completely eliminated from the fatty tissue.116
6.3	 Alitretinoin
Alitretinoin is a vitamin A derivative and is registered for severe chronic hand eczema. 
Recently the first study on the use of alitretinoin in HS has been published.119 Fourteen 
patients were treated with 10 mg alitretinoin daily for a period of 24 weeks. Six patients 
showed significant improvement, with a reduction of 50% in the Sartorius score. An-
other five patients reported improvement; however, this was less than a 50% reduction 
in the Sartorius score. Only three patients did not respond.119 Alitretinoin is very similar 
to acitretin, accept for its much shorter half-life, making it a better treatment option 
for female patients. Contraceptives have to be used up to one month after treatment 
discontinuation.
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7. otHEr mEDICAl trEAtmEntS
7.1	 Zinc
Zinc plays a role in the innate and adaptive immunity. It is believed that zinc can alter 
the differentiation and function of T cells, and that it activates natural killer cells and the 
phagocytic function of granulocytes. In addition, it leads to an increased production 
of IL-6, IL-1β and TNF-α.120,121 In a pilot-study, 22 patients started with 90 mg of zinc and 
the dose was reduced with 15 mg every two months. Eight patients showed complete 
remission, and partial remission was achieved in the other 14 patients. Relapse occurred 
when doses lower than 30 to 60 mg were given. Gastrointestinal discomfort was the 
most common side effect and was reported by four patients.121
7.2	 Metformin
Metformin is an insulin sensitizer and is a first-line treatment option for patients with 
diabetes type II. Metformin also has anti-oxidative and anti-androgenic properties and 
has been shown to inhibit human immortalized keratinocytes in vitro.122,123 Metformin 
was initially reported to have an effect on HS, after a woman reported worsening of her 
HS after metformin was stopped.124 In prospective study, 25 HS patients were treated 
with a progressive dose scheme up to a maximum of 500 mg three times a day. Eighteen 
patients showed clinical improvement, with seven having a reduction of more than 50% 
in the Sartorius score. The other seven patients were unresponsive to the treatment. Only 
minor gastrointestinal side effects were reported at the beginning of the treatment.123
8. HormonAl trEAtmEnt
The role of sex hormones in the pathogenesis of HS is still under debate. The clinical 
course of HS would suggest a role of sex hormones, due to the post-pubertal onset, 
female predisposition, reports of peri-menstrual flares, and improvement during 
pregnancies.25,104,125 However, no difference was found in androgen levels between HS 
patients and body mass index (BMI)-matched controls.126
8.1	 Finasteride
Finasteride is a 5α-reductase inhibitor that inhibits the conversion of testosterone to 
dihydrotestosterone.127 It was originally approved for treatment of benign prostatic 
hypertrophy and later for androgenetic alopecia in men. To date, the use of finasteride 
has been reported in twelve HS patients, eight adults and four children. Seven adult 
patients showed a good response on 5 mg finasteride daily after a treatment period of 
two to twelve weeks.128,129 Two patients showed recurrence, one month after discontinu-
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ation. The four female children were treated with finasteride 1.25-10 mg daily with good 
effect. However, all received additional treatment with oral contraceptives, antibiotics, 
or surgery.129,130
Side effects of finasteride in men are decreased libido and gynecomastia. Finasteride 
should not be used during pregnancy due to feminization of the male fetus.127
8.2	 Cyproterone	acetate
In 1986, Sawers et al. reported on the effectiveness of the antiandrogen cyproterone 
acetate combined with estrogen in four female HS patients.131 However, a double-blind 
controlled trial comparing ethinyloestradiol 50μg/cyproterone 50 mg with ethinyloes-
tradiol 50μg/norgestrel 500μg showed no difference between the two groups. However, 
of the 18 patients from both groups that completed the trial, twelve showed a good 
response, suggesting that both hormonal therapies can be effective in HS.132 However, 
larger, well powered studies on the use of hormonal therapy in HS are lacking.
9. PAIn trEAtmEnt
Pain management is a crucial part of the treatment of HS. However, no studies are avail-
able on the use of analgesics in HS. Only two reviews have been published on the pain 
management in HS patients.133,134 Even though these are comprehensive reviews on a 
broad spectrum of analgesics, its use in HS is mostly based on clinical experience.133,134 
First of all it is recommended that a visual analogue scale (VAS) is used to assess the pain 
level of the patients, and this can also be a guide to evaluate if the prescribed analgesics 
are sufficient. For moderate constant pain, oral acetaminophen (paracetamol) 1000 mg 
four times per day is often the first step in pain treatment. In general, acetaminophen is 
well tolerated; however, excessive doses can lead to liver toxicity.133,134 When acetamino-
phen does not sufficiently reduce the level of pain, or when the patient complains of 
sporadic acute pain, NSAIDs are indicated. The dose depends on which NSAID is chosen, 
and standard regimens are recommended.3 There is no evidence that one NSAID is 
superior to another.133,134 Long-term use of NSAIDs can increase the risk of gastric ulcers, 
therefore proton pump inhibitors are recommended when patients use NSAIDs on a 
frequent basis. When patients have high levels of chronic pain, opiates are indicated.3 
Codeine is the first option of this drug class, due to its lower risk on addiction. When 
higher levels of pain medication are needed, referral to a pain team is recommended.133
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10. lIFEStylE CHAngES
Smoking and obesity are strong risk factors for HS. Most HS patients are active smokers 
(66-71%) or ex-smokers (8-15%), and 51-82% of patients are overweight or obese, with 
a BMI > 25kg/m2.135–138 Disease severity is positively correlated with BMI,135–137 and case 
reports have demonstrated remission of HS after extensive weight loss.139,140 In one 
study patients were asked after bariatric surgery if they had suffered from HS before 
the operation and if the symptoms had changed after the operation. After a decrease 
in BMI of 15%, half of the patients stated they were free of inflammation and another 
20% reported to have fewer symptoms.141 Since HS is also associated with metabolic 
syndrome,142 patients with HS should be strongly advised to reduce weight.
The exact effect of smoking cessation on HS is still unclear. However, it is thought that 
smoking can trigger the onset of HS, and heavy smokers tend to have a more severe 
disease than non- or mild smokers.135–137 In a study on the clinical course, patients were 
asked 22 years after the diagnosis was made, if they still suffered from HS. Nonsmok-
ers and ex-smokers were more often disease-free than active smokers, indicating that 
smoking cessation contributes to disease remission. This is supported by a case report 
of two patients who became free of symptoms after they quitted smoking. However, 
mostly cessation does not give instant improvement of the disease,143 often leading to 
disappointment in the patients and causing them to restart smoking. Patients should 
be well educated that they should not expect instant relief after cessation but that it 
helps towards improvement or even remission over the years. We believe that active 
referral of patients with HS to their general practitioner or any other “Stop smoking” and/
or “Weight loss” program is essential.
11. FuturE oPtIonS
Recently, elevated levels of IL-17 and IL-23 have been found in lesional HS skin.18,19 These 
findings point towards new treatment options. Biologics targeting IL-17 are secukinumab, 
ixekizumab and brodalumab. Secukinumab is a fully human IgG1 monoclonal antibody 
against IL-17A, whereas ixekizumab is a humanized IgG4 monoclonal antibody that 
neutralizes IL-17A, and brodalumab a human IgG2 monoclonal antibody that blocks IL-
17R, a receptor subunit shared by IL-17A, IL-17F, and IL17A/F heterodimer ligands.144,145 It 
is also possible to target IL-23 alone, with tildrakizumab or guselkumab. Tildrakizumab 
is a humanized IgG1k monoclonal antibody against IL-23p19, whereas it does not bind 
to IL-12 or the p40 subunit, just like guselkumab which is a human IgG1 monoclonal 
antibody against IL-23p19.144
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Another immunomodulating drug is apremilast. It is a selective inhibitor of phospho-
diesterase 4, and has shown in vivo to inhibit the production of the pro-inflammatory 
cytokines (e.g. IL-2, IL-5, IL-12A, IL-13, IL-17 IL-23A, TNF-α, INF-α and INF-γ), and chemokines 
(e.g. CXCL9 and CXCL10).146
Even though, these therapeutic options have shown to be effective in psoriasis,144–146 
no studies are available on their use in HS.
12. ConCluSIon
Hidradenitis suppurativa is a chronic inflammatory skin disease. Over the years multiple 
treatment options for HS have been suggested; however, so far none has been cura-
tive for HS. In mild disease, clindamycin lotion or resorcinol cream can give long-term 
remission. When these are insufficient or in more severe HS, mostly tetracyclines are 
first-line systemic options. However, the combination of clindamycin with rifampicin is 
the best-documented antibiotic treatment for HS, and is often effective in moderate to 
severe HS. Although antibiotics can be effective in reducing the number of inflamed le-
sions, recurrence rate is high after discontinuation. A more long-term treatment option 
is possible using retinoids, especially acitretin; however, due to their teratogenicity, they 
are less useful for females in the reproductive age. When patients fail to respond to most 
common treatments, biologics (e.g. infliximab or adalimumab) are the next step. Mul-
tiple anti-inflammatory drugs have been suggested for HS, such as dapsone, fumarates 
or cyclosporine. However, their effectiveness in HS is based on small case series with 
varying results. Although not addressed in this review, surgical interventions are often 
needed to achieve remission, especially when sinus tracts or scaring are present. For 
every patient treatment should be chosen based on the clinical presentation of the HS 
and the preferences of the patient.
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ABStrACt
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, with-
out curative treatment; some patients fail all regular treatments. Fumarates are effective 
in patients with psoriasis, which is attributed to their anti-inflammatory effects. Because 
in HS patients pro-inflammatory cytokine levels are elevated and are thought to play a 
key role in the pathogenesis of HS, we hypothesized that fumarates could be effective 
in patients with HS.
methods: In a prospective, open-label, pilot study, seven patients with moderate to 
severe HS, refractory to regular HS drug treatments, were included. Fumarates were 
administered for a minimal period of 20 weeks in a progressive dosage scheme up to a 
daily dose of 720 mg dimethylfumarate, following the European psoriasis S3-guidelines. 
Effectiveness was assessed using a physician’s global assessment score.
results: Three men and four women were included. After 20 weeks of treatment with 
fumarates, three patients (43%) showed improvement and continued treatment. At 
28 weeks one patient, with mild improvement, stopped because of gastrointestinal 
complaints. Two patients continued treatment for at least one year, remaining clear of 
inflammatory lesions. In four patients (57%) fumarates were discontinued at week 20 
because of lack of efficacy. Most reported side effects were gastrointestinal complaints 
(57%) and flushing (85%).
Conclusion: Fumarates proved effective in three of seven HS patients, who were refrac-
tory to multiple regular HS treatments. Therefore, fumarates can be considered as a 
therapeutic option in patients who have failed multiple conventional HS therapies.
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IntroDuCtIon
Hidradenitis suppurativa (HS), or acne inversa, is a chronic, debilitating skin disease, 
characterized by recurrent inflammatory boils and abscesses, mainly located in areas 
of the skin folds, such as axillae, groin and perianal regions.1 HS is common, with an 
estimated prevalence of 1% in the general population.2 HS can have a severe negative 
impact on the quality of life,3 partly because the disease is difficult to treat. To date, there 
is no cure for HS. Generally, treatment consists of long-term drug therapy, surgery or 
both.1 However, inflammations often flare after the drug treatment is discontinued, and 
after surgery patients can develop new inflammatory lesions at other or adjacent body 
areas. Therefore, there is a clear need for effective long-term treatment for HS.
Fumarates have shown to be effective in patients with moderate to severe psoriasis,4,5 
but also in granuloma annulare and cutaneous sarcoidosis.6,7 This is attributed to their 
immunomodulatory and anti-inflammatory effects.8 Because elevated levels of inflam-
matory mediators, such as interleukin (IL)-1β and tumor necrosis factor alpha (TNF-α), 
are found in HS and are considered to play an important role in the pathogenesis of HS,9 
we argued that fumarates could also be effective in patients with HS.10 To investigate this 
hypothesis, we conducted a prospective, single-center, open-label pilot study, to assess 
the effectiveness and short-term tolerability of fumarates in patients with moderate to 
severe HS who were refractory to conventional HS therapies.
SuBjECtS AnD mEtHoDS
We conducted a prospective, single-center, open-label pilot study. Seven patients with 
HS were included from the Department of Dermatology, Erasmus University Medical 
Center, Rotterdam, The Netherlands. The inclusion criteria were age older than 18 years, 
moderate to severe HS (Hurley stages II or III),1 recipient of multiple common HS treat-
ments with insufficient or temporary effect. Fumarates were thus considered as a therapy 
of last resort for these patients. Patients were treated with oral fumarates according 
to a progressive dosage scheme as recommended by the European S3-guidelines for 
psoriasis (Table I),4 for a minimum of 20 weeks, up to a maximum daily dosage of 720 mg 
dimethylfumarate (DMF). Patient visits were scheduled at baseline, week 4, 8, 12 and 20. 
At each visit blood count, liver and kidney function, and general urine analysis and urine 
sediment were collected. All female patients had a pregnancy test at baseline.
At each visit, patients were asked about side effects and clinical photographs were 
taken. The efficacy outcome was assessed using a physician’s global assessment (PGA) 
compared with baseline: -2, clear worsening; -1, slight worsening; 0, no change; 1, slight 
improvement; 2, clear improvement; and 3, total clearance of inflammatory lesions.
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rESultS
The characteristics of the seven patients included are shown in Table II. All patients were 
active smokers, were overweight with a median body mass index of 33.3 kg/m2 [interquar-
tile range (IQR): 29.9-41.8], and a median disease duration of 28.0 years [IQR: 18.0-35.0]. 
All patients were previously treated with topical antibiotics, long-term oral antibiotics 
(e.g. minocycline, doxycycline, clindamycin, rifampicin). In addition, most were treated 
with isotretinoin, dapsone, biologics (infliximab, adalimumab or etanercept), or wide 
local excision of all HS affected skin with primary closure or healing by secondary inten-
tion (Table II).
table I. Dosage scheme for fumarates (no. of tablets per day)
Week
Dimethylfumarate
30 mga 120 mgb
1 0 – 0 – 1 –
2 1 – 0 – 1 –
3 1 – 1 – 1 –
4 – 0 – 0 – 1
5 – 1 – 0 – 1
6 – 1 – 1 – 1
7 – 1 – 1 – 2
8 – 2 – 1 – 2
9 – 2 – 2 – 2
Fumarates were administrated as a formulation of enteric-coated tablets containing: a30 mg dimethylfumarate and 75 
mg monoethylfumarate salts, or b120 mg dimethylfumarate and 95 mg monoethylfumarate salts (Apotheek de Magistrale 
Bereider, Oud-Beijerland, The Netherlands).
table II. Patient characteristics and outcomes by physician’s global assessment (PGA) score
Patient
no.
Sex Age
years
BmI
kg/m2
Hurley
stage
Current
smoker
Previous treatments PgAa (weeks)
4 8 12 20 28
1 M 46 25.0 III Yes ABT, ABO, TNF-in (I), iso, WLE -1 1 0 0 -
2 M 44 41.8 III Yes ABT, ABO, TNF-in (A), iso, WLE 0 2 2 2 2
3 F 50 34.6 II Yes ABT, ABO, iso, WLE 0 0 1 0 2
4 F 35 29.8 II Yes ABT, ABO, TNF-in (A), iso, WLE -1 1 1 0 1
5 M 53 31.7 II Yes ABT, ABO, daps, iso, WLE -1 -2 0 0 -
6 F 63 33.3 II Yes ABT, ABO, TNF-in (I) 0 -1 -1 -1 -
7 F 38 45.7 II Yes ABT, ABO, TNF-in (E), iso, WLE 0 0 -2 0 -
ABT - topical antibiotics; ABO - oral antibiotics; BMI - body mass index; daps - dapson; iso - isotretinoine; TNF-in - tumor ne-
crosis factor alpha inhibitors (I - infliximab, A - adalimumab, E - etanercept); WLE - wide local excision of all HS affected skin
a PGA score compared with baseline: -2, clear worsening; -1, slight worsening; 0, no change; 1, slight improvement; 2, clear 
improvement; and 3, total clearance of inflammatory lesions
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Dosage	scheme
In six patients the standard progressive dosage scheme was followed and therapeutic 
dosage of 720 mg dimethylfumarate was reached after eight weeks of treatment. In 
patient 7 the dosage increase was slower because of severe flushing, but she reached 
the therapeutic dosage after eleven weeks of treatment.
Outcome
After eight weeks of treatment, in three out of seven patients (43%), slight to clear im-
provement compared with baseline was noted (Table II). At 20 weeks, patient 2 showed 
Patient 2 at baseline
Patient 2 after 28 weeks of treatment
Figure 1. Patient 2 at baseline and after 28 weeks of treatment with fumarates, note the decreased 
skin inflammation.
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clear improvement; however, four patients (57%) discontinued fumarates because of 
lack of efficacy (Table II). As patients 2, 3 and 4 experienced smaller inflammatory lesions 
that resolved faster, they continued on fumarates, reaching mild to clear improvement 
after 28 weeks of treatment (Figure 1). Patient 2 and 3 continued therapy, and after one 
year of treatment both patients still had clear improvement of their HS lesions. Patient 4 
stopped at 28 weeks because of persistent diarrhea, showing clear worsening of her HS 
after discontinuation.
Tolerability
Flushing was mentioned by six patients (85%), four patients (57%) experienced some 
level of gastrointestinal discomfort (nausea, diarrhea or constipation), and three pa-
tients complained about fatigue (43%). Other complaints included pruritus, burning or 
tingling skin sensation. Side effects resolved in four patients before the 20 week visit. 
Patient 1 and 5 showed mild lymphopenia, and patient 3 showed mild increased serum 
creatinine. No significant changes in ALAT, ASAT, γ-GT, leukocytes or eosinophilic granu-
locytes were observed.
DISCuSSIon
This prospective, single-center, open-label pilot study shows that fumarates induced 
clinically meaningful improvement in three out of seven HS patients, who were previ-
ously refractory to conventional HS treatments. Patient 2 and 3 reached clear improve-
ment after 28 weeks of treatment, and continued on fumarates maintaining the clinical 
response for up to one year. Patient 4 showed mild improvement after 28 weeks, but 
had to stop because of gastrointestinal complaints. After discontinuation, she showed 
clear worsening of her HS. Even though a response of three out of seven seems low, 
we considered it meaningful because these patients were previously unresponsive to 
multiple common HS treatments.
Common side effects of fumarates are gastrointestinal complaints and flushing.4 In 
our study four patients (57%) experienced gastrointestinal complaints and six out of 
seven patients (85%) experienced flushing. The latter percentage is higher than the 
earlier reported 31% in psoriasis patients.6 None of the patients had to stop prematurely 
due to worsening of blood parameters. Since fumarates are not metabolized through 
the cytochrome P450-dependent pathways, drug interactions would be less likely and 
have, to date, not been reported.11
The mode of action of fumarates in improving HS is thought to be via its immuno-
modulatory and anti-inflammatory effects.8,12 In patients with HS, similar to patients with 
psoriasis,13 IL-12 and IL-23 are found abundantly expressed by macrophages in lesional 
Fumarates as a treatment option | Chapter 10
167
10
HS skin.14 DMF reduces the capacity of dendritic cells and macrophages to produce IL-12 
and IL-23.15 In addition, in the presence of monomethylfumarate, the active metabolite 
of DMF, dendritic cells produce minimal levels of IL-12p70 and IL-10, and only low levels 
of TNF-α.15,16 Finally, in high enough concentrations DMF causes a significant reduction 
of nuclear factor kappa B (NF-kB),17 leading to an inhibition of NF-kB-mediated tran-
scription of cytokines such as IL-1, TNF-α and IL-8.8 In patients with HS, elevated levels of 
TNF-α, IL-1β and IL-10 are found in lesional skin as well as in unaffected skin,9 and it has 
been argued that these cytokines are important in the pathogenesis of HS.10 We argue 
that fumarates could be effective in HS through inhibition of these key cytokines.
The limitations of this pilot study are the small sample size, the fact that it was not 
randomized nor placebo-controlled, and that only patients refractory to multiple con-
ventional HS therapies were included.
In conclusion, this study shows that fumarates induced clinically meaningful improve-
ment in three out of seven patients with recalcitrant moderate to severe HS. Therefore, 
fumarates can be considered a treatment option for HS, when patients are refractory to 
regular therapies and no other treatment options are available.
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Severe hidradenitis suppurativa 
treated with wide excision:
a meaningful local cure rate and
high patient satisfaction
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ABStrACt
Background: Hidradenitis suppurativa is a chronic inflammatory skin disease, without 
cure. Surgical treatment under general anesthesia whereby all affected tissue is excised 
if often needed to achieve remission.
objectives: To investigate the clinical characteristics, recurrence rate and patient sat-
isfaction in patients with severe HS who had undergone wide surgical excision under 
general anesthesia.
methods: The records of patients who had undergone wide surgical excision between 
2007 and 2014 at our Dermatology Department, were retrospectively reviewed. In addi-
tion patients were sent a questionnaire comprising questions on recurrence and patient 
satisfaction.
results: In total 86 patients responded, who had 260 surgical procedures. Mostly the 
inguinal (n=95, 36.5%) and gluteal/perianal region (n=67, 25.8%) were treated, with 
secondary-intention healing (97.3%). After a follow-up of on average 3 years, in 50.8% 
the treated anatomical area remained disease-free, natural disease progression was 
seen in 12.7%, and recurrence within the surgical scar or less than 0.5 cm from the scar in 
36.5% of cases. Most patients were glad that they had the operation (91.8%) and would 
recommend it to other HS patients (91.8%).
Conclusion: Wide surgical excision induced remission in 50.8% of the affected HS ana-
tomical areas in patients with severe HS. A prospective study is needed to determine the 
best surgical and closure techniques in severe HS.
Wide excision surgery | Chapter 11
173
11
IntroDuCtIon
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, characterized by 
painful deep-seated nodules and abscesses mainly located in the inverse body areas, 
such as the axillary, inguinal and anogenital regions.1 The prevalence of HS varies from 
1% to 4% across Europe.2,3 HS usually develops after puberty with a peak age of onset 
in the early twenties, and the prevalence seems to diminish over time;1,4 also it is more 
common in women with a female-to-male ratio of 3:1.3 HS has a major negative impact 
on the quality of life with a high psychological burden that can lead to isolation.5
To date, there is no cure for HS. Patients are generally treated with long-term anti-
biotics, or in more severe cases, with tumor necrosis factor alpha (TNF-α) inhibitors.5 
Surgery gives the highest chance for remission of HS.1,6 The most common surgical 
procedures are: incision with drainage, deroofing, and limited or wide excision. Incision 
with drainage is usually performed in acute stages to drain pus from abscesses and to 
relieve pain, but recurrence rates up to a 100% have been reported.4,7,8 Deroofing is a 
surgical technique whereby the lesions are explored using a probe and the roof is ex-
cised; it is most effective for recurrent superficial lesions in a mild phase of the disease.9 
In case of a more severe disease, the lesions can be totally excised using limited excision 
or wide excision surgery, in which smaller excisions tend to have a higher recurrence 
rate than wider excisions.4,7
Even though wide excision is a common surgical procedure for HS, studies in large co-
horts of HS patients on the recurrence rate and patient satisfaction are scarce. Therefore, 
we conducted a retrospective study to investigate the clinical characteristics, recurrence 
rate and patient satisfaction of HS patients who had undergone wide surgical excision 
under general anesthesia at our department.
PAtIEntS AnD mEtHoDS
We identified all patients with HS who underwent wide excision surgery under gen-
eral anesthesia between 2007 and 2014, at the Department of Dermatology at Erasmus 
University Medical Center in Rotterdam, The Netherlands. Data were collected from the 
medical files of the patients, and in addition, for each patient an individual HS-specific 
questionnaire was made, based on the number of surgical procedures and locations that 
were treated. The questionnaire, an information letter and informed consent form were 
sent to the patients. The medical ethical committee of the Erasmus University Medical 
Center Rotterdam has reviewed and approved the protocol, MEC-2013-596.
Part IV | Treatments of HS
174
Wide	excision	surgery
Under general anesthesia, using electro-surgery, the HS affected area (clinically recog-
nized by suppurating sinuses, erythema or induration) was completely excised up to 
the subcutaneous fat or even up to the muscular fascia if necessary. Special care was 
taken that all sinus tracts were identified and excised. After excision the wounds were 
left open for healing by secondary intention or (in limited number of cases) were ap-
proximated using resorbable stitches or closed via split-skin grafting. When the wounds 
were left open for secondary intention healing, the wounds were packed with iodine 
ointment and non-adhesive gauzes followed by bandages. Patients were advised to 
rinse the wound twice daily and reapply the iodine ointment and non-adhesive gauzes. 
Most patients were discharged one day after surgery.
Questionnaire
For each patient a questionnaire was made, based on the surgical procedures and the 
locations treated. Each excised location was counted as an individual surgical procedure. 
Per surgical procedure patients were asked if they had a recurrence, formulated as a new 
inflammatory boil immediately within the scar or within less than 0.5 cm of the scar.9 
Patients were also asked about the impact of the surgery, whether they were satisfied 
with the cosmetic results (using a four scale grading system), whether they were glad 
that they had the operation and if they would recommend this operation to other HS 
patients (yes or no question).
Data	analysis
Results of treatments were based on both medical data files and questionnaires. Statisti-
cal analysis of the data was performed using SPSS version 22 for Windows (IBM Corp, 
Armonk, NY). Continuous data are presented as mean ± standard deviation (SD) or as 
median with the interquartile range [IQR]. Independent t-test or Mann Whitney U test 
were used to compare continuous variables. Ordinal data are presented as number with 
the corresponding percentage, and the chi-square test or the Fisher exact test (n < 5) 
were used to compare ordinal data. A P-value less than 0.05 was considered statistical 
significant.
rESultS
The questionnaire was sent to 120 HS patients, of whom 86 responded (71.7%) of which 
50 were males (58.1%) and 36 females (41.9%). Patients responding to the call were 
more often males and were significantly older, but there was no difference in disease 
severity according to the Hurley classification, nor in the number of procedures (Table I). 
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Patients developed HS at a median age of 20.0 years [IQR: 16.0-30.8], and the mean time 
between onset and surgery was 18.0 ± 11.8 years. One third had a family history of HS 
(n=29, 33.7%), and most patients were active smokers (n=57, 66.3%) or ex-smokers (n=21, 
24.4%) (Table II).
Performed	surgical	procedures
The 86 patients underwent in total 122 operations in which 260 locations were treated. 
The most frequently treated anatomical skin region was the inguinal region (n=95, 
36.5%), followed by the gluteal/perianal (n=67, 25.8%) and axillary (n=57, 21.9%) region 
(Table III). In most cases the wounds were left open after surgery for healing by second-
ary intention (n=253, 97.3%).
Outcome
The mean follow-up time was 36.2 ± 19.1 months, with a range of 6 up to 79 months. In 
90.8% of cases the follow-up was more than a year. After 132 procedures (50.8%) remission 
was achieved of the operated anatomical area. New inflammatory nodules developed in 
the same anatomical area after 33 procedures (12.7%), but not in the scar, these were 
considered as natural disease progression. In 95 cases (36.5%) recurrence occurred in or 
within less than 0.5 cm from the scar (Table III). Recurrence occurred mostly in younger 
patients (age at time of operation 39.0 ± 12.4 vs 47.2 ± 12.1 years; P < 0.001), and mostly 
in the genital region, whereas remission more often occurred in the gluteal/perianal 
region (Figure 1). The median time whereafter recurrence occurred was 6.0 months [IQR: 
table I. Characteristics of patients responding and nonresponding to the questionnaire
responders
(n=86)
nonresponders
(n=34)
P-valuea
gender, n (%) 0.05
- Male 50 (58.1) 13 (38.2)
- Female 36 (41.9) 21 (61.8)
Age years, mean ± SD 46.0 ± 12.9 34.8 ± 11.5 <0.001
Hurley stage, n (%) 0.90
- Stage I 12 (14.0) 3 (8.8)
- Stage II 33 (38.4) 15 (44.1)
- Stage III 26 (30.2) 10 (29.4)
- Missing 15 (17.4) 6 (17.7)
number of operations, n (%) 0.31
- 1-2 44 (51.1) 19 (55.9)
- 3-4 27 (31.4) 9 (26.5)
- 5-6 9 (10.5) 6 (17.6)
- ≥ 7 6 (7.0) 0
a P-value for independend t-test, chi-square or Fisher exact test
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3.0-13.0]. When comparing characteristics of patients who had at least one recurrence 
with patients without recurrence, there was no difference in gender, smoking history, 
BMI, or disease severity according to Hurley (data not shown).
Patient	satisfaction
Most patients were glad that they had the operation (n=79, 91.9%) and would recom-
mend the surgical procedure to other HS patients (n=79, 91.9%). Two-thirds of the 
patients were satisfied to very satisfied with the cosmetic results after the operation. 
However, half of the patients thought that the operation had a medium to major impact 
(Table IV).
DISCuSSIon
In this retrospective study we analyzed data of 260 surgical procedures performed on 86 
HS patients between 2007 and 2014. All patients had undergone wide excision surgery 
under general anesthesia, in which all affected tissue was excised up to the healthy sub-
cutaneous fat or the muscular fascia. Most patients had severe HS (Hurley stage II or III), 
table II. General characteristics of included HS patients who had undergone wide surgical excision
n=86
gender, n (%)
- Male 50 (58.1)
- Female 36 (41.9)
Age at disease onset years, median [IQR] 20.0 [16.0-30.8]
time between onset and operation years, mean ± SD 18.0 ± 11.8
Positive family history of HS, n (%) 29 (33.7)
BmI subgroups,a n (%)
- Normal 27 (31.4)
- Overweight 34 (39.5)
- Obese 25 (29.1)
Smoking status, n (%)
- Current smokers 57 (66.3)
- Ex-smokers 21 (24.4)
- Nonsmokers 8 (9.3)
Hurley stage, n (%)
- Stage I 12 (16.9)
- Stage II 33 (46.5)
- Stage III 26 (36.6)
- Missing 15
a Body mass index (BMI): Normal weight: BMI <25 kg/m2; Overweight: BMI 25-29.9 kg/m2; Obese: BMI ≥ 30 kg/m2
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table III. General characteristics of the performed surgical procedures
n=260
operation location, n (%)
- Axillary 57 (21.9)
- Inguinal/femoral 95 (36.5)
- Genital 32 (12.3)
- Gluteal/anal 67 (25.8)
- Othera 9 (3.5)
Closure technique, n (%)
- Open for secondary healing 253 (97.3)
- Primary closure 5 (1.9)
- Split-skin graft 2 (0.8)
Follow-up time months, mean ± SD 36.2 ± 19.1
result after the operation, n (%)
- Remission of anatomical area 132 (50.8)
- Natural disease progression in anatomical area 33 (12.7)
- Recurrence within the scar, or <0.5cm adjunct 95 (36.5)
time to recurrence months, median [IQR] 6.0 [3.0-13.0]
Functional properties after surgery,b n (%)
- Improved 44 (30.1)
- No diff erence 87 (59.6)
- Worsened 15 (10.3)
a Other: abdominal, intermammary or submammary region.
b The question on limb movement was only asked to patients who had undergone surgery in the axillary or inguinal/
femoral area.
0% 
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100% 
Axillary Inguinal Genital Gluteal Other 
Recurrence 20 37 17 17 4 
No recurrence 37 58 15 50 5 
Recurrence rate per treated anatomical area 
Figure 1. Recurrence rate after wide excision in hidradenitis suppurativa presented as percentage 
with the corresponding number. Other: abdominal, intermammary or submammary region.
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which is also supported by the long disease duration of 18 years before they underwent 
surgery.10 We did not ask the patients about the reason for the delay before undergoing 
surgery; however, this would be worthwhile to explore. In our department we have two 
surgical treatment options for patients with HS; deroofing under local anesthesia for 
mild HS, or wide excision under general anesthesia for severe or widespread HS. Since 
men tend to develop a more severe disease,10 they might require wide excision surgery 
more often, explaining the higher percentage of men in our cohort. Our population was 
otherwise similar to the overall HS population with regard to smoking status, BMI and 
family history of HS.4,5,10,11
After a mean follow-up time of 3 years, in 63.5% of cases no recurrence was seen within 
the scar or less than 0.5 cm from the surgical scar; whereas in 36.5% of the surgical pro-
cedures a recurrence occurred within the scar. This recurrence rate could be explained 
by the high number of severely affected HS patients in this study, because patients with 
more affected body sites are at higher risk of recurrence.12 However, we did not observe a 
difference in recurrence rate between patients with different Hurley stages. In addition, 
36.5% of the surgical procedures were performed in the inguinal area, which has been 
shown to have higher recurrence rates than other body regions.7,13,14 Nonetheless, 92% 
of the patients were satisfied with the operation and its outcome and would recommend 
the procedure to other patients with HS, which is comparable to deroofing.9 Despite the 
large scars, 67% of the patients were satisfied to very satisfied with the cosmetic results.
table IV. Patient satisfaction
n=86
n (%)
Are you glad you had the operation?
- Yes 79 (91.9)
- No 7 (8.1)
would you recommend other patients to have the operations?
- Yes 79 (91.9)
- No 7 (8.1)
How much impact did the operation have?
- No impact 10 (11.6)
- Little impact 32 (37.2)
- Medium impact 26 (30.2)
- Major impact 18 (21.0)
Are you satisfied with the cosmetic result?
- Very satisfied 8 (9.4)
- Satisfied 49 (57.7)
- Unsatisfied 24 (28.2)
- Very unsatisfied 4 (4.7)
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Our recurrence rate is similar to other studies in which severe HS patients were surgi-
cally treated (Table V). Blok et al. analyzed the results of surgery on 113 severe HS patients 
under general anesthesia. They reported remission in 36%, whereas in 29% recurrence 
occurred due to irradical surgery and in 34% due to natural disease progression.11 Bieniek 
et al. performed surgery on 57 HS patients of whom 75% had Hurley stage II or III.12 They 
observed complete recovery in 34 patients (60%), whereas partial recovery (31%) or no 
improvement (9%) was observed in the other 23 patients. Lower recurrence rates (19% 
and 2.5%) were reported by Alharbi et al. and Rompel and Petres. However, of the latter 
study the disease severity was unknown;15,16 also 19% to 58% of the patients needed 
multiple procedures before clearance was achieved.15,16 Comparing different studies on 
recurrence rate is impossible,9,11 since mostly no definition of recurrence was stated, and 
not all studies, on wide surgical excision, used the same closing technique.
In our study, most wounds were left open for healing by secondary intention. This 
prevents recurrence due to entrapment of epithelial strands or debris, which can hap-
pen after primary closure. Watson et al. demonstrated that primary closure had a higher 
recurrence rate than closure by split-skin graft or local flap cover.17 Whereas, Rompel and 
Petres did not observe any differences in recurrence rate between healing by secondary 
intention, primary suture, local flap plasties, or free skin grafts.16 A prospective study 
comparing the different closure techniques is needed to determine which surgical 
technique is superior to another.
Surgery remains the best option for patients to achieve remission. Antibiotics can 
initially provide good results; however, up to 62% of the patients who were in remission 
with antibiotics showed recurrence of the disease after discontinuation.18,19 This also ap-
plies for treatment with anti-TNF biologics. Miller et al. treated patients with adalimumab 
for twelve weeks, with a follow-up of twelve weeks without any treatment. After twelve 
weeks of treatment a decrease of eleven points in the Sartorius score was observed; 
however, after the follow-up period, scores had returned to pre-treatment levels.20 In 
general, the combination of medical and surgical treatment gives the best results. First 
table V. Remission and recurrence rate after surgical treatment for hidradenitis suppurativa
no. Follow-up 
(months)
method of closure remission 
rate
recurrence
rate
Rompel et al.16 106 pt 36 Primary, flaps, STSG, per secundam 97.5% 2.5%
Alharbi et al.15 32 pt 24 Primary, STSG, flaps 81.2% 18.8%
Bieniek et al.12 57 pt 24 Primary, STSG, flaps, per secundam 59.7% 40.3%
Blok et al.11 363 op 43 Per secundam 36.5%  29.3%a
flaps - different forms of flap coverage have been described in the studies (e.g. local, rotation and transposition); op - op-
erations; STSG - split-thickness skin graft; pt - patients
a after 124 (34.2%) operations natural disease progression
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antibiotics or biologics should be given to reduce the inflammation, after which all the 
sinuses and scarring can be excised during surgery.5,8
Even though we report on a large cohort with a long follow-up in which a dermatolo-
gist with a long-standing experience with HS surgeries performed the procedures, our 
study has some limitations. Questionnaires were used in addition to the medical records 
to determine recurrence. Although the response rate was high (72%), there could be a 
chance that patients with active disease responded more often, resulting in an overesti-
mation of the recurrence rate.
Concluding, we report on a sizable cohort of HS patients who had wide surgical exci-
sion under general anesthesia. After a mean follow-up period of three years, 51% of the 
procedures led to remission within the treated anatomical area and in 36% a recurrence 
was observed. A prospective study comparing different surgical techniques using a 
uniform definition for recurrence is required to determine which surgical technique 
produces the best outcome in HS.
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Hidradenitis suppurativa (HS) is a common chronic inflammatory skin disease.1,2 With a 
prevalence ranging from 0.05% to 4%, HS should not be called an orphan disease.3 The 
prevalence of HS and psoriasis is similar, but HS has a greater negative impact on quality 
of life.4 Nonetheless, a pubmed search with the key words “hidradenitis suppurativa” 
and “acne inversa” gives around 1,250 hits; whereas in a similar search for psoriasis there 
are 40,000 hits. There are still multiple unanswered questions about the pathogenesis, 
clinical course, comorbidities and treatment options for HS.5 This indicates that this 
debilitating disease does not yet get the attention that it deserves, and therefore still 
can be considered an orphan disease. 
In this thesis we have focused on the clinical aspects of HS. In the first part we de-
termined the prevalence and factors associated with early-onset, disease severity and 
remission. For the second part of this thesis we have focused on two specific comor-
bidities of HS, namely anemia and inflammatory bowel disease (IBD), which both have 
an aberrant immunological reaction as a common factor with HS. The third part of this 
thesis is about the impact of HS. We investigated the influence of HS on sexual health, 
and quality of life (QoL), and determined the socioeconomic status of patients with HS 
relative to dermatological control patients. The last part of this thesis is about the treat-
ments of HS. First, the medical treatment options are reviewed in detail, followed by the 
effectiveness of fumarates as therapeutic option for HS and finally, the efficacy of wide 
surgical excision was determined. The main findings of each part of this thesis will be 
discussed in this last chapter.
PArt I: onSEt AnD ClInICAl CourSE oF HIDrADEnItIS SuPPurAtIVA
Generally the onset of HS is after puberty; mostly in de second or third decade of life, 
with a peak in onset between 20 and 24 years.2,6,7 Even though pre-pubertal onset has 
occasionally been described, it has always been thought to be rare.8,9 Nonetheless, we 
saw several patients who reported an onset of HS in their early teens or even starting 
in their infancy. Therefore, we assumed that the prevalence of pre-pubertal onset of HS 
would be higher than previously suggested. In Chapter 2 we showed that 66 of the 855 
HS patients (7.7%) reported early-onset HS, defined as onset of symptoms before the 
age of thirteen. We chose this cutoff point based on the mean age of the menarche of 
13.5 years in the Netherlands.10 Since generally puberty occurs later in boys, it is conceiv-
able that most patients with onset before their thirteenth birthday were prepubertal or 
in early puberty. Our results were shortly after confirmed by Bettoli et al.11 and Blok et 
al.12 They reported that, respectively, 21% to 38% of their patients had symptoms of HS 
before the age of sixteen. Our findings that early-onset HS was associated with female 
sex and a family history of HS were also confirmed.11,13 The latter suggests that a genetic 
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predisposition might influence the age of onset of HS.13,14 Heterozygous mutations in 
the γ-secretase genes PSENEN, PSEN1, and NCSTN have been found in families in which 
multiple family members of successive generations had HS,15,16 although these muta-
tions could not be found in different larger HS populations.16 Also the exact pathogenic 
mechanism of the γ-secretase pathway in HS is not yet fully understood.
Interestingly, although smoking is often suggested as a triggering factor for HS, we 
found that early-onset patients were more often nonsmokers and if they started smok-
ing, this was mostly after they already had symptoms of HS. A likely explanation is that 
early onset patients were too young to smoke when they had their first HS symptoms, 
and thereafter were warned not to start smoking because this could worsen their HS 
symptoms. Also, in the population of Bettoli et al. only two of 19 patients under the age 
of 16 were active smokers.11
Although smoking appeared not to be a risk factor in the development of early-onset 
HS; in Chapter 3 we demonstrate that patients with more pack-years did have a more se-
vere disease. In the analysis of 846 HS patients we also found that male sex, obesity, and 
disease duration were associated with disease severity; these findings are in line with 
previous studies.7,17,18 We also investigated whether there was a difference in disease 
characteristics between the male and female patients, and found that female patients 
had on average an earlier onset of HS and more frequently reported a family history 
of HS. Also, in female patients the inguinal and mammary regions were more often af-
fected, which confirms the statement that the front part of the body is predominantly 
involved in women.14 In men, the backside of the body is more involved,14 which was 
confirmed by finding that in male patients, the perianal and gluteal areas were more 
often involved. Also the atypical sites were more frequently affected in men. This might 
correspond with the follicular phenotype of Canoui-Poitrine et al. in which mostly male 
patients were severely affected at the ears, chest, armpits and breast.6
Another risk factor for severe HS was disease duration, which suggests that disease 
progression occurs over time. The chronic character of HS was confirmed and studied 
in more detail in Chapter 4. In a retrospective study we asked patients if they still had 
inflammatory nodules, 22 years after a dermatologist made the diagnosis of HS. In total, 
77 of the 127 patients (60.6%) still had active disease. Especially smoking and obese pa-
tients still suffered from HS. Of the active smokers only 17% reported remission, versus 
33% of the ex- and nonsmokers. Also 23% of the obese patients were disease-free, versus 
43% of the nonobese patients. Although nonsignificant, more patients without a family 
history of HS became disease-free than patients with a first- or second-degree relative 
suffering from HS (33% vs 48%). These results show that HS is a very chronic disease, but 
also that a third of the HS patients do become disease-free over the course of time.
Based on the higher remission rates among nonsmokers and nonobese, we argue that 
patients should be strongly advised to quit smoking and lose weight. It is however im-
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portant that patients are informed that smoking cessation does not lead to immediate 
remission.17 Our clinical experience is that patients often stop smoking for a brief period 
(half a year or a year) and do not observe any difference in disease severity or activity, 
and therefore restart smoking, because ‘it does not help anyway’. Therefore, it would be 
worthwhile explaining to patients that cessation does aid towards remission, but that it 
takes years to obtain the effect. There is more evidence for the effect of weight loss on 
remission. Kromann et al. interviewed 249 patients who underwent gastric bypass or 
gastric banding operations to find out if they had HS symptoms before and/or after sur-
gery.19 Only patients who had lost at least 15% in body mass index (BMI) were included. 
Before surgery 35 patients reported to have HS, whereas after weight loss 17 patients 
did not experience HS symptoms anymore (49%), seven reported fewer symptoms 
(20%) and eleven reported no change or worsening of symptoms (31%).19 The efficacy 
of weight loss was further supported by two cases of obese patients who showed major 
improvement of their HS symptoms after extensive weight loss.20,21
Another important side finding in Chapter 4 was that female patients did not become 
disease-free after menopause. Of the post-menopausal women 48% reported fewer 
symptoms, but the remaining did not notice any difference or even experienced wors-
ening of their HS after menopause. Therefore, to prevent disappointment, physicians 
should not inform female patients that they will become disease-free after menopause.
Conclusion	of	part	one	of	this	thesis:
HS is a chronic and severe disease, which can have its onset before puberty. Twenty-
two years after diagnosis, still two-thirds of the patients suffer from HS. Even though 
a genetic predisposition is associated with early disease onset and might lower the 
chance of remission, it is not associated with disease severity. Smoking and obesity are 
not associated with early disease onset, but are strongly associated with disease severity 
and tend to prevent remission.
PArt II: ComorBIDItIES oF HIDrADEnItIS SuPPurAtIVA
Multiple comorbidities have been reported to be associated with HS; the most frequently 
reported are: metabolic syndrome (including diabetes mellitus and hypertension), de-
pression, inflammatory bowel disease and spondyloarthropathy.22,23 In addition, patients 
with HS often report fatigue, which can be a great burden for the patients.24,25 A possible 
cause of this fatigue can be an underlying marked anemia. In Chapter 5 we presented 
two cases of patients with severe HS and marked anemia, which resolved after the HS 
was adequately treated. Tennant et al. reported that ten out of their 42 patients with 
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severe HS (24%) had marked anemia (Hb < 6.3 mmol/L), and suggested that anemia was 
probably caused by chronic inflammation.26
The renal production of erythropoietin is inhibited in the presence of interferon gam-
ma (IFN-γ), interleukin (IL)-1 and tumor necrosis factor alpha (TNF-α).27,28 These cytokines 
also reduce erythropoiesis in the bone marrow. Furthermore, IL-1, IL-6, IL-10 and TNF-α 
can enhance uptake of iron by activated macrophages,27 whereas TNF-α decreases the 
intestinal iron absorption,29,30 both resulting in less iron available for erythropoiesis. In 
HS, elevated levels of IL-1β, IL-10 and TNF-α have been demonstrated.31 Therefore, it is 
possible that these upregulated pro-inflammatory cytokines might contribute to the 
development of anemia in patients with severe HS. On the other hand, a recent case-
control study showed that anemia was not more prevalent in patients with HS than in 
a population based control group,32 thus indicating that routinely checking for anemia 
is not necessary in patients with mild HS. Nonetheless, when patients with severe HS 
complain about fatigue, anemia should be checked for.
Inflammatory bowel disease (IBD), which is an umbrella term that includes Crohn’s 
disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease, caused by an 
aberrant immunity in a genetically susceptible host.33 HS and IBD are often associated, 
and it has been suggested that up to 23% of patients with IBD also suffer from HS.34–36 
In Chapter 6 we showed that 36 of 1,076 HS patients (3.3%) also suffer from IBD, which is 
four to eight times more than the prevalence of IBD in the general Northern European 
population. CD, with a prevalence of 2.5%, was eight to eighteen times more prevalent 
in patients with HS than in the general population. The association between HS and CD 
is not surprising as they share multiple similarities:
• Smoking is a triggering factor for both HS and CD, and smokers tend to have a more 
severe disease than nonsmokers.7,33 On the other hand, in patients with UC, smoking 
tends to have a protective effect.33
• HS and cutaneous CD share clinical and histological similarities making it difficult 
to differentiate in certain cases.37,38 Both can present with perianal inflammatory 
lesions, abscesses and sinus tract formation. It is not possible to differentiate histo-
logically between HS and CD, because in both diseases diffuse tissue inflammation 
with epithelioid granulomas is present.37,38 Cutaneous CD is most likely when only 
the perianal region is affected and enterocutaneous fistulas are present, whereas 
concurrent HS is more likely when other body areas are also affected.39–41
• HS and IBD both have a genetic basis. In CD, polymorphisms in DNA-regions 
containing nucleotide oligomerization domain 2 (NOD2) genes are implicated.33,42 
Approximately 30% of the European CD patients have at least one of the three 
polymorphisms of NOD2.33 However, in two pilot studies polymorphisms of the 
CARD15/NOD2 could not be confirmed in patients with HS.42,43 In a large cohort of 
IBD patients, a higher frequency of the single-nucleotide polymorphisms SULT1B1, 
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SULT1E1 and ELOVL7 were found in patients with HS and IBD.36 In HS, mutations in 
the γ-secretase genes have been observed, but no causative genes have yet been 
identified.16
• A shared common inflammatory pathway is suggested between HS and IBD.41,44 
In the intestinal mucosa of IBD patients, as well as in lesional skin of HS patients, 
elevated levels of IL-1β and TNF-α have been observed.33,45,46 Also the cytokines of 
the IL-23/Th17 pathway have been found to be elevated in both diseases.33,46,47
• Both diseases respond well to treatment with biologics, probably because of the 
shared immunological pathways. Notably, the effectiveness of TNF-α inhibitors in HS 
was first described in two CD patients. Their concomitant HS also responded to the 
infliximab treatment they received for their CD.48,49 Interestingly, in HS as well as in 
CD infliximab and adalimumab have shown to be effective, whereas etanercept does 
not improve symptoms in either two diseases.23,50
Patients with HS and IBD did not present with a distinct HS phenotype, we did not 
observe a difference in disease severity or body regions affected by HS. Dermatologists 
should therefore ask HS patients about gastrointestinal symptoms. When there is a 
suspicion of IBD, patients should be referred to a gastroenterologist for further analysis. 
Also, when patients present with intersphincteric fistulas, an endoscopy or radiological 
imaging is advisable. Although, we have seen patients with solely HS that presented 
with intersphincteric fistulas.
Conclusion	of	part	two	of	this	thesis:
Patients with HS that present with severe fatigue should be checked for anemia. Also, 
referral to a gastroenterologist is advisable when patients present with gastrointestinal 
symptoms such as recurrent abdominal pain or bloody stool; since 3.3% of the patients 
with HS have concomitant IBD.
PArt III: tHE ImPACt oF HIDrADEnItIS SuPPurAtIVA
HS is a very debilitating disease with a high negative impact on QoL. Relative to other 
dermatological diseases, patients with HS often have the lowest QoL.4,51,52 Due to the 
chronic painful lesions and disfiguring scars, patients often feel embarrassed towards 
their partners; some reported that their partners had lost interest in sexual activity 
when they had active lesions or that their sexual life had even completely stopped.25 
Even though HS clearly influences the sexual functioning of the patients, only one study 
has previously investigated the impact of HS on sexual health. This study among 44 HS 
patients showed significant impairment of sexual health compared with age-, sex-, and 
BMI-matched controls.53
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In Chapter 7 we confirmed the major impact of HS on sexual health and QoL. In a mul-
ticenter cross-sectional study, 300 patients with HS completed multiple sexual health 
questionnaires and a dermatological quality of life questionnaire. Compared with scores 
from the literature from healthy men and women, the sexual health scores of the HS 
patients were far worse.54,55 Of the female patients 62% had scores corresponding with 
sexual dysfunction and a high number of men suffered from erectile dysfunction.55,56 
Surprisingly, involvement of the anogenital area or disease severity did not influence 
sexual health in men or women. Most women stated that HS influenced their sexual 
health because of its impact on their physical appearance; however, it seems that the 
physical symptoms of HS can not completely explain the impaired sexual health in HS. 
Therefore, it is possible that psychological factors also play a role.
The mean Dermatology Life Quality Index (DLQI) score of 12.5 confirms that HS has a 
very large impact on the patients’ QoL.4,7,24 Low QoL was associated with anogenital in-
volvement and with more active and severe disease. In female patients, QoL was associ-
ated with sexual health, but this association was not observed in male patients. Matusiak 
et al. also found that patients with anogenital involvement had a greater impaired QoL;24 
this might be because perianal involvement is associated with a more severe disease, as 
showed in Chapter 3, and patients with a more severe disease have a lower QoL.24,51,52,57 
Interestingly, female patients with an older age of onset had poorer sexual functioning 
than females with a young age of onset. Possibly, patients who develop HS when they 
are already sexually active, are more aware of the changes that occur in their sexual life.58 
Interestingly, a younger age of onset was associated with a lower QoL, which might be 
the result of the negative correlation between age of onset and disease severity shown 
in Chapter 2.52,59 When comparing our results on sexual health and QoL of HS patients 
with the literature on patients with psoriasis, we saw that HS and psoriasis have similar 
effects on sexual health,60,61 whereas the DLQI scores of HS patients were worse than 
those of patients with psoriasis.60,62–64
HS patients also report a great unmet need regarding the attention given by physician 
to their sexual function. Almost half of the patients indicated that they did not receive 
enough attention for their sexual function, whereas a third stated that their doctor 
should have given more attention to their sexual problems. It is possible that physicians 
do not give enough attention towards sexual problems because of unawareness, shame, 
difficulty in treatment, limited time, or the complexity of sexual problems.65 Nonethe-
less, because of the major impact HS has on the sexual health of patients, physicians 
should pay more attention towards sexual problems and offer patients psychological 
support if needed.
Even though multiple studies have shown a diminished QoL in HS, the effect of HS 
on the professional life of patients varies among studies. Some studies report that HS 
patients miss only two to three workdays per year,51,66 whereas Matusiak et al. reported 
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that patients miss on average 34 workdays per year because of their HS.67 In the latter 
study, seven out of the 30 interviewed HS patients did not get a promotion, and three 
even lost their jobs because of HS.67
On the basis of our clinical experience, we got the impression that patients with HS 
had a lower socioeconomic status (SES) than other dermatological patients. Therefore, 
in Chapter 8 we compared the SES of HS patients with age and sex matched control 
patients with other skin diseases. We used a SES indicator developed by Statistics 
Netherlands, based on the mean household income and mean real estate value per 
postal code area.68 The SES of the patients with HS was significantly lower than those 
of the control patients. Of the HS patients 46% had a low SES and only 15% a high SES, 
whereas in the control group with other skin diseases 34% had a low SES and 26% a high 
SES. We presumed that the low SES in HS could be caused by the distressing nature of 
HS, and therefore we expected that patients with a more severe disease would have a 
lower SES. Surprisingly, we did not find a difference in disease severity using the Hurley 
score among the different SES groups. Patients with low SES had more affected body 
areas, but this was not significant in the multivariable model. Involvement of the axillary 
region was associated with a lower SES, but for the other body sites this association 
could not be observed.
We also hypothesized that patients with a young age of onset might have a lower SES, 
because of missed education or job opportunities; but we did not find a difference in 
age of onset between the SES groups. The current age was associated with SES, which 
is not surprising since in general with increasing age people have a higher income and 
are able to buy a more expensive house than at start of career.68 We observed that HS 
patients with a low SES were more often obese. This finding is in line with the results of 
Lakerveld et al.69 who showed that people from low SES neighborhoods have a higher 
BMI. Inhabitants from these neighborhoods also showed more obesity-related behavior, 
such as eating less fruit and vegetables, whereas they drank more sugar-containing 
drinks.69 In addition, people with a low SES are also more often smokers.70,71 Because 
smoking and obesity are both risk factors for HS,7,17 it is possible that the unhealthy 
lifestyle associated with low SES increases the risk of developing HS. However, a large 
prospective population-based cohort study should be conducted to determine if a low 
SES truly predisposes HS.
Conclusion	of	part	three	of	this	thesis:
HS is associated with a reduced sexual health, QoL and SES. Impairment in sexual health 
is associated with female gender and late onset of HS. Important risk factors for a dimin-
ished QoL were early disease onset, disease activity and severity. Low SES was associated 
with axillary involvement, high body mass index, but not with disease severity or age of 
disease onset.
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PArt IV: trEAtmEntS oF HIDrADEnItIS SuPPurAtIVA
Over the years multiple treatment options for HS have been suggested; however, none 
has proven curative. In Chapter 9 the medical treatment options for HS are reviewed 
in detail. Based on this review and clinical experience we would like to propose the fol-
lowing medical treatment regime for patients with HS (Figure 1). In mild disease, when 
patients present with one to four solitary lesions of limited size,72 one may start with the 
combination of clindamycin 1% lotion and resorcinol 15% cream.73–75 Clindamycin lotion 
should be used as long as the infl ammatory lesions are present. Resorcinol cream has 
shown to reduce the duration of infl ammatory lesions.74,76 In our clinical experience, it 
can also be used to prevent the formation of new lesions, due to its keratolytic proper-
ties it reduces the blockage of the hair follicles.74,76 For a single recalcitrant infl ammatory 
nodule, intralesional injection with corticosteroids (5 to 10 mg/ml) can induce a rapid 
reduction.1,23,76
When these local treatments are insuffi  cient or in more widespread HS, oral antibiotics 
with anti-infl ammatory properties are often required. The fi rst step is treatment with 
antibiotics from the tetracycline group, because of their anti-infl ammatory properties 
and mild side eff ect profi le.77–79 In our experience doxycycline 100 mg daily or mino-
cycline 100 mg daily can have a good eff ect in mild HS when given for a minimum of 
three months.78,80 One should keep in mind that these antibiotics are mostly eff ective 
Mild  
disease 
•  Topical resorcinol 15% cream 
•  Topical clindamycin 1% lotion 
•  Intralesional steroid injections (5-10 mg/ml) 
Moderate 
disease 
•  Doxycycline 100 mg daily or minocycline 100 mg daily 
•  Clindamycine 300 mg twice daily and rifampicin 600 mg daily 
•  Acitretin 0.5 mg/kg daily (male patients) 
Severe 
disease 
•  Metronidazol 500 mg three times per day, moxiﬂoxacin 400 mg 
daily and rifampicin 10 mg/kg daily 
•  Adalimumab 40 mg weekly 
•  Inﬂiximab 5 mg/kg every six weeks 
Figure 1. The medical treatment options for patients with hidradenitis suppurativa, ranked by dis-
ease severity.
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because of their immunomodulating effect and that most bacteria cultured in HS are 
resistant for tetracyclines; therefore, they should not be prescribed to treat bacterial 
superinfections.77 The second step is the combination of clindamycin 300 mg twice daily 
with rifampicin 600 mg daily. This combination therapy has shown to be effective in 
moderate to severe HS.81–84 It differs between studies whether rifampicin is given 600 
mg daily,81,82 or 300 mg twice daily.83,84 From a microbiological point of view it has been 
suggested that 600 mg once daily would lower the chance of bacterial resistance;85 
however, no studies are available on the effectiveness of different dose schemes in HS. 
The third step in antibiotic treatment is the combination of metronidazole 500 mg three 
times per day, moxifloxacin 400 mg daily and rifampicin 10 mg/kg daily.86 We observed 
that this combination, when given for minimum of six weeks, can reduce inflammation 
and induration even in severe HS. However, patients often report side effects, mostly 
gastrointestinal complaints, headaches or dizziness, leading to dose reduction or early 
termination.86,87 For all antibiotics it applies that recurrence is high after discontinua-
tion.83,86,88
For male patients presenting with multiple noninflammatory nodules and comedones, 
treatment with acitretin 0.5 mg/kg can be effective because of its keratolytic proper-
ties.89,90 Because acitretin is highly teratogenic and birth control measures should be 
used up to three years after treatment, it is less suitable for women in the reproductive 
age.
When patients have moderate to severe HS and fail most common treatments, biolog-
ics are indicated.23,72,91 Especially adalimumab and infliximab showed to be effective in 
HS.72,91,92 Adalimumab 40 mg weekly can be effective in widespread HS;72 however, in 
our experience it is less suitable when severe induration is present. Infliximab 5 mg/kg 
can also reduce severe inflammation and induration when given every six weeks after 
initiation. However, infliximab is given intravenously mostly in a hospital setting, and 
therefore it is more time consuming than adalimumab, which patients can administer 
themselves at home. Both adalimumab and infliximab are expensive drugs, and not all 
insurance companies are willing to cover the cost. For the future, the cheaper biosimilars 
might be an option for patients with HS.93 Even though both adalimumab and infliximab 
can suppress symptoms for a long time, recurrence can occur during treatment, and 
often occurs after discontinuation.23,92,94
Since none of these treatments are curative for HS, multiple anti-inflammatory drugs 
have been suggested for HS in small case series of patients with refractory HS.95–99 
In Chapter 10 we showed the results of therapy with oral fumarates in HS from our 
open-label pilot study. Seven patients with HS, who were refractory to conventional 
HS therapies, were treated with fumarates in a progressive dose scheme, up to 720 mg 
dimethylfumarate for a minimum of 20 weeks. Three patients showed clinical improve-
ment after 20 weeks of treatment, of whom two continued up two years, still being in 
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remission. However, four patients stopped after 20 weeks because of lack of efficacy and 
one patient stopped after 28 weeks because of gastrointestinal side effects. Fumarates 
might be effective because of their immunomodulatory and anti-inflammatory effects, 
by reducing the production of pro-inflammatory cytokines such as IL-12p70, IL-10 and 
TNF-α.100–103 Even though a response of three out of seven seems low, we considered it 
meaningful because these patients were previously unresponsive to multiple common 
HS treatments, including antibiotics and biologics. Therefore, fumarates can be consid-
ered in patients who are refractory to multiple common therapies and where no other 
treatment options are available. Patients should be informed about possible side effects 
during treatment, especially diarrhea and flushing, and the benefits should be weighed 
against the side effects in each individual patient.
Using medical treatments it is possible to reduce inflammation and suppress symp-
toms; however, recurrence rates are high after discontinuation.23,88 Also, sinus formation 
seldom resolves with drug treatments. Therefore surgical intervention of the existing 
sinuses and fibrotic tissue is necessary to maintain remission.1,23,104 In mild cases deroof-
ing has shown to be effective, with a low recurrence rate of 17%.105 During a deroofing 
a blunt probe is used to explore the sinuses, whereafter the sinus roof is electrosurgi-
cal excised leaving the floor exposed. After carefully examining the margin walls for 
remaining sinus tracts, the defects is left open for healing by secondary intention.105,106 
However, deroofing is not suited for severe cases.105
In Chapter 11 we reviewed the results of wide surgical excision performed in 86 
patients with severe HS. The patients underwent 122 operations, in which 260 locations 
were treated. During this surgery, performed under general anesthesia, the complete HS 
affected area (clinically recognized by suppurating sinuses, erythema or induration) was 
excised using electro-surgery up to the subcutaneous fat or even up to the muscular 
fascia if necessary. As with deroofing special care was taken that all sinus tracts were 
identified and excised. After excision the wounds were mostly left open for healing by 
secondary intention. This way epithelial strands or debris would not be entrapped and 
wounds could drain.88
Using this extensive treatment option we were able to cure the anatomical region in 
half of the patients, whereas in another 13% the operated area remained free of inflam-
mation but recurrence occurred in the same anatomical region due to natural disease 
progression. This remission rate might seem low, since other studies report remission 
rates between the 37% and 98%.12,107–109 However, all our patients had severe HS with a 
disease duration of 18 years before they had the operation, resulting in a high disease 
burden. Direct comparison of our results to other surgical treatment studies is very 
difficult because different surgical techniques, definitions of recurrence and follow-up 
times are used. We used the same definition for recurrence as was used in the study on 
deroofing by van der Zee et al;105 namely, a new inflammatory nodule in the scar or within 
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0.5 cm adjunct to the scar. Mostly, studies only report the percentage of recurrence, 
but not whether this new lesion was inside the scar or far distant from the operations 
site.107–109 Only Blok et al.12 reported if a recurrence was caused by irradical surgery or due 
to natural disease progression.12
Despite the recurrence rate in our study, patient satisfaction was high. In total, 92% 
of the patients were glad that they had the operation and would recommend it to 
other patients with HS. These figures are comparable to patients who had undergone 
a deroofing procedure.105 Despite the large scars, 67% of the patients were satisfied to 
very satisfied with the cosmetic results, making wide surgical excision a good treatment 
option for patients with severe HS.
Conclusion	of	part	four	of	this	thesis:
Multiple medical treatments are available for HS, such as topical or oral antibiotics, reti-
noids and biologics. Even though most can suppress symptoms of HS for a long period, 
they are seldom curative. Fumarates can be effective in refractory HS; however, their 
effectiveness is limited. Surgery is the most definite treatment for HS; using wide surgi-
cal excision, we were able to induce remission in half of the treated anatomical areas.
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SummAry
Chapter 1 gives a general introduction to this thesis. Hidradenitis suppurativa (HS) is a 
chronic, debilitating skin disease with prevalence of 1% in Europe. The disease is charac-
terized by painful inflammatory nodules, abscesses, sinus tract formation and scarring. 
The lesions are mainly located in the inverse body areas, such as the axillae and groin. 
The pathogenesis of HS is still not fully understood, but is probably multifactorial. The 
primary event is thought to be infundibular hyperkeratosis, causing follicular occlusion, 
followed by rupture of the hair follicle with an inflammatory response. Multiple factors 
have been associated with HS, especially smoking and obesity. More recently, a genetic 
background and an aberrant innate immune response have gained more attention as 
predisposing factors. HS is a profoundly debilitating disease with a great negative im-
pact on the quality of life. HS patients often suffer from depression, have an impaired 
sexual health, and may have difficulty performing their work duties. To date, there is no 
cure for most patients; treatment often consists of a combination of drug treatments 
and surgery. In this thesis we have focused on the clinical aspects of HS. In the first part 
we determined the prevalence and factors associated with early onset, disease severity 
and remission. In the second part we studied two specific comorbidities of HS, namely 
anemia and inflammatory bowel disease. In the third part we discussed the impact of HS 
on quality of life, sexual health and socioeconomic status. For the last part of this thesis 
we have focused on the treatment options of HS.
In chapter 2 we determined the prevalence of early-onset HS. We found that 66 of the 
855 patients (7.7%) reported onset of HS before the age of thirteen. Patients with early-
onset HS more often had a family history of HS (55.6% vs 34.2%; OR 2.1, 95% CI 1.2-3.6; 
P = 0.006), suggesting that a genetic predisposition might influences the age of onset. 
Also, early-onset patients developed inflammatory lesions at more body sites than 
patients with normal-onset HS (OR 3.0, 95% CI 1.8-4.9; P < 0.001), whereas the distribu-
tion of the Hurley stages showed no difference between the two groups (OR 1.1, 95% CI 
0.7-1.8; P = 0.72). Surprisingly, early-onset patients were more often nonsmokers (27.3% 
vs 14.3%; P  =  0.01) or began smoking after the onset of HS. Our results suggest that 
early-onset HS is not as rare as always believed. Patients with early-onset HS should be 
closely monitored and receive appropriate treatments in order to prevent extention of 
the disease.
In chapter 3 we sought to identify disease-related factors associated with disease se-
verity, sex, and family history. To do so, we collected data of 846 patients with HS. Of 
these patients, 45.5% had Hurley stage I, 41.5% had Hurley stage II, and 13.0% had Hurley 
stage III. We found that disease severity was associated with male sex (OR 2.11; P < 0.001), 
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disease duration (OR 1.03; P < 0.001), body mass index (OR 1.03; P = 0.01), smoking pack-
years (OR 1.02; P = 0.001); and axillary (OR 2.24; P < 0.001), perianal (OR 1.92; P < 0.001), 
and mammary lesions (OR 1.48; P = 0.03). Female patients appeared to have an earlier 
onset of HS, were more often affected at the inguinal and mammary region, and more 
frequently had a family history of HS. Male patients were more often affected at the glu-
teal, perianal and atypical regions (e.g. ears, chest, back). Patients with a family history 
of HS had on average an earlier disease onset, a longer disease duration, and had a more 
extensive disease. These severity risk factors could help physicians to select patients who 
need close monitoring and who would benefit from early, aggressive therapy, although 
it remains to be shown whether disease progression can be prevented in this way.
In chapter 4 we described the long-term prognosis and the clinical course of HS and its 
association to known risk factors. Through a postal questionnaire 212 HS patients were 
invited to participate in the study. All patients were diagnosed by a dermatologist. The 
mean follow-up time after diagnosis was 22 years (range 12-32). In total, 129 patients 
returned valid questionnaires (60.8%). Remission was reported by 39.4% and improve-
ment by 31.5% of the patients, but 20.5% reported unchanged severity and 8.7% expe-
rienced disease worsening. More nonsmokers reported remission (48.5%) than active 
smokers (28.8%), suggesting that the chance of remission was greater in patients who 
did not smoke or had stopped smoking. We also found a higher proportion of nonobese 
patients (44.8%) reporting remission than obese patients (22.6%), which further sup-
ports the importance of weight loss in patients with HS. This study supports the previous 
finding that HS is a very chronic disease, but that changing lifestyles (smoking cessation 
and weight loss) might aid towards disease remission.
In chapter 5 we presented two cases of severe HS with debilitating fatigue, based on 
chronic marked anemia. The anemia and associated fatigue were disease activity depen-
dent and resolved after adequate treatment of the extensive HS lesions. We argue that 
the chronic inflammation with elevated levels of circulating pro-inflammatory cytokines 
and the continuous sanguineous drainage from the HS lesions, might contribute to 
the development of anemia. Therefore, it is important to keep in mind that fatigue in 
patients with HS can be caused by anemia, which is reversible after adequate treatment 
of the HS.
In chapter 6 we determined the prevalence of inflammatory bowel disease (IBD) in pa-
tients with HS. In addition, we investigated whether patients with HS and IBD had a dis-
tinct HS phenotype. In total, 1,076 HS patients were asked during consultation whether 
they had IBD. The medical files of the affirmative responders were checked to confirm 
the diagnosis of IBD. We found a prevalence of IBD of 3.3% in our HS cohort, which is four 
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to eight times higher than in the general northern European population. Most of the 
patients had Crohn’s disease (27/36), which is not surprising since HS and Crohn’s disease 
share various similarities. They both have a clinical course with periods of exacerbations 
and remission, and respond to tumor necrosis factor alpha inhibitors. In both diseases 
an aberrant immunity is thought to play an important role in the pathogenesis. Patients 
with HS and IBD did not present a distinct HS phenotype, since we only observed a 
difference in body mass index, but not in gender, family history of HS, smoking status, 
disease severity, or body regions affected.
In chapter 7 we investigated the quality of life (QoL) in patients with HS with a focus on 
sexual health. In total, 916 HS patients received an invitation to participate in this multi-
center cross-sectional survey, of whom 300 patients completed the questionnaires. HS 
patients showed a diminished sexual health and QoL (Female Sexual Functioning Index 
score: 21.6 ± 9.6, International Index of Erectile Function score: 49.7 ± 20.7, Arizona Sexual 
Experience scale: 16.7 ± 5.3 and Dermatology Life Quality Index score: 12.5 ± 7.5). Sexual 
health was associated with QoL in women but not in men. Female gender and late onset 
of HS were associated with poor sexual function. Impairment of QoL was associated with 
anogenital involvement, early onset of HS, disease severity and disease activity. This 
study confirms that HS is associated with an impaired sexual health and QoL. Physicians 
should ask HS patients about their sexual functioning and, when needed, offer them 
psychological support.
In chapter 8 we determined the socioeconomic status (SES) in patients with HS rela-
tive to control patients, and whether specific clinical HS characteristics correlate with 
SES. Data were collected of patients with HS and sex and age matched dermatologi-
cal patients in a 1:2 ratio. The SES was based on an indicator developed by Statistics 
Netherlands, which was derived from the mean household income and real estate value 
on neighborhood level. The SES distribution among 1,018 HS patients was significantly 
lower (low SES: 46.4%, medium SES: 39.0%, high SES: 14.6%), than among 2,039 age and 
sex matched dermatological control patients (low SES: 34.3%, medium SES: 40.1%, high 
SES: 25.6%; P < 0.001). In HS patients, low SES was associated with axillary involvement 
(OR 1.42, 95% CI 1.02-1.99), high body mass index (OR 1.03, 95% CI 1.01-1.06) and lower 
age (OR 0.98, 95% CI 0.97-0.99), but not with disease severity according to Hurley or age 
of onset. In the general population, a low SES is associated with an unhealthy lifestyle 
such as smoking and obesity, therefore low SES might be a risk factor for developing HS. 
However, a prospective cohort study is needed to determine causality.
Chapter 9 is a comprehensive review on the medical treatments of HS and their mode 
of action. In mild disease, clindamycin lotion or resorcinol cream can give long-term 
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remission. In more severe HS, oral antibiotics are often needed. Their effectiveness in 
HS is mostly based on their anti-inflammatory properties and to lesser extent on their 
anti-bacterial effects. Antibiotics from the tetracycline group are often first-line systemic 
options. In moderate to severe HS, the combination of clindamycin with rifampicin is 
often effective; but for all antibiotics, recurrence rates are high after discontinuation. 
Retinoids can be a more long-term treatment option; especially acitretin has shown to 
be effective in HS due to its keratolytic properties. However, because retinoids are highly 
teratogenic, they are less suited for females in the reproductive age. When patients fail 
to respond to most common treatments and have moderate to severe HS, treatment 
with biologics, such as infliximab and adalimumab, is indicated. Even though biologics 
are seldom curative in HS, they can suppress the symptoms and can often be given for 
a prolonged period. Multiple other anti-inflammatory drugs have been suggested for 
HS, such as dapsone, azathioprine or cyclosporine. However, their effectiveness in HS 
is based on small case series with varying results. Besides medical treatment, lifestyle 
changes are important in the treatment of HS. Patients should be strongly encouraged 
to reduce weight and quit smoking.
In chapter 10 we reported on the effectiveness of fumarates in patients with moderate 
to severe HS in a prospective, open-label, pilot study. Seven patients, who were previ-
ously refractory to regular HS treatments, were treated with fumarates for 20 weeks in 
a progressive dosage scheme up to a daily dose of 720 mg dimethylfumarate. After 20 
weeks of treatment, three patients (43%) showed improvement and continued treat-
ment. At 28 weeks one patient, with mild improvement, stopped because of gastroin-
testinal complaints. Two patients continued treatment for at least one year, remaining 
clear of inflammatory lesions. In four patients (57%) fumarates were discontinued at 
week 20 because of lack of efficacy. Most reported side effects were gastrointestinal 
complaints (57%) and flushing (85%). Fumarates are effective in patients with psoriasis, 
which is attributed to their anti-inflammatory effects. In HS patients, pro-inflammatory 
cytokines levels are elevated and are thought to play a key role in the pathogenesis of 
HS. Therefore, fumarates might also be effective in patients with HS.
In chapter 11 we investigated the clinical characteristics, recurrence rate and patient 
satisfaction of patients with severe HS who had undergone wide surgical excision under 
general anesthesia. The medical files were retrospectively reviewed and patients were 
sent a questionnaire comprising questions on recurrence and patient satisfaction. In 
total 86 patients responded, who had undergone a total of 260 surgical procedures. The 
inguinal (n=95, 36.5%) and gluteal/perianal region (n=67, 25.8%) were mostly treated. 
In general, the wounds were left open for secondary intention healing (97.3%). After a 
mean follow-up of 3 years, in 50.8% the treated anatomical area remained disease-free; 
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natural disease progression was seen in 12.7%, and recurrence within the surgical scar or 
less than 0.5 cm from the scar in 36.5% of cases. Most patients were glad that they had 
the surgery (91.8%) and would recommend it to other HS patients (91.8%). This makes 
wide surgical excision a good treatment option for patients with severe HS.
In chapter 12 the results of all studies in this thesis are discussed. We showed that HS 
is a chronic and severe disease that can even develop during childhood. Although we 
found that a genetic predisposition was associated with early disease onset and might 
lower the chance of remission, it was not associated with disease severity. Smoking and 
obesity were not associated with early disease onset, but they were strongly associated 
with disease severity and tended to prevent remission. HS patients can develop anemia 
of chronic disease, and therefore anemia should be checked for in patients who pres-
ent with fatigue. HS is also associated with IBD; in our HS cohort we found that 3.3% 
of patients had concomitant IBD. This is four to eight times higher than in the general 
population. HS has a great impact on the lives of patients; we showed that HS is associ-
ated with a diminished sexual health, QoL and SES. Impairment in sexual health was 
associated with female gender and late onset of HS. Early disease onset, disease activity 
and severity were risk factors for a diminished QoL. Low SES was associated with axillary 
involvement, high body mass index, and low age, but not with disease severity or age of 
onset. Multiple medical treatments are available for HS, such as topical or oral antibiot-
ics, retinoids and biologics. Even though most can suppress symptoms of HS for a long 
period, they are seldom curative. Fumarates can be effective in refractory HS; however, 
their effectiveness is limited. Surgery is the most definite treatment for HS; using wide 
surgical excision we were able to induce remission in half of the treated anatomical 
areas.
212
SAmEnVAttIng
Hoofdstuk 1 geeft een algemene inleiding van dit proefschrift. Hidradenitis suppurativa 
(HS) is een chronische, invaliderende, huidziekte met een prevalentie van 1% in Europa. 
De ziekte wordt gekenmerkt door pijnlijke inflammatoire nodi en abcessen, gevolgd 
door sinusvorming en verlittekening. Met name de lichaamsplooien zijn aangedaan, 
zoals de oksels en de liezen. De pathogenese van HS is nog niet geheel duidelijk, maar is 
waarschijnlijk multifactorieel. Er wordt gedacht dat door hyperkeratose van het infundi-
bulum occlusie optreedt van de haarfollikel wat leidt tot ophoping van cellulair debris, 
waardoor de follikel kan scheuren, gevolgd door een overmatige inflammatoire reactie. 
Meerdere factoren zijn geassocieerd met HS, met name roken en obesitas. Recentelijk 
is er meer aandacht gekomen voor een genetische aanleg en een overactieve immuun-
reactie als uitlokkende factoren voor HS. HS is een invaliderende ziekte met een zeer 
negatieve invloed op de kwaliteit van leven. Daarnaast lijden HS patiënten vaak aan de-
pressie, hebben zij een verminderde seksuele gezondheid en kunnen zij moeilijkheden 
ondervinden bij het verrichten van hun werk. Tot op heden bestaat er geen genezing 
voor HS; meestal bestaat de behandeling uit een combinatie van medicamenteuze en 
chirurgische behandelingen. In dit proefschrift hebben wij ons gefocust op de klinische 
aspecten van HS. In het eerste deel hebben we de prevalentie bepaald en gekeken naar 
factoren die zijn geassocieerd met het op jonge leeftijd ontwikkelen van HS, ziekte-ernst 
en remissie. Voor het tweede deel hebben we gekeken naar twee specifieke comorbidi-
teiten van HS, namelijk anemie en inflammatoire darmziekte. Het derde deel gaat over 
de invloed van HS op seksuele gezondheid, kwaliteit van leven en socioeconomische 
status. Het laatste deel van dit proefschrift gaat over de behandeling van HS.
In hoofdstuk 2 hebben we de prevalentie bepaald van patiënten die HS op jonge 
leeftijd hebben gekregen (early-onset HS). In totaal hebben 66 van de 855 HS patiënten 
klachten gekregen voor de leeftijd van dertien jaar (7.7%). Patiënten met early-onset HS 
hebben vaker een positieve familieanamnese voor HS (55.6% vs 34.2%; OR 2.1, 95% CI 
1.2-3.6; P = 0.006). Dit geeft de indruk dat een genetische predispositie mogelijk invloed 
heeft op de ontstaansleeftijd van HS. Daarnaast blijkt dat patiënten met early-onset HS 
op meer locaties HS ontwikkelen dan patiënten met een normale ontstaansleeftijd voor 
HS (OR 3.0, 95% CI 1.8-4.9; P < 0.001). Echter, er is geen verschil gevonden tussen de 
twee groepen in ziekte-ernst volgens Hurley (OR 1.1, 95% CI 0.7-1.8; P = 0.72). Verassend 
genoeg blijken early-onset patiënten vaker niet-rokers te zijn (27.3% vs 14.3%; P = 0.01), 
en beginnen ze vaak pas met roken nadat ze al klachten hebben van HS. Onze resultaten 
laten zien dat early-onset HS niet zo zeldzaam is als altijd gedacht. Het is belangrijk om 
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patiënten die op een vroege leeftijd HS krijgen goed te controleren en ervoor te zorgen 
dat ze adequate behandeling krijgen om uitbreiding van de ziekte te voorkomen.
In hoofdstuk 3 hebben we gekeken naar ziekte gerelateerde factoren die geassocieerd 
zijn met ziekte-ernst, geslacht en positieve familieanamnese voor HS. Hiervoor hebben 
we data verzameld van 846 patiënten met HS. Van deze patiënten heeft 45.5% Hurley 
stadium I, 41.5% Hurley stadium II en 13.0% Hurley stadium III. Ziekte-ernst blijkt geas-
socieerd met het mannelijk geslacht (OR 2.11; P < 0.001), ziekteduur (OR 1.03; P < 0.001), 
body mass index (OR 1.03; P = 0.01), het aantal gerookte pack-years (OR 1.02; P = 0.001); 
en axillaire (OR 2.24; P < 0.001), perianale (OR 1.92; P < 0.001), en mammaire laesies (OR 
1.48; P = 0.03). Bij vrouwelijke patiënten ontstaat HS vaker op jongere leeftijd, zijn zij 
vaker aangedaan in de liezen en rond de borsten, en hebben zij vaker een positieve 
familieanamnese voor HS. Bij mannen zijn daarentegen vaker de billen, de perianale 
regio en atypische locaties aangedaan. Patiënten met een positieve familieanamnese 
voor HS krijgen vaker HS op een jongere leeftijd, hebben een langere ziekteduur en een 
uitgebreidere ziekte. Deze risicofactoren voor ziekte-ernst kunnen de arts helpen om 
patiënten te selecteren die extra geobserveerd moeten worden en mogelijkerwijs baat 
kunnen hebben bij vroege en agressieve therapie.
In hoofdstuk 4 hebben we gekeken naar de prognose op de lange termijn, het klinische 
beloop van HS en hebben we de associatie met bekende risicofactoren beschreven. 
Door middel van een vragenlijst zijn 212 patiënten met HS benaderd om deel te nemen 
aan deze studie. Deze patiënten zijn gemiddeld 22 jaar geleden door een dermatoloog 
gediagnostiseerd met HS. In totaal hebben 129 patiënten de vragenlijst ingevuld terug-
gestuurd (60.8%). Remissie is door 39.4% van de patiënten gerapporteerd en verbete-
ring door 31.5%. Daarentegen heeft 20.5% van de patiënten aangegeven geen verschil 
te hebben gemerkt in ziekte-ernst en 8.7% geeft zelfs verergering aan. Niet-rokers zijn 
vaker in remissie dan actieve rokers (48.5% vs 28.8%) en niet-obese patiënten zijn vaker 
in remissie dan obese patiënten (44.8% vs 22.6%). Deze studie bevestigt dat HS een 
chronische ziekte is, maar dat het veranderen van de levensstijl (stoppen met roken en 
afvallen) kan bijdragen tot remissie.
In hoofdstuk 5 worden twee patiënten gepresenteerd met ernstige HS en een invali-
derende vermoeidheid, als gevolg van chronische bloedarmoede. Anemie en de geas-
socieerde vermoeidheid zijn ziekteafhankelijk gebleken en zijn verbeterd na adequate 
behandeling van de HS laesies. Wij denken dat de chronische inflammatie, verhoogde 
bloedspiegels van pro-inflammatoire cytokines en continue bloederige drainage uit de 
HS laesie kunnen bijdragen aan het ontstaan van anemie. Daarom is het belangrijk om 
214
rekening te houden met de mogelijkheid dat vermoeidheid bij patiënten met HS ver-
oorzaakt kan worden door anemie, welke reversibel is als de HS goed behandeld wordt.
In hoofdstuk 6 hebben we de prevalentie bepaald van inflammatoire darmziekten 
(inflammatory bowel disease; IBD) in patiënten met HS. Daarnaast hebben we gekeken 
of patiënten met zowel IBD als HS een apart HS fenotype hebben. In totaal is aan 1076 
HS patiënten gevraagd of zij IBD hebben en van de patiënten die hier positief op heb-
ben geantwoord zijn de medische dossiers nagekeken. We hebben een prevalentie 
gevonden van IBD van 3.3% in onze HS populatie, wat vier tot acht keer hoger is dan in 
de algemene Noord Europese populatie. Patiënten met HS hebben vaker de ziekte van 
Crohn (27/36) dan colitis ulcerosa (9/36), wat niet verassend is aangezien de ziekte van 
Crohn en HS veel overeenkomsten hebben. Beide ziektes worden gekenmerkt door peri-
odes van exacerbatie en remissies, reageren goed op tumor necrose factor alfa remmers 
en bij beide ziektes wordt gedacht dat een afwijkend immuunsysteem een rol speelt in 
de pathogenese. Patiënten met HS en IBD blijken geen apart HS fenotype te hebben, 
aangezien enkel een lagere body mass index gevonden is in de patiënten met HS en IBD. 
Er is geen verschil gevonden in geslacht, genetische predispositie, rookgedrag, ziekte-
ernst of lichaamsgebieden aangedaan, tussen HS patiënten met of zonder IBD.
In hoofdstuk 7 hebben we de kwaliteit van leven onderzocht bij patiënten met HS, waar-
bij er met name gekeken is naar de seksuele gezondheid. In totaal zijn 916 HS patiënten 
uitgenodigd om deel te nemen aan deze multicenter cross-sectionele studie, waarvan 
300 patiënten de compleet ingevulde vragenlijsten hebben geretourneerd. Patiënten 
met HS blijken een verminderde seksuele gezondheid en kwaliteit van leven te hebben 
(Female Sexual Functioning Index score: 21.6 ± 9.6, International Index of Erectile Func-
tion score: 49.7 ± 20.7, Arizona Sexual Experience scale: 16.7 ± 5.3 and Dermatology Life 
Quality Index score: 12.5 ± 7.5). Seksuele gezondheid is geassocieerd met kwaliteit van 
leven bij vrouwen, maar niet bij mannen. Vrouwelijk geslacht en late ontstaansleeftijd 
van HS zijn geassocieerd met slecht seksueel functioneren. Verminderde kwaliteit van 
leven is geassocieerd met laesies in het anogenitaal gebied, vroege ontstaansleeftijd 
van HS, ziekte-ernst en ziekte activiteit. Deze studie bevestigt dat HS geassocieerd is 
met een verminderde seksuele gezondheid en kwaliteit van leven. Artsen moeten 
daarom meer aandacht besteden aan de seksuele gezondheid van hun HS patiënten en 
zo nodig psychologische hulp aanbieden.
In hoofdstuk 8 hebben we de socio-economische status (SES) bepaald van patiënten 
met HS en deze vergeleken met dermatologische controle patiënten. Daarnaast is er 
gekeken of klinische HS karakteristieken correleren met SES. Data zijn verzameld van HS 
patiënten en leeftijd en geslacht vergelijkbare controle patiënten in een ratio van 1:2. De 
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SES is gebaseerd op een indicator ontwikkeld door het Centraal Bureau van de Statistiek, 
met als basis het gemiddelde huishoudinkomen en WOZ-waarde per postcode gebied. 
Univariate en multivariate ordinale logistische regressie zijn gebruikt om te bepalen of 
klinische karakteristieken geassocieerd zijn met SES in de HS patiënten. De SES verde-
ling blijkt significant lager te zijn bij de 1018 HS patiënten (lage SES: 46.4%, midden 
SES: 39.0%, hoge SES: 14.6%) in vergelijking met leeftijd en geslacht overeenkomstige 
controle patiënten (lage SES: 34.3%, midden SES: 40.1%, hoge SES: 25.6%; P < 0.001). Een 
lage SES is bij de HS patiënten geassocieerd met axillaire betrokkenheid (OR 1.42; 95% 
CI 1.02-1.99), hoge body mass index (OR 1.03; 95% CI 1.01-1.06) en lage leeftijd (OR 0.98; 
95% CI 0.97-0.99). Patiënten met HS hebben niet alleen een significant lagere SES dan 
andere dermatologie patiënten maar ook dan de Nederlandse populatie. Lage SES is 
geassocieerd met obesitas, maar niet met ziekte ernst. In de algemene populatie is een 
lage SES geassocieerd met een ongezonde levensstijl zoals roken en overgewicht; lage 
SES zou daarom mogelijk een risicofactor kunnen zijn voor het ontwikkelen van HS. Een 
prospectieve cohort studie is echter nodig om causaliteit aan te kunnen tonen.
Hoofdstuk 9 is een uitgebreide review over de medicamenteuze behandelingen van 
HS. Bij milde ziekte, kunnen clindamycine lotion en resorcinol crème langdurig remissie 
geven; bij uitgebreidere ziekte zijn orale antibiotica vaak geïndiceerd, waarbij de effec-
tiviteit voornamelijk gebaseerd is op de anti-inflammatoire eigenschappen, en in min-
dere mate op de antibacteriële werking. Antibiotica uit de tetracycline groep zijn vaak 
therapie van eerste keus. Bij matige tot ernstige HS is de combinatie van clindamycine 
met rifampicine vaak effectief. Voor alle antibiotica geldt dat na stoppen het recidief per-
centage hoog is. Retinoïden zijn een goede lange termijnoplossing voor HS, met name 
acitretine is effectief gebleken door zijn keratolytische werking. Aangezien retinoïden 
teratogeen zijn, zijn ze minder geschikt voor vrouwen in de vruchtbare leeftijd. Wanneer 
patiënten met matige of ernstige HS onvoldoende reageren op de standaard behande-
lingen, komen ze in aanmerking voor behandeling met biologicals zoals infliximab en 
adalimumab. Hoewel biologicals zelden genezend zijn, kunnen ze de symptomen deels 
voor langere tijd onderdrukken en vaak langdurig gegeven worden. Verder zijn er meer-
dere anti-inflammatoire medicijnen beschreven voor HS, zoals dapson, azathioprine of 
cyclosporine; de effectiviteit hiervan is echter gebaseerd op kleine patiëntengroepen 
met wisselende resultaten. Naast de medicamenteuze behandeling is het belangrijk dat 
patiënten hun levensstijl aanpassen: patiënten moet worden aangeraden te stoppen 
met roken en af te vallen.
In hoofdstuk 10 worden de resultaten besproken van het prospectieve open-label pilot 
onderzoek naar de effectiviteit van fumaarzuur bij patiënten met matige tot ernstige HS. 
Zeven patiënten die voorheen niet reageerden op reguliere HS behandelingen zijn 20 
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weken behandeld met fumaarzuur in een oplopende dosis tot 720 mg dimethylfumaraat 
per dag. Na 20 weken zijn bij drie patiënten (43%) de klachten duidelijke verbeterd en 
daarom is de behandeling gecontinueerd. Na 28 weken moest één patiënte stoppen in 
verband met maag/darm klachten. Twee patiënten zijn door gegaan met fumaarzuur 
en na een jaar hebben zij nog steeds een duidelijke verbetering van hun HS laesies. 
Vier patiënten stopten na 20 weken vanwege onvoldoende effect (57%). De meest 
voorkomende bijwerkingen die zijn gemeld zijn maag/darm klachten (57%) en flushing 
(opvliegers) (85%). Fumaarzuur is effectief in patiënten met psoriasis, wat wordt gewijt 
aan de anti-inflammatoire effecten van fumaarzuur. Bij patiënten met HS zijn verhoogde 
bloedspiegels van pro-inflammatoire cytokines gevonden, en waarschijnlijk spelen 
deze een belangrijke rol in de pathogenese van HS. Daarom zijn fumaraten mogelijk 
ook effectief in patiënten met HS.
In hoofdstuk 11 hebben we gekeken naar de klinische karakteristieken, het recidief 
risico en de tevredenheid van patiënten die behandeld zijn met ruime excisie onder 
algehele narcose. Hiervoor zijn de dossiers retrospectief bekeken, en zijn patiënten 
benaderd middels een vragenlijst over mogelijke recidieven en patiënttevredenheid. 
In totaal hebben 86 patiënten geantwoord die samen 260 chirurgische procedures 
hebben ondergaan. De inguinale (n=95, 36.5%) en natale regio (n=67, 25.8%) zijn het 
vaakst geopereerd. Over het algemeen zijn de wonden open gelaten voor genezing 
per secundam (97.3%). Na een gemiddelde follow-up tijd van drie jaar, is bij 50.8% het 
geopereerde gebied nog volledig vrij van ontstekingen. Natuurlijke ziekteprogressie 
wordt gezien bij 12.7%, terwijl recidieven in het litteken of binnen een straal van 0.5 
cm van het litteken worden gezien bij 36.5% van de operaties. Patiënten zijn zeer vaak 
tevreden over de behandeling (91.8%) en zouden de operatie aan andere HS patiënten 
aanraden (91.8%). Hierdoor is ruime excisie chirurgie een goede optie voor patiënten 
met een ernstige HS.
In hoofdstuk 12 worden alle resultaten uit dit proefschrift besproken. We hebben 
aangetoond dat HS een chronische en ernstige ziekte is die al tijdens de kindertijd kan 
ontstaan. Hoewel een genetische predispositie geassocieerd is met het vroege ontstaan 
van de ziekte en mogelijk de kans op remissie verlaagt, is het niet geassocieerd met 
ziekte-ernst. Roken en overgewicht zijn niet geassocieerd met het vroege ontstaan van 
HS, maar zijn wel sterk geassocieerd met ziekte-ernst en lijken de kans op remissie te ver-
minderen. HS patiënten kunnen anemie door chronische ziekte ontwikkelen en daarom 
moet anemie worden uitgesloten bij patiënten met ernstige vermoeidheid. HS is ook 
geassocieerd met IBD; in ons HS cohort bleek 3.3% van de HS patiënten IBD te hebben. 
Dit is vier tot acht maal hoger dan in de algemene populatie. HS heeft een negatieve 
invloed op het leven van patiënten; we hebben aangetoond dat HS is geassocieerd met 
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een verlaagde seksuele gezondheid, kwaliteit van leven en socio-economische status. 
Vermindering van seksuele gezondheid is geassocieerd met het vrouwelijke geslacht 
en het ontwikkelen van HS op latere leeftijd. Risicofactoren voor een verlaagde kwaliteit 
van leven zijn het op jonge leeftijd ontwikkelen van HS, verhoogde ziekte activiteit en 
ziekte-ernst. Lage SES is geassocieerd met axillaire laesies, hoge body mass index, en 
lage leeftijd, maar is niet geassocieerd met ziekte-ernst of de ontstaansleeftijd van HS. 
Meerdere medicamenteuze behandelingen zijn beschreven voor HS, zoals topicale of 
orale antibiotica, retinoïden en biologicals. Hoewel deze de ziekte vaak voor langere 
tijd kunnen onderdrukken zijn ze zelden genezend. Fumaraten blijken effectief bij een 
aantal patiënten die voorheen niet reageerden op reguliere HS behandelingen, echter 
hun effectiviteit is gelimiteerd. Chirurgische behandeling is vaak de meest definitieve 
oplossing voor HS. Door middel van ruime chirurgische excisie is remissie geïnduceerd 
in de helft van de behandelde anatomische locaties.
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AGI anogenital involvement
ASEX Arizona Sexual Experience scale
BD twice daily
BMI body mass index
CD Crohn’s disease
CI confidence interval
CNS central nervous system
CoNS coagulase-negative staphylococci
DLQI Dermatology Life Quality Index
DM diabetes mellitus
DMF dimethylfumarates
ES effect size
FSFI Female Sexual Function Index
Hb hemoglobin
HiSCR Hidradenitis Suppurativa Clinical Response
HS hidradenitis suppurativa
HS-IBD patients with hidradenitis suppurativa and inflammatory bowel disease
HSSI Hidradenitis Suppurativa Severity Index
HS-PGA Hidradenitis Suppurativa Physician Global Assessment
IBD inflammatory bowel disease
IIEF International Index of Erectile Function
IL interleukin
IQR interquartile range
MCV mean corpuscular volume
n number
NF-kB nuclear factor kappa B
NOD2 nucleotide oligomerization domain 2
NSAID nonsteroidal anti-inflammatory drugs
OR odds ratio
PG pyoderma gangrenosum
PGA physicians global assessment
PtGA patient global assessment
QoL quality of life
SAPIR sexually active patients in a relationship
SAPNIR sexually active patients not in a relationship
SD standard deviation
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SE sensitivity
SES socioeconomic status
SP specificity
TB tuberculosis
TID three times daily
TNF-α tumor necrosis factor alpha
UC ulcerative colitis
VAS visual analog scale
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1. Prepubertal onset of hidradenitis suppurativa is not as rare as reported, and is associated 
with a family history of hidradenitis suppurativa and a more widespread disease. 
	 This	thesis
2. Smoking cessation aids to remission in the course of years. 
	 This	thesis
3. Inflammatory bowel disease, especially Crohn’s disease, is more prevalent in patients with 
hidradenitis suppurativa.
	 This	thesis
4. The socioeconomic status of patients with hidradenitis suppurativa is significantly lower 
than of patients with other dermatological diseases. 
	 This	thesis
5. Wide excision surgery is effective in severe hidradenitis suppurativa, leading to 50% remis-
sion/cure in an anatomical area.
	 This	thesis
6. A problem in the field of hidradenitis suppurativa that should be solved, is finding an 
appropriate replacement of the misnomers hidradenitis suppurativa, acne inversa, acne 
ectopica and Verneuil’s disease. 
7. Hidradenitis suppurativa: It looks infectious, but it is not. 
	 G.B.E.	Jemec.	Exp	Dermatol,	2008
8. Anemia of chronic disease can be caused by failure of an increase in erythropoietin levels. 
	 Thesis	of	J.J.	Bode,	1961
9. The assumption that your weight is based on genetics, leads to a higher body weight. 
	 M.C.	Parent	and	J.L.	Alquist.	Health	Educ	Behav,	2015
10. Dyslexia also has its advantages, because dyslectic people are better at planning and 
keeping the overview.
	 C.	Leather	et	al.	Dyslexia,	2011
11.	 Laissez lire, et laissez danser; ces deux amusements ne feront jamais de mal au monde. 
	 Voltaire,	1764
12. With a little bit of luck, good support and a lot of hard work, almost anything can be
 accomplished. 
	 This	thesis
